Drug, bio-affecting and body treating compositions inventions 06/08

20080153738 - Compositions and methods for treatment of hyperplasia: In accordance with the present invention, there are provided methods for treating hyperplasia in a subject in need thereof. In another aspect of the invention, there are provided methods for reducing neointimal hyperplasia associated with vascular interventional procedures. Formulations contemplated for use herein comprise proteins and at least one pharmaceutically... Agent: Morrison & Foerster LLP

20080153739 - Compositions and methods for treatment of hyperplasia: In accordance with the present invention, there are provided methods for treating hyperplasia in a subject in need thereof. In another aspect of the invention, there are provided methods for reducing neointimal hyperplasia associated with vascular interventional procedures. Formulations contemplated for use herein comprise proteins and at least one pharmaceutically... Agent: Morrison & Foerster LLP

20080153737 - Method of delivering rna interference and uses thereof: The invention provides a method of RNA interference, which comprises contacting the cell with a fusion protein-double stranded RNA complex, the complex comprising the double stranded RNA segment containing a double stranded RNA of interest and a fusion protein, the fusion protein comprising (1) a targeting moiety, which will specifically... Agent: David S. Resnick

20080153740 - Methods for increasing protein polyethylene glycol (peg) conjugation: The present invention relates to highly conjugated proteins and methods for making such proteins. In particular, the present invention relates to methods for linking additional sites to a protein for conjugation with activated polyethylene glycol (PEG) linkers, without denaturing the protein. The invention also relates to highly conjugated proteins with... Agent: Morrison & Foerster LLP

20080153741 - Compounding ingredients for cosmetic formulation for improving skinditch density and cosmetic: It is intended to provide compounding ingredients for cosmetics for improving skinditch density and cosmetics. The present invention provides compounding ingredients for cosmetics containing, as an active ingredient, nucleoprotein and/or DNA or RNA enzymatic or hydrolytic degradation product(s), a deoxyoligonucleotide, deoxymononucleotide, oligopeptide, oligonucleotide, or mononucleotide separated from the degradation product,... Agent: Oliff & Berridge, Plc

20080153742 - Fas peptide mimetics and uses thereof: Exocyclic peptide mimetics that disable Fas were developed. A three dimensional model of the Fas receptor-ligand complex was constructed and structurally predicted regions of the receptor that were relevant to binding ligand were used to create constrained peptide mimetics. Exocyclic anti-Fas peptide mimetics were identified that block Fas receptor-ligand interactions,... Agent: Woodcock Washburn LLP

20080153743 - Methods relating to the treatment of fibrosis: The invention provides α-helix mimetic structures of formula (I) with the definitions of A, B, D, E, G, W, R1 and R2 as set out in the description and a chemical library relating thereto. The compounds, pharmaceutical compositions comprising the compounds, and methods of the invention using the compounds, relate... Agent: Nixon Peabody LLP - Patent Group

20080153744 - Novel cyclosporin alkynes and their utility as pharmaceutical agents: e

20080153751 - Albumin fusion proteins: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080153745 - Compositions of trna and uses thereof: Compositions and methods of producing components of protein biosynthetic machinery that include orthogonal tRNA's, orthogonal aminoacyl-tRNA synthetases, and orthogonal pairs of tRNA's/synthetases are provided. Methods for identifying these orthogonal pairs are also provided along with methods of producing proteins using these orthogonal pairs.... Agent: Attn: John W. Wallen, Iii Ambrx, Inc.

20080153746 - Diagnosis and treatment of myeloid and lymphoid cell cancers: Disclosed is a method of diagnosing and treating myeloproliferative or lymphoproliferative cell disorders, such as cancer, with chlorotoxin and/or derivatives, analogs or fragments thereof, which are effective to bind to an inhibit abnormal myeloid or lymphoid cell growth.... Agent: C Hunter Baker Choate Hall & Stewart

20080153752 - Inhibitors of glycosaminoglycans: The present invention provides peptide derivatives with a specific affinity for glycosaminoglycan molecules. These peptide derivatives include multimers as well as chemically modified peptides and may be prepared by a variety of methods. The peptides of the invention have numerous functions, including but not limited to use as inhibitors of... Agent: Bozicevic, Field & Francis LLP

20080153753 - Method of treating side effects induced by therapeutic agents: The invention relates to agents for the prevention of organ damage, in particular of the kidneys and the inner ear, induced by the administration of aminoglycosides. Agents according to the invention are all substances which are megalin and/or cubilin antagonists (inhibitors). In particular, these are molecules (compounds) having polybasic structures... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080153749 - Methods and compositions for cell-cycle regulation: In some aspects, the invention provides methods and compositions including HTm4, an HTm4 activator, and/or an HTm4 variant to potentiate a KAP phosphatase activity and or inhibit a CDK2 kinase activity. In some embodiments, a functional C-terminal fragment of HTm4 is provided. In other aspects, the invention provides methods and... Agent: Wolf Greenfield & Sacks, P.c.

20080153748 - Novel molecules for the treatment and privention of fungal diseases: This disclosure provides a method and a product to treat fungal nail infections and Athlete's foot in a fast and non expensive way. The product contains one or more lytic peptides in water solution.... Agent: John Dodds

20080153750 - Process for production of diphtheria toxin: The present invention provides a method of purifying diphtheria toxin comprising (1) fermenting a microorganism strain capable of producing diphtheria toxin using glucose as a carbon source, said method comprising adding glucose to a growing culture whereby the addition of glucose maintains microorganism growth effective to support diphtheria toxin production;... Agent: Ge Healthcare, Inc.

20080153747 - Proteinaceous compounds and uses therefor: The present invention discloses proteinaceous compounds that comprise at least a biologically active portion of a taipan natriuretic peptide (TNP) or a variant or derivative thereof. The invention also relates to the use of these compounds in methods for stimulating vasodilation, natriuresis, diuresis, renin-suppression, bactericidal activity, weight-loss or bone growth... Agent: Knobbe Martens Olson & Bear LLP

20080153754 - Phenotypic reversion of pancreatic carcinoma cells: The present invention provides peptides (including analogs and derivatives thereof) corresponding to residues 96-110 and 35-47 of ras-p2 1, which peptides have attached thereto a membrane-penetrating leader sequence. The subject peptides, analogs and derivatives thereof are useful in treatment of cancers and have been shown to induce phenotypic reversion of... Agent: Dilworth & Barrese, LLP

20080153755 - Treatment of tumors: Where it was generally thought that the smallest breakdown products of proteins had no specific biological function on their own, it now emerges that the body may utilize the normal process of proteolytic breakdown to generate important compounds such as gene-regulatory or anti-tumor compounds. Such anti-tumor compounds are useful for... Agent: Trask Britt

20080153756 - Novel peptides and methods for the treatment of inflammatory disorders: Novel peptides, nucleic acids encoding them, and derivatives of the peptides are described. The peptides and nucleic acids are of use in modulating α4 integrin function and in treating α4 integrin-mediated inflammatory disorders.... Agent: Occhiuti Rohlicek & Tsao, LLP

20080153757 - Skin rejuvenation cream: The subject invention relates to a skin cream that can be used to moisturize and rejuvenate skin that has been damaged by exposure to sunlight or which has simply been affected over the years by intrinsic aging. It can also be used to slow the rate of photo-induced aging to... Agent: Alvin T. Rockhill

20080153758 - Compounds which inhibits protein prenylation e.g. geranylgeransferse or farnesyltransferase inhibitors for treating parkinson's disease: The invention relates to compounds and their uses, particularly in the pharmaceutical industry. The invention more specifically relates to new uses of compounds that inhibit the prenylation of proteins, in particular the geranylgeranyl and/or farnesyl modifications of proteins, for treating neurodegeneration involving oxidative stress and, more particularly, Parkinson's disease. The... Agent: Occhiuti Rohlicek & Tsao, LLP

20080153759 - Treatment methods using polypeptides related to amyloid precursor protein: in which X1 and X2 are up to 30 amino acid residues and the formula represents a reverse-order sequence corresponding to amino acid residues 332 to 328 of human APP and from zero to 30 successive amino acid residues of human APP extending in each direction therefrom, The invention also... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20080153760 - Haircare use of c-glycoside derivatives:

20080153761 - Compositions for protection against superficial vasodilator flush syndrome, and methods of use: Compositions for protection against SVFS induced by niacin, a carcinoid, mesenteric fraction, serotonin, post-menopause, alcohol or monosodium glutamate, comprising a flavonoid compound of the structure 2-phenyl-4H-1-benzopyran or 2-phenyl-4-keto-1-benzopyran or glycosides thereof, administered alone or together with an anti-superficial vasodilation dose of one or more of a non-bovine sulfated proteoglycan, a... Agent: Dr. Melvin Blecher

20080153762 - Process for harvesting plants of the apocynaceae family: m

20080153766 - Antisense modulation of stearoyl-coa desaturase expression: Antisense compounds, compositions and methods are provided for modulating the expression of stearoyl-CoA desaturase. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding stearoyl-CoA desaturase. Methods of using these compounds for modulation of stearoyl-CoA desaturase expression and for treatment of diseases associated with expression of stearoyl-CoA... Agent: Mcdermott Will & Emery

20080153771 - Composition and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases: Compositions and methods are provided for treatment of diseases involving unwanted neovascularization (NV). The invention provides treatments that control NV through selective inhibition of pro-angiogenic biochemical pathways, including inhibition of the VEGF pathway gene expression and inhibition localized at pathological NV tissues. Tissue targeted nanoparticle compositions comprising polymer conjugates and... Agent: Ropes & Gray LLP

20080153763 - Efficient process for producing dumbbell dna: 4) treating the heated and annealed amplified DNA product of step 3) with DNA ligase, wherein the sense and antisense primers used in step 1) are phosphorylated at the 5′ end, or the amplified DNA product is phosphorylated at the 5′ end after step 1) but before step 4).... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080153770 - Expression vectors with improved safety: The present invention relates to the use of internal promoters in mammalian expression vectors including plasmid vectors and enhancer-deleted retroviral vectors. The retroviral vectors have improved safety and optimal levels of transgene expression and vector titers.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080153765 - Methods of use of bcl-6-derived nucleotides to induce apoptosis: This invention provides methods methods of inducing apoptosis in a bcl-6-expressing cell and methods of treating a subject with a cancer comprising a bcl-6-expressing cell, comprising administration of a composition that reduces the amount of the bcl-6 protein or of an mRNA molecule encoding same, a composition comprising a nucleic... Agent: Pearl Cohen Zedek Latzer, LLP

20080153767 - Modulation of forkhead box o1a expression: Antisense compounds, compositions and methods are provided for modulating the expression of forkhead box O1A. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding forkhead box O1A. Methods of using these compounds for modulation of forkhead box O1A expression and for treatment of diseases associated with... Agent: Isis Pharmaceuticals Inc

20080153769 - Modulators of coagulation factors: The invention provides improved nucleic acid ligands that inhibit coagulation and improved modulators of the nucleic acids to provide ideal modulators of coagulation. These improved nucleic acids and modulators are particularly useful for inhibiting coagulation in a host undergoing a therapeutic regime such as surgery or coronary artery bypass.... Agent: King & Spalding LLP

20080153772 - Oligonucleotides for rna interference and biological applications thereof: The invention relates to compositions comprising double-stranded oligonucleotides of identical or different sequences and/or length, said oligonucleotides having sequences 3′N1N2 . . . Ni−1Ni . . . Nj5′ wherein—3Ni . . . Nj5′ is half of a double-stranded 19-28 mer oligonucleotide of sequence complementary to a target nucleic acid sequence... Agent: Nixon & Vanderhye, Pc

20080153764 - System and methods for short rna expression: The invention provides inducible expression systems for making short RNA transcripts that can be used in cells and transgenic animals for a variety of applications, including but not limited to, producing and studying the effects of RNAi and microRNA mediated gene silencing.... Agent: Fish & Richardson Pc

20080153768 - Treatment of neurological disorders by dsrna administration: The present invention relates to methods to treat neurological disorders comprising intrathecal injection of an effective amount of a double-stranded (ds) RNA into a subject in need, wherein the dsRNA inhibits the expression of a target gene and to pharmaceutical compositions useful for such treatment.... Agent: Novartis Institutes For Biomedical Research, Inc.

20080153774 - 4' -c-substituted-2-haloadenosine derivative: e

20080153773 - Modulators of phosphotyrosyl phosphatase activator: Atomic coordinates for human phosphotyrosyl phosphatase activator (PTPA) and ATPγS bound by PTPA, as well as methods for using these atomic coordinates to prepare ATPase inhibitors of PTPA and ATPase inhibitors prepared using such methods are provided herein. Comprehensive biochemical analyses of the interactions of PTPA with ATP and protein... Agent: Pepper Hamilton LLP

20080153775 - Weight reduction program and method: A new weight reduction program and method 1 having three phases, an acute weight loss phase 2, a transitional phase 3 and a long-term maintenance phase 4. Appetite suppressants 12 (such as phenylkylamine sympathomimetic amine 13), calcium pyruvate 17, a multiple vitamin-mineral supplement 16, amino acids and cyanocobalomine 10 are... Agent: Edward M. Livingston, Pa

20080153776 - Method of treating inflammation of the eye: The present invention includes a method of treating inflammation of the eye comprising administering to an eye of a patient suffering from inflammation of the eye, a composition comprising an aqueous solution of alginate having a minimum of about 50% mannuronate residues based upon the total number of saccharide monomeric... Agent: Bausch & Lomb Incorporated

20080153777 - Mosquito control method: A method of controlling or eradicating mosquito populations in aqueous environments, the method comprising the creation of an aqueous environment having greater than about 2% of sugars such as dextrose, sucrose and fructose in varying ratios. Mosquito larvae fail to develop beyond the second instar stage in solutions of approximately... Agent: Rogers Towers, P.a.

20080153778 - N-aryl pyrazole compounds, compositions, and methods for their use: m

20080153779 - Gastric retention and controlled release delivery system: The present invention provice a device (FIG. 3) for providing communication through power lines (FIG. 2) comprised of multiple conductors by transmitting the data signals through a plurality of the conductors. One embodiment of the present invention comprises a transmit circuit communicatively coupled to a first conductor for applying the... Agent: Emisphere Technologies, Inc

20080153780 - Use of a vanilloid receptor agonist together with a glycosaminoglycan or proteoglycan for producing an agent for treating articular pains and method for applying said agent: The invention relates to the use of a vanilloid receptor agonist together with a glycosaminoglycan for producing an agent for treating pain.... Agent: Rankin, Hill & Clark LLP

20080153781 - Anti-wrinkle agent: A medicament having an anti-wrinkle action, which comprises as an active ingredient a retinoid having a fundamental structure of a phenyl substituted carbamoyl benzoic acid or a phenyl substituted carboxamide benzoic acid (for example, 4-(2,4-bistrimethylsilylphenylcarboxamide) benzoic acid, 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl) carbamoyl] benzoic acid, or the like).... Agent: Greenblum & Bernstein, P.L.C

20080153782 - Use of lecithin as a medication for the treatment of psoriasis: Methods and compositions for the prevention and treatment of recent and old dermatitis, especially psoriasis, using lecithin or a lecithin-rich extract. According to one embodiment, phospholipids constituting the lecithin are esterified by Omega 3-type polyunsaturated fatty acids, in particular by docosahexaensic acid (DHA) and eicosapentaenoic acid (EPA) or by an... Agent: Dennison, Schultz & Macdonald

20080153783 - Pyrimidyl phosphonate antiviral compounds and methods of use: Pyrimidine I and pyrimidinone II phosphonate compounds and methods for viral inhibition are disclosed. The compounds include at least one phosphonate group covalently attached at any site.... Agent: Gilead Sciences Inc

20080153784 - Long term sustained release pharmaceutical composition containing aqueous suspension of bisphosphonate: Pharmaceutical compositions for long-term sustained release of bisphosphonate drugs are provided. In one embodiment, the composition includes an aqueous suspension of a solid which includes a salt of a bisphosphonate drug and a salt of pentavalent phosphorus oxoacid. The compositions can be used to treat a variety of bone diseases,... Agent: Christie, Parker & Hale, LLP

20080153785 - Pharmaceutical compositions containing biophosphonate for improving oral absorption: Provided is a pharmaceutical composition having improved oral absorption of a bisphosphonate drug, comprising at least one active substance selected from bisphosphonate drugs having non-permeability to a lipid biomembrane due to ionization and high water-solubility in vivo and having bioavailability of less than 10%, and at least one selected from... Agent: The Webb Law Firm, P.c.

20080153786 - Controlled release of drugs into/through the skin: The slow and sustained, controlled release of a drug into and through the skin includes topically applying onto the skin of an individual in need of such treatment, a composition containing at least one solubilized drug, at least one film-forming silicone, and at least one volatile solvent.... Agent: Buchanan, Ingersoll & Rooney Pc

20080153787 - 18-methyl-19-norandrost-4-ene 17, 17-spiro ether (18-methyl-19-nor-20-spirox-4-en-3-one), and pharmaceutical products comprising the same: e

20080153788 - Novel composition to increase muscle strength: The present invention relates to a composition comprising a sufficient amount of at least two ketosteroid derivatives of testosterone's metabolism in association with a pharmaceutically acceptable carrier for increasing testosterone's physiological levels in a male subject.... Agent: Bereskin And Parr

20080153790 - Medical devices containing rapamycin analogs: A medical device comprises a supporting structure capable of containing or supporting a pharmaceutically acceptable carrier or excipient, which carrier or excipient may contain one or more therapeutic agents or substances, with the carrier preferably including a coating on the surface thereof, and the coating containing the therapeutic substances, such... Agent: Squire, Sanders & Dempsey L.l.p.

20080153789 - Topical administration of danazol: Pharmaceutical preparations for topical or local administration of drugs directly to the skin for treatment of disorders of the subcutaneous fatty tissue, in particular in cases of cellulite, are disclosed herein. In a preferred embodiment, the drug is danazol or gastrinone. In another embodiment, the drug is danazol in combination... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080153791 - 11beta -hydroxysteroid dehydrogenases: The present invention relates to novel 11β-HSD inhibitors as well as to the use of 11 β-HSD inhibitors for the manufacture of pharmaceutical agents for the prevention and/or treatment of metabolic diseases, cancer, cell proliferation, glaucoma, diseases associated with abnormal growth hormone secretion as well as wound healing disorders.... Agent: Rothwell, Figg, Ernst & Manbeck, P.c.

20080153793 - Coatings comprising self-assembled molecular structures and a method of delivering a drug using the same: A coating for an implantable medical device is disclosed, the coating including a self-assembled molecular structure. The coating can be used for altering the release rate of a therapeutic substance from the implantable device.... Agent: Squire, Sanders & Dempsey LLP

20080153792 - Drug identification and treatment method: The invention relates to methods to identify compounds that can treat autoimmune conditions and treat specified clinical disorders such as multiple sclerosis, ulcerative colitis or arthritis. Compounds include 17α-ethynylandrost-5-ene-3β,15β,7α,17β-tetrol, 4α-acetoxy-17α-ethynylandrost-5-ene-3β,7β,17β-triol, 17α-ethynylandrost-5-ene-3β,4β,7α,17β-tetrol, 17α-ethynylandrost-5-ene-3α,4β,7α,17β-tetrol and 17α-ethynylandrost-5-ene-3α,4β,17β-triol-7-one.... Agent: Hollis-eden Pharmaceuticals, Inc.

20080153797 - Drug identification and treatment method: The invention relates to methods to identify compounds that can treat autoimmune conditions and treat specified clinical disorders such as multiple sclerosis, ulcerative colitis or arthritis. Compounds include 17α-ethynylandrost-5-ene-3β,11β,7α,17β-tetrol, 4α-acetoxy-17α-ethynylandrost-5-ene-3β,7β,17β-triol, 17α-ethynylandrost-5-ene-3β,4β,7α,17β-tetrol, 17α-ethynylandrost-5-ene-3α,4β,7α,17β-tetrol and 17α-ethynylandrost-5-ene-3α,4β,17β-triol-7-one.... Agent: Hollis-eden Pharmaceuticals, Inc.

20080153794 - Medicaments and methods for wound healing: The present invention relates to the manufacture of medicaments. In particular, the invention relates to the manufacture of medicaments for accelerating the healing of wounds. The invention also relates to methods of treatment for accelerating the healing of wounds. In particular the invention relates to medicaments and methods for the... Agent: Nixon & Vanderhye, Pc

20080153795 - Medicaments and methods for wound healing: The present invention relates to the manufacture of medicaments for accelerating the healing of wounds. The invention also relates to methods of treatment for accelerating the healing of wounds. In particular the invention relates to medicaments and methods for the acceleration of healing of skin wounds. The invention relates to... Agent: Nixon & Vanderhye, Pc

20080153796 - Promotion of wound contraction: The present invention relates to medicaments and methods for promoting wound contraction. In certain embodiments the invention provides medicaments and methods capable of promoting wound contraction without acceleration of re-epithelialisation.... Agent: Nixon & Vanderhye, Pc

20080153798 - Methods of inhibiting nitric oxide synthase using corrin derivatives: The present invention provides methods of inhibiting nitric oxide synthase (NOS) using corrin derivatives that bind NOS but do not bind NO. It also provides methods of inhibiting NOS in vivo by administering corrin derivatives, and methods of treating diseases and medical conditions using this inhibition of NOS.... Agent: Mandel & Adriano

20080153800 - Novel crystalline compound: A novel crystalline form of 3-{[5-(azetidin-1-ylcarbonyl)pyrazin-2-yl]oxy}-5-[(1-methylethyl)oxy]-N-1H-pyrazol-3-ylbenzamide is described in the specification. This compound is a glucokinase (GLK or GK) activator and useful as a pharmaceutical agent in the treatment or prevention of a disease or medical condition mediated through GLK, leading to a decreased glucose threshold for insulin secretion. Processes... Agent: Morgan Lewis & Bockius LLP

20080153799 - Novel quinoline-carbaxamides as jak3 kinase modulators: The present invention relates to novel compounds which are JAK3 Kinase inhibitors, methods for their preparation and pharmaceutical compositions comprising them. A compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein X is —CHOH or —C═O;... Agent: Astrazeneca R&d Boston

20080153801 - Benzoxazepine compounds, their production and use: [wherein R stands for a lower alkyl group optionally substituted with a hydroxyl group, X stands for an optionally substituted carbamoyl group or an optionally substituted heterocyclic group having a deprotonatable hydrogen atom, R1 stands for a lower alkyl group and W stands for a halogen atom] having activities of... Agent: Edwards Angell Palmer & Dodge LLP

20080153802 - Alpha-helical mimetics: Benzoyl urea derivatives that are alpha helical peptides mimetics that mimic BH3-only proteins, compositions containing them, their conjugation to cell-targeting-moieties, and their use in the regulation of cell death are disclosed. The benzoyl urea derivatives are capable of binding to and neutralizing pro-survival Bcl-2 proteins. Use of benzoyl urea derivatives... Agent: Proskauer Rose LLP

20080153804 - Gamma d-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it: n

20080153803 - Gamma-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it:

20080153805 - Sulfonamide derivatives:

20080153806 - Novel diazabicyclic aryl derivatives and their medical use: This invention relates to novel diazabicyclic aryl derivatives, which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse... Agent: Birch Stewart Kolasch & Birch

20080153807 - Pharmaceutical use of fused 1,2,4-triazoles: The use of fused 1,2,4-triazoles for modulating the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and the use of these compounds as pharmaceutical compositions has been described. Also a novel class of fused 1,2,4-triazoles, their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the... Agent: Novo Nordisk, Inc. Intellectual Property Department

20080153808 - Alpha-2 receptor pan agonist and serotonin-norepinephrine reuptake inhibitor compositions for treating chronic pain: Disclosed herein is a pharmaceutical composition comprising a serotonin-norepinephrine reuptake inhibitor and a pan-alpha-2 receptor agonist. The composition is effective for treating chronic pain, and methods of treating pain using the composition and compounds comprising it are also disclosed.... Agent: Allergan, Inc.

20080153809 - Novel amides useful for treating pain: s

20080153810 - Indazole derivatives useful as melanin concentrating receptor ligands: The present invention relates to novel compounds, in particular, novel indazole that may be used as melanin concentrating hormone receptor ligands, methods of preparing such compounds, compositions containing such compounds, and methods of using such compounds to treat MCH related disorders.... Agent: Forest Laboratories, Inc. Attn: Charles S. Ryan

20080153813 - 6-aminoimidazo[1,2-b]pyridazine analogs as rho kinase inhibitors for the treatment of rho kinase-mediated diseases and conditions: Methods for using 6-aminoimidazo[1,2-b]pyridazine analogs are disclosed herein to treat rho kinase-mediated diseases or rho kinase-mediated conditions, including controlling intraocular pressure and treating glaucoma, are disclosed. Ophthalmic pharmaceutical compositions useful in the treatment of eye diseases such as glaucoma, and additionally useful for controlling intraocular pressure, the compositions comprising an... Agent: Alcon

20080153811 - Methods of treating cognitive impairment and dementia: This invention relates to methods for treating, managing and preventing cognitive impairment associated with various diseases and disorders, age-associated memory impairment, and dementia.... Agent: Lexicon Pharmaceuticals, Inc.

20080153812 - Novel compounds: i

20080153814 - 8-chloro-2,3-benzodiazepine derivatives: The invention relates to new 8-chloro-2,3-benzodiazepine derivatives of the general formula (I), wherein R stands for a lower alkyl group or a group of the general formula —NH—R′, wherein R′ stands for a lower alkyl or a lower cycloalkyl group), and pharmaceutically acceptable acid addition salts thereof. The invention also... Agent: K.f. Ross P.c.

20080153816 - Indole compounds, method of preparing them and uses thereof: e

20080153815 - Pinane-substituted pyrimidinediamine derivatives useful as axl inhibitors: Pinane-substituted pyrimidinediamine derivatives derivatives and pharmaceutical compositions containing the derivatives are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase Axl. Methods of using the derivatives in treating diseases or conditions associated with Axl catalytic activity are also disclosed.... Agent: Seed Intellectual Property Law Group Pllc

20080153817 - Treatment for alzheimer's disease and related conditions: Compounds of formula (I): are useful in the treatment of diseases associated with deposition of β-amyloid in the brain.... Agent: Merck And Co., Inc

20080153818 - Methods for preventing inflammation during surgery: The present invention provides compositions and methods for preventing inflammation and retinal edema resulting from an ocular surgical procedure by administering to a patient undergoing surgery a therapeutically effective amount of a composition comprising an active agent selected from the group consisting of RTK inhibitors and anti-VEGF compounds, and a... Agent: Teresa J. Schultz Ip Legal (tb4-8)

20080153819 - Methods for treating macular edema and pathologic ocular angiogenesis using a neuroprotective agent and a receptor tyrosine kinase inhibitor: The present invention provides methods for inhibiting increased vascular permeability and/or pathologic ocular angiogenesis and providing neuroprotection of the affected retina via administration of a combination of one or more molecules that potently inhibit select receptor tyrosine kinases (RTKs) or vascular endothelial growth factor (VEGF) and one or more neuroprotectants.... Agent: Alcon

20080153820 - Thieno(3,2-d)pyrimidines and furano(3,2-d)pyramidines and their use as purinergic receptor antagonists: A compound of formula (I), wherein X is S or O; R1 is selected from H, alkyl, aryl, hydroxy, alkoxy, aryloxy, thioalkyl, thioaryl, halogen, CN, COR5, CO2R5, CONR5R7, CONR5NR6R7, NR6R7, NR5CONR6R7, NR5COR6, NR5CO2R8, and NR5SO2R8; R2 is selected from aryl attached via an unsaturated carbon atom; R3 is selected from... Agent: Michele M. Simkin Foley & Lardner LLP

20080153821 - Nitrogen-containing 5-membered ring compound: c

20080153822 - Methods of treating pain:

20080153823 - Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors: This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.... Agent: Millen, White, Zelano & Branigan, P.c.

20080153824 - Method for controlling fungal diseases in leguminous plants: Method for controlling rust infections in leguminous plants by using orysastrobin, mixtures of orysastrobin and a fungicidally active compound II from the group of the azoles, acylalanines, amine derivatives, anilinopyrimidines, dicarboximides, dithiocarbamates, heterocylic compounds, phenylpyrroles, cinnamides, and analogs, or other fungicides according to the description, and also compositions and seed... Agent: Hutchison Law Group Pllc

20080153825 - Alpha-2b receptor agonist and 5ht4 serotonin receptor compositions for treating gastrointestinal motility disorders: Disclosed herein is a pharmaceutical composition comprising a 5-HT4 serotonin receptor agonist and an alpha-2B receptor agonist. The composition is effective for treating gastrointestinal motility disorders, and methods of treating such disorders using the composition and compounds comprising it are also disclosed.... Agent: Allergan, Inc.

20080153826 - Substituted aryl cycloalkanol derivatives and methods of their use: The present invention is directed to substituted aryl cycloalkanoyl derivatives, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromyalgia syndrome, nervous system disorders,... Agent: Wyeth Patent Law Group

20080153827 - Method for the treatment or prevention of cardiac hypertrophy: A method for the treatment or prevention of cardiac hypertrophy or diastolic heart failure resulting from cardiac hypertrophy by administering levosimendan or its metabolite (II) or any of their pharmaceutically acceptable salts to a mammal in need of such treatment.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080153828 - Imidazopyridazine compounds: The present invention relates to novel substituted imidazo[1,2-b]pyridazine compounds of Formula (I) pharmaceutical compositions thereof, and the use such compounds as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric disorders and neurological diseases.... Agent: Eli Lilly & Company

20080153829 - Pan-alpha-2 receptor agonist and 5ht4 serotonin receptor compositions for treating gastrointestinal motility disorders: Disclosed herein is a pharmaceutical composition comprising a 5-HT4 serotonin receptor agonist and a pan-alpha-2 receptor agonist. The composition is effective for treating gastrointestinal motility disorders, and methods of treating such disorders using the composition and compounds comprising it are also disclosed.... Agent: Allergan, Inc.

20080153830 - Alpha and/or beta-adrenergic antagonists and agonists to treat pain: The present disclosure provides for improved methods for treating pain, including pain associated with chronic inflammatory diseases, neuropathic pain and cancer by using α-adrenergic antagonists and β-adrenergic agonists (particularly β2-adrenergic agonists) alone or in combination.... Agent: Jennings, Strouss & Salmon, P.L.C

20080153831 - Isoflavone-containing compositions for the treatment of osteoporosis and inflammatory joint disease: Compositions and methods for the prevention and treatment of osteoporosis are provided herein. The compositions contain one or more isoflavones, such as genistein and derivatives thereof, in combination with one or more folates, such as a reduced folate and/or folic acid; and/or one or more polyunsaturated fatty acids (PUFAs), such... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080153832 - Pan-alpha-2 receptor agonist and relaxant compositions for treating gastrointestinal motility disorders: Disclosed herein is a pharmaceutical composition comprising a relaxant and a pan-alpha-2 receptor agonist. The composition is effective for treating gastrointestinal motility disorders, and methods of treating such disorders using the composition and compounds comprising it are also disclosed.... Agent: Allergan, Inc.

20080153833 - Substituted pteridines for the treatment of inflammatory diseases: s

20080153836 - 1h-quinazoline-2,4-diones:

20080153834 - Certain substituted amides, method of making, and method of use thereof:

20080153835 - Therapeutic agents useful for treating pain: wherein A, Ar, R3, R6, and m are disclosed herein, or a pharmaceutically acceptable salt thereof (a “Cyanoiminopiperazine Compound”), compositions comprising an effective amount of a Cyanoiminopiperazine Compound, and methods for treating or preventing pain, urinary incontinence, an ulcer, inflammatory-bowel disease, irritable-bowel syndrome, an addictive disorder, Parkinson's disease, parkinsonism, anxiety,... Agent: Jones Day

20080153837 - Novel fluorene derivatives, composition containing said derivatives and the use thereof: This invention relates to derivatives of 4-(benzimidazol-2-yl)fluorene and 4-(azabenzimidazol-2-yl)fluorene, to pharmaceutical compositions comprising such derivatives, and to methods of treatment of disorders related to Hsp90 protein activity, comprising administering such derivatives.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. Llc

20080153838 - Compounds having tie2 (tek) activity: or salt, prodrug or solvate thereof, wherein R1, R5, R6, D, A, B, L, n, m and p are as defined in the description. The invention also relates to pharmaceutical compositions of said compounds, the use of said compounds as medicaments and in the production of an anti-angiogenic effect in... Agent: Astrazeneca R&d Boston

20080153840 - Reduction of cardiovascular symptoms: The present application discloses methods for treating patients with a dysfunction of the ion channels of the heart suffering from one or more cardiovascular diseases to reduce the proarrhythmic effect of drugs and/or conditions that reduce or inhibit IKr.... Agent: Cv Therapeutics, Inc.

20080153839 - Use of anisic acid for promoting desquamation: Use of anisic acid or a derivative thereof for promoting desquamation of the skin and/or for stimulating epidermal renewal. Associated compositions. Especially useful for improving the radiance of the complexion and/or the grain of the skin and/or for smoothing out the skin's microrelief, and/or for attenuating age spots.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080153841 - Treatment of premature ejaculation: This invention relates to the use of cyclic guanosine 3′,5′-monophosphate phosphodiesterase type five inhibitors, including in particular the compound sildenafil, for the treatment of premature ejaculation in patients with normal erectile function.... Agent: Pfizer Inc Steve T. Zelson

20080153842 - Combination of src kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases: Compositions and methods are disclosed which are useful of the treatment and prevention of proliferative disorders.... Agent: Louis J. Wille Bristol-myers Squibb Company

20080153843 - Substituted sulfonamide compounds: Substituted sulfonamide derivatives, a process for their preparation, pharmaceutical compositions containing these compounds, and to the use of substituted sulfonamide derivatives in the treatment or inhibition of pain and/or various disorders or disease states.... Agent: Crowell & Moring LLP Intellectual Property Group

20080153844 - Substituted pyrazole kinase inhibitors: b

20080153845 - Trpv1 antagonists and uses thereof: The present invention is directed to the use of TRPV1 antagonists as inhibitors of certain taste perceptions and functions. The invention is also directed to, among other things, compositions comprising the TRPV1 antagonists that can be used in pharmaceutical, food, and other products to inhibit certain taste functions and perceptions.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080153846 - Aminomethyl beta-secretase inhibitors for the treatment of alzheimer's disease: The present invention is directed to aminomethyl compounds which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of... Agent: Merck And Co., Inc

20080153848 - Crystalline base of trans-1-((1r,3s)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine: Crystalline base of compound trans-1-((1R,3S)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine, processes for the preparation of purified free base or salts of this compound, pharmaceutical compositions comprising the base and medical use thereof, including for treatment of schizophrenia and other psychotic disorders.... Agent: Lundbeck Research Usa, Inc. Attention: Stephen G. Kalinchak, Legal

20080153847 - Process for making trans-1-((1r,3s)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine: Described is a method for making the trans-1-((1R,3S)-6-chloro-3-phenylin-dan-1-yl)-3,3-dimethylpiperazine (formula I) and salts thereof and a similar method for making 4-((1R,3S)-6-chloro-3-phenylin-dan-1-yl)-1,2,2-trimethylpiperazine (formula IX) and salts thereof, which method comprises conversion of a compound of formula IVa to the compound of formula I or the compound of formula IX, respectively.... Agent: Lundbeck Research Usa, Inc. Attention: Stephen G. Kalinchak, Legal

20080153850 - Adamantyl derivates as p2x7 receptor antagonists: The invention provides compounds of formula (I) pharmaceutically acceptable salt or solvate thereof, in which R1, A1, m and A are as defined in the specification; a process for their preparation; pharmaceutical compositions containing them; and their use in therapy.... Agent: Fish & Richardson P.c.

20080153849 - Process for the preparation of crystalline (6rrs)-n(5)-formyl-5,6,7,8-tetrahydrofolic acid: The inventive method for the production of crystalline (6RS)-N(5)-formyl-5,6,7,8-tetrahydrofolic acid or amorphic (6S)-N(5)-formyl-5,6,7,8-tetrahydrofolic acid is characterized in that an aqueous solution of (6RS)- or (6S)-calcium folinate, which has a temperature of 40° C. to 50° C., and an aqueous solution of hydrochloric acid or acetic acid are added to stirred... Agent: Bingham Mccutchen LLP

20080153852 - 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use: Compounds of formula I are disclosed, as well as compositions comprising them and methods of their use to treat, prevent and/or manage diseases and disorders:... Agent: Lexicon Pharmaceuticals, Inc.

20080153851 - Cycloalkyl piperidine tachykinin receptor antagonists: The present invention is directed to certain piperidine compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in... Agent: Merck And Co., Inc

20080153853 - Use of mtki 1 for treating or preventing brain cancer: The present invention is concerned with the finding that some the macrocyclic quinazoline derivative 4,6-ethanediylidenepyrimido[4,5-b][6,1,12]benzoxadiazacyclo-pentadecine, 17-bromo-8,9,10,11,12,13,14,19-octahydro-20-methoxy-13-methyl-, described as compound 22 in PCT publication W02004/105765, is useful in the manufacture of a medicament for the treatment or prevention of a primary brain cancer or brain metastasis. It accordingly provides methods for... Agent: Philip S. Johnson Johnson & Johnson

20080153855 - Chemical compounds: R5 is a hydrogen atom or hydroxy group; and Ar is a 5- to 10-membered aromatic ring system where up to 4 ring atoms may be heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted by one or more substituents as defined in the specification.... Agent: Fish & Richardson P.c.

20080153854 - Novel fused heterocycles and uses thereof:

20080153856 - A2b adenosine receptor antagonists: Disclosed are novel compounds that are A2B adenosine receptor antagonists, useful for treating various disease states, including asthma and diarrhea.... Agent: Cv Therapeutics, Inc.

20080153857 - Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues: Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for... Agent: Edwards Angell Palmer & Dodge LLP

20080153858 - Antitumorigenic drug combination: This invention relates to compositions and methods for treating cancer comprising therapeutically effective amounts of ABT-751 and pemetrexed.... Agent: Paul D. Yasger Abbott Laboratories

20080153859 - Multiply-substituted tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents: i

20080153864 - Spiroazabicyclic heterocyclic compounds:

20080153860 - Spirocyclic azaadamantane derivatives and methods of use: The invention relates to compounds that are spirocyclic azaadamantane derivatives derivatives, particularly spirocyclic azaadamantanyl ether or amine derivatives, compositions comprising such compounds, methods of using such compounds and compositions, processes for preparing such compounds, and intermediates obtained during such processes.... Agent: Paul D. Yasger Abbott Laboratories

20080153861 - Spiropiperidine derivatives: e

20080153862 - Spiropiperidine derivatives:

20080153863 - Spiropiperidine derivatives:

20080153865 - Water soluble paclitaxel derivatives: Disclosed are water soluble compositions of paclitaxel and docetaxel formed by conjugating the paclitaxel or docetaxel to a water soluble polymer such as poly-glutamic acid, poly-aspartic acid or poly-lysine. Also disclosed are methods of using the compositions for treatment of tumors, auto-immune disorders such as rheumatoid arthritis. Other embodiments include... Agent: Foley And Lardner LLP Suite 500

20080153866 - Amorphous taclolimus solid dispersion having an enhanced solubility and pharmaceutical composition comprising same: An amorphous taclolimus solid dispersion comprising taclolimus, a substituted cyclodextrin derivative and an organic acid, which has a high thermodynamic stability and solubility, can provide an enhanced release rate and bioavailability.... Agent: Sughrue Mion, Pllc

20080153867 - Compounds with a combination of cannabinoid-cb1 antagonism and acetylcholinesterase inhibition:

20080153868 - Substituted tetrahydroisoquinolines as beta-secretase inhibitors: wherein R, R8 and R9 are as defined herein, their pharmaceutical compositions and methods of use. These compounds inhibit the processing of amyloid precursor protein (APP) by β-secretase and, more specifically, inhibit the production of Aβ-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders... Agent: Louis J. Wille Bristol-myers Squibb Company

20080153869 - Kinase inhibitors: The invention relates to compounds having one of the below formulae that may be used to inhibit kinases as well as compositions of matter and kits comprising these compounds, and methods using the compounds.... Agent: Takeda San Diego, Inc.

20080153870 - Cocaine receptor binding ligands: A class of binding ligands for cocaine receptors and other receptors in the brain. Specifically, a novel family of compounds shows high binding specificity and activity, and, in a radiolabeled form, can be used to bind to these receptors, for biochemical assays and imaging techniques. Such imaging is useful for... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080153871 - Antagonists of the trpv1 receptor and uses thereof: c

20080153874 - Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain: Disclosed herein is a pharmaceutical composition comprising a pain-relieving anticonvulsant and an alpha-2B receptor agonist. The composition is effective for treating chronic pain, and methods of treating chronic pain using the composition and the compounds comprising it are also disclosed.... Agent: Allergan, Inc.

20080153872 - Bis-(coumarin) compounds with anti-inflammatory activity: Certain bis-(coumarin) compounds as well as the products of their intramolecular cyclization including pharmaceutically acceptable salts, hydrates, solvates, clathrates, prodrugs, tautomers and stereoisomers thereof are disclosed. Certain processes and intermediates for the preparation of certain bis-(coumarin) compounds, as well as for the use of these compounds as therapeutically active agents... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20080153873 - Dihydrobenzofuranyl derivatives and methods of their use: or a pharmaceutically acceptable salt thereof, which are monoamine reuptake inhibitors, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions, including, inter alia, vasomotor symptoms sexual dysfunction, gastrointestinal disorders and genitourinary disorder, depression disorders, endogenous behavioral disorder, cognitive disorder, diabetic neuropathy, pain, and... Agent: Wyeth Patent Law Group

20080153875 - Novel indole derivatives and their use as medicament: The invention relates to novel indole derivatives of the general formula 1, to their preparation and to their use as medicaments, in particular for treating tumors.... Agent: Goodwin Procter L.l.p Attn: Patent Administrator

20080153876 - Unit dose formulations and methods of treating thrombosis with an oral factor xa inhibitor: Unit doses of factor Xa inhibitor compounds and methods of using these compounds for inhibiting blood coagulation in a human patient are taught herein. The unit dose of the factor Xa inhibitor compounds disclosed herein required to inhibit coagulation in a primate is lower than the unit dose required to... Agent: Foley & Lardner LLP

20080153877 - Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy: Provided herein are methods for using at least one histone deacetylase inhibitor to decrease cellular DNA repair activity, methods for monitoring the decrease of cellular DNA repair activity using at least one biomarker, methods of treating cancer by using at least one histone deacetylase inhibitor to decrease cellular DNA repair... Agent: Wilson Sonsini Goodrich & Rosati

20080153878 - Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors: The present invention provides novel indanone derivatives which can be advantageously used for treating and/or preventing of a medical condition for which inhibition of a cholinesterase is desired.... Agent: Fenwick & West LLP

20080153879 - Method of managing or treating pain: A composition for the intranasal delivery of fentanyl or a pharmaceutically acceptable salt thereof to an animal includes an aqueous solution of fentanyl or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable additive selected from (i) a pectin and (ii)a poloxamer and chitosan or a salt or derivative thereof;... Agent: Panitch Schwarze Belisario & Nadel LLP

20080153881 - Alpha-2b receptor agonist and acid reducer compositions for treating gastrointestinal motility disorders: Disclosed herein is a pharmaceutical composition comprising an acid reducer and an alpha-2B receptor agonist. The composition is effective for treating gastrointestinal motility disorders, and methods of treating such disorders using the composition and compounds comprising it are also disclosed.... Agent: Allergan, Inc.

20080153880 - Pan-alpha-2 receptor agonist and acid reducer compositions for treating gastrointestinal motility disorders: Disclosed herein is a pharmaceutical composition comprising an acid reducer and a pan-alpha-2 receptor agonist. The composition is effective for treating gastrointestinal motility disorders, and methods of treating such disorders using the composition and compounds comprising it are also disclosed.... Agent: Allergan, Inc.

20080153883 - Novel compounds as cannabinoid receptor ligands and uses thereof: s

20080153882 - Pharmaceutical composition comprising ppar regulator: wherein R1 and R2, each represents hydrogen or alkyl; R3 represents C1-C6 alkyl or hydroxymethyl; R4 represents hydrogen, C1-C6 alkyl, alkoxy or halogen; R5 represents substituted phenyl; X represents vinylene (CH═CH), oxygen, sulfur or methylamino; Y represents a single bond, oxygen, sulfur or carbonyl; Z represents a single bond or... Agent: Frishauf, Holtz, Goodman & Chick, Pc

20080153884 - Emulsifiable concentrates: An object of the present invention is to provide an emulsifiable concentrate which comprises pyriproxyfen as an active ingredient, wherein the emulsifiable concentrate is excellent in emulsion stability under conditions of low-rate dilution not only in soft water but also in hard water. The present application provides for an emulsifiable... Agent: Wenderoth, Lind & Ponack, L.l.p.

20080153885 - Pharmaceutical compositions and method for treating inflammation in cattle and other animals: Novel transdermal preparations combining a non-steroidal anti-inflammatory drug (NSAID) such as flunixin, are disclosed. Methods for using and administering such preparation in the treatment of inflammatory conditions in bovines, including bovine respiratory disease, are also disclosed.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080153886 - Use of heterocyclic compounds as neurogenic agents: v

20080153888 - Alpha-2-delta ligand/nsaid therapeutic treatment of lower urinary tract disorders: The invention relates to a method of treating at least one symptom of lower urinary tract disease in a subject in need of treatment comprising administering to said subject a combination of an α2δ calcium channel subunit (A2d) ligand and a non-steroidal anti-inflammatory drug (NSAID), wherein the administered amounts of... Agent: Darby & Darby P.c.

20080153887 - Mitotic kinesin inhibitors: The present invention relates to oxadiazoles that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also relates to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.... Agent: Merck And Co., Inc

20080153889 - Compositions and methods for the treatment of renal and cardiovascular disease: Derivative compounds of 11-nonyloxy-undec-8(Z)-eonic acid that mimic epoxide metabolites are provided. Also provided are compositions comprising a therapeutically effective amount of the derivative compounds. The present invention further provides methods for the use of such compositions for the treatment of renal or cardiovascular disease and/or related conditions,... Agent: Sutherland Asbill & Brennan LLP

20080153890 - Phosphinic amino acid compounds: r

20080153891 - Synergistic anti-cancer compositions: The present invention provides compositions useful in treating cancer. The compositions include a synergistic combination of an antineoplastic thiol-binding mitochondrial oxidant with an antineoplastic nucleic acid binding agent, an antineoplastic antimetabolite base analog, or docetaxel. Also provided are methods of assaying the synergistic effects of the combinations and methods of... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080153892 - Inhibitors of glutaminyl cyclase: and combinations thereof for the treatment of neuronal disorders, especially Alzheimer's disease, Down Syndrome, Parkinson disease, Corea Huntington, pathogenic psychotic conditions, schizophrenia, impaired food intake, sleep-wakefulness, impaired homeostatic regulation of energy metabolism, impaired autonomic function, impaired hormonal balance, impaired regulation, body fluids, hypertension, fever, sleep dysregulation, anorexia, anxiety related disorders... Agent: Sonnenschein Nath & Rosenthal LLP

20080153894 - Cyclooxygenase-2 inhibitor and antibacterial agent combination for intramammary treatment of mastitis: A method is provided for treatment of an infective condition in an udder of a milk producing animal. The method comprises intramammary administration of an antibacterial agent in combination therapy with a selective COX-2 inhibitor in therapeutically effective amounts of each. Also provided is a pharmaceutical composition comprising an antibacterial... Agent: Pharmacia & Upjohn

20080153893 - Pyrazole carboxamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1: Pyrazole carboxamides of structural formula I are selective inhibitors of the 11β-hydroxysteroid dehydrogenase-1. The compounds are useful for the treatment of diabetes, such as noninsulin-dependent diabetes (NIDDM), hyperglycemia, obesity, insulin resistance, dyslipidemia, hyperlipidemia, hypertension, Metabolic Syndrome, and other symptoms associated with NIDDM.... Agent: Merck And Co., Inc

20080153895 - Antiviral indoles: r

20080153897 - Creatine pyroglutamic acid salts and methods for their production and use in individuals: A method for the use of creatine pyroglutamic acid salts is provided by the present invention. The salt of the present invention act substantially simultaneously to increase the neural health of a mammal.... Agent: Torys LLP

20080153896 - Polymorphic forms of an hmg-coa reductase inhibitor and uses thereof: The invention provides polymorphic forms of the HMG-CoA reductase inhibitor (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxymethylphenylamino)carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid, hemi calcium salt. The invention also provides methods for preparing these polymorphic forms, pharmaceutical formulations containing these polymorphic forms and methods of using the polymorphic forms of this HMG-CoA reductase inhibitor.... Agent: Sheridan Ross Pc

20080153898 - Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use: Acyloxyalkyl carbamate prodrugs of trans-4-(aminomethyl)-cyclohexanecarboxylic acid, pharmaceutical compositions thereof, methods of making prodrugs of trans-4-(aminomethyl)-cyclohexane-carboxylic acid, and methods of using prodrugs of trans-4-(aminomethyl)-cyclohexanecarboxylic acid and pharmaceutical compositions thereof to treat or prevent various diseases or disorders are disclosed. Acyloxyalkyl carbamate prodrugs of trans-4-(aminomethyl)-cyclohexanecarboxylic acid and pharmaceutical compositions thereof suitable for... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080153900 - Compositions and methods for treating or preventing imflammatory diseases: Methods and compositions for treating or preventing inflammatory diseases such as psoriasis or multiple sclerosis are provided, comprising the step of delivering to the site of inflammation an anti-microtubule agent, or analogue or derivative thereof.... Agent: Seed Intellectual Property Law Group Pllc

20080153899 - Fatty amine drug conjugates: The invention provides conjugates of fatty amines and pharmaceutical agents useful in treating cancer, viruses, psychiatric disorders. Compositions, pharmaceutical preparations, and methods of preparations of the fatty amine-pharmaceutical agent conjugates are provided.... Agent: Wolf Greenfield & Sacks, P.c.

20080153901 - Avermectin/benzoyl peroxide compositions for treating afflictions of the skin, e.g., rosacea: The invention relates to a pharmaceutical composition, especially a dermatological composition, containing, in a physiologically acceptable medium, at least one compound of the avermectin family, and benzoyl peroxide, and also to its use for the manufacture of a medicament for treating skin conditions, especially rosacea.... Agent: Buchanan, Ingersoll & Rooney Pc

20080153902 - Phenyloctanamides: Compounds of the general formula (I) in which the substituents R, R1, R2, R3, R4, R5 and R6 are each as defined in claim 1 have renin-inhibiting properties and can be used as medicaments.... Agent: Wenderoth, Lind & Ponack, L.l.p.

20080153903 - Inhibitors of protein kinase c-delta for the treatment of glaucoma: The present invention relates to methods to treat and/or prevent increased intraocular pressure in a subject by administering a protein kinase C-delta (PKCδ) inhibitor. In further embodiments, the present invention relates to methods to treat and/or prevent glaucoma by administering a PKCδ inhibitor.... Agent: Alcon

20080153904 - Synergistic and residual pesticidal compositions containing plant essential oils with enzyme inhibitors: Synergistic and residual pesticidal compositions containing synergistic and residual mixtures of plant essential oils in admixture with enzyme inhibitors, with or without other compounds not previously used as active ingredients in pesticidal formulations. In addition, the present invention is directed to a method for controlling pests by applying a pesticidally-effective... Agent: Nixon & Vanderhye, Pc

20080153905 - Esters of 2-phenylalkanenitriles and antifungal compositions containing them: Esters of 2-phenylalkanenitriles, such as 3-acetoxy-2-(2-chloro-5-(difluoromethoxy)phenyl)propanenitrile and 3-acetoxy-2-(4-chlorophenyl)propanenitrile, and compositions containing such esters, are useful as fungicides at very low concentrations.... Agent: Leonard P. Miller

20080153906 - Water-soluble phenicol prodrugs in a lipophilic vehicle system: The present invention discloses pharmaceutical compositions containing a suspension of a therapeutically effective amount of a water-soluble prodrug of a phenicol in a lipophilic vehicle system.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080153908 - Method of treating mucin deficiency with an active pharmaceutical and related composition: The present invention includes a method of treating a patient suffering from mucin deficiency comprising administering to an eye of a patient suffering from mucin deficiency, a composition comprising an active pharmaceutical selected from the group consisting of acetate, propionate or butyrate in their salt or acid forms and combinations... Agent: Bausch & Lomb Incorporated

20080153907 - Pharmaceutical composition for the treatment of cancer comprising lhm-ra complex: Provided is a pharmaceutical composition for the treatment of liver cancer, including a layered metal hydroxide-retinoic acid (LMH-RA) hybrid as a novel drug delivery system which shows few side effects of retinoic acid, good drug stability, sustained drug release, and improved drug delivery efficiency.... Agent: Rothwell, Figg, Ernst & Manbeck, P.c.

20080153909 - Compositions and methods for treating eye disorders and conditions: The present invention relates to compositions comprising omega-6 and/or omega-3 fatty acids and uses thereof. The present invention also relates to methods of treatment using such compositions.... Agent: Cozen O'connor, P.c.

20080153910 - Lysine in therapeutic angiogenesis for cardiac and cerebral/neural reperfusion: A method of stimulating angiogenesis in a mammal suffering from heart or cerebral or neural disease, comprising administering to said mammal a therapeutic composition comprising free cationic amino acid lysine or free salt thereof, in an amount that induces cardiac or cerebral or neural reperfusion in the mammal.... Agent: Notaro And Michalos

20080153911 - Antimicrobial agent comprising a cysteine compound covalently bound to a substrate in particular by binding through an s-s bridge via a spacer molecule: The invention relates to an antimicrobial agent where a cysteine compound is covalently bound to a substrate, in particular by binding through an S—S bridge via a spacer molecule to the substrate. The spacer comprises a carbon chain, optionally interrupted by one or more heteroatoms, e.g. O, S, N, P... Agent: Schwegman, Lundberg & Woessner, P.a.

20080153912 - Compositions and methods of their use for improving the condition and appearance of skin: The present invention relates to compositions and methods for treating, preventing and improving the condition and/or aesthetic appearance of skin, particularly, treating, preventing, ameliorating, reducing and/or eliminating fine lines and/or wrinkles of skin, where the compositions include active agents which increase expression levels of genes associated with the dermatological signs... Agent: Avon Products, Inc.

20080153913 - Nutritional supplement and protocol: Particular nutritional supplements and protocols emphasize the use of ethylenediamine tetraacetic acid as a mouth rinse, and as an enteric-coated oral pharmaceutical, further supplemented on a daily basis with both a combination of phosphatidyl lipids and alpha lipoic acid and a nutritional supplement containing approximately equal amounts of Reishi and... Agent: Godbey Griffiths Reiss, Lllp

20080153914 - Injectable preparations of diclofenac and its pharmaceutically acceptable salts: The present invention provides injectable formulations of water-soluble salts of diclofenac in single doses of less than 2 ml, which cause significantly less pain at the site of injection and can be administered by intradeltoid route, in addition to intragluteal and slow intravenous route. More specifically the injectable preparations contain... Agent: Sughrue Mion, Pllc

20080153915 - Pharmaceutical preparation for the oral cavity: e

20080153916 - Use of adamantyl methoxydiphenyl propenoic acid for the treatment of acne: The use of a substance belonging to the class of atypical retinoids for the topical treatment of acne is described. In particular the effects on an animal model for this skin disease of a pharmaceutical or cosmetic compound for topical use containing adamantyl methoxydiphenyl propenoic acid formulated in a gel... Agent: Lucas & Mercanti, LLP

20080153917 - Sigma receptor ligands: The present invention concerns phenylcyclopentylacetamides and phenylcyclopropylcarboxamides and analogues thereof, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080153918 - Modafinil polymorphic forms: Polymorphic forms of modafinil racemate, methods of preparation thereof, pharmaceutical compositions and methods of therapeutic treatment involving modafinil polymorphic forms.... Agent: Woodcock Washburn LLP

20080153919 - Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain: The present invention provides a method of treating fibromyalgia syndrome (FMS), chronic fatigue syndrome (CFS), and pain in an animal subject. The method generally involves administering a therapeutically effective amount of a dual serotonin norepinephrine reuptake inhibitor compound or a pharmaceutically acceptable salt thereof, wherein said dual serotonin norepinephrine reuptake... Agent: Darby & Darby P.c.

20080153920 - Fetal physiology during maternal surgery or diagnosis: The occurrence of hypercapneic acidosis in a fetus during a laparoscopic procedure carried out on a pregnant female, is prevented or ameliorated by inclusion in or addition to the carbon dioxide insufflation gas, of a nitric oxide donor, e.g., ethyl nitrite. Administration of nitric oxide donor in insufflation gas causes... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c Attn: Patent Intake Customer No. 30623

20080153921 - Lycopene formulations for the treatment of atherosclerotic conditions: This invention relates to the use of formulations comprising an amphipathic or lipophilic anti-oxidant, such as lycopene, and a solubilising agent, such as whey protein, in the treatment of atherosclerotic disorders. Methods and materials for the treatment of atherosclerotic disorders using such formulations are provided.... Agent: Nixon & Vanderhye, Pc

20080153922 - Filler, process for producing the same, and cosmetic: i

20080153923 - Methods of manufacturing copolymers with zwitterionic moieties and dihydroxyphenyl moieties and use of same: Copolymers are manufactured to include a zwitterionic monomer (e.g., methacryloyloxyethyl phosphorylcholine monomer), a dihydroxyphenyl derivatized monomer, and optionally one or more additional monomers. The dihydroxyphenyl derivatized monomer gives the copolymers excellent adhesion properties. Optional monomers include a cationic amino monomer, a hydrocarbon monomer, and/or a hydrophilic monomer. The copolymers are... Agent: Workman Nydegger

20080153924 - Rheological additive in the form of a preactivated paste: A specific process for the preparation of this rheological additive, a composition comprising said additive, a process for the preparation of said composition and specific uses, in particular specific coatings obtained from said additive, are also concerned.... Agent: Whyte Hirschboeck Dudek S C

20080153925 - Use of amphiphilic copolymers as solubilising agents: wherein R1 and R2 each independently represent H or CH3, R3 represents a C6-C10-aryl or C7-C12-aralkyl which may be unsubstituted or substituted with one or more C1-C9-alkyl and/or C1-C5-alkoxy substituents, and n represents an integer from 0 to 100; and (ii) at least one second monomer selected from the group... Agent: Connolly Bove Lodge & Hutz, LLP

20080153927 - Alpha-2b receptor agonist and relaxant compositions for treating gastrointestinal motility disorders: Disclosed herein is a pharmaceutical composition comprising a relaxant and an alpha-2B receptor agonist. The composition is effective for treating gastrointestinal motility disorders, and methods of treating such disorders using the composition and compounds comprising it are also disclosed.... Agent: Allergan Inc.

20080153928 - Method for providing and analyzing an animal population having an essentially identical metabolome: The present invention relates to a method for providing an animal population having an essentially identical metabolome comprising compiling an animal population being of essentially the same age, keeping said animal population for a time period sufficient for acclimatization under the following housing conditions: (i) constant temperature, (ii) constant humidity,... Agent: Connolly Bove Lodge & Hutz, LLP

20080153926 - Methods and compositions for modulating mitochondrial alderhyde dehydrogenase-2: The present invention provides screening methods for identifying agents that modulate the activity of mitochondrial aldehyde dehydrogenase-2 (AldDH2), as well as agents identified by the screening methods. The present invention further provides methods of reducing ischemic tissue damage or free-radical induced damage in an organ, the methods generally involving contacting... Agent: Bozicevic, Field & Francis LLP Stanford University Office Of Technology Licensing

20080146488 - Complexed polypeptide and adjuvant for improved vaccines: Attachment of the strongly immunogenic polypeptide to a more weakly immunogenic polypeptide can precipitate and focus a CpG adjuvant to increase in vivo priming of a cytotoxic T-lymphocyte (CTL) response, and thus increase the immunogenicity of the more weakly immunogenic polypeptide. Accordingly, compositions that include a bipartite immunogenic polypeptide are... Agent: Fish & Richardson P.c.

20080146490 - Glp-1 analogue formulations: The present invention relates to compositions forming a low viscosity mixture of: a) at least one neutral diacyl lipid, such as a diacyl glycerol; b) at least one phospholipid, such as a phosphatidyl choline; c) at least one biotolerable solvent, such as an oxygen containing solvent; d) at least one... Agent: Nixon Peabody, LLP

20080146489 - Regional delivery of therapeutic agents for the treatment of vascular diseases: The present invention relates to the regional delivery of therapeutic agents for the treatment of vascular diseases wherein regional delivery refers to delivery of a therapeutically effective amount of the therapeutic agent to an area of the vessel that includes not only afflicted tissue but non-afflicted tissue at the periphery... Agent: Squire, Sanders & Dempsey LLP

20080146491 - Use of calcitonin and calcitonin-like peptides to treat and prevent multiple sclerosis: Methods for treating and preventing multiple sclerosis by administering to a patient an effective amount of calcitonin, calcitonin-like peptides or calcitonin mimetics to a patient. Additionally, 1,25-dihydroxyvitamin D analogs can be used in combination with the calcitonin, calcitonin-like peptides or calcitonin mimetics.... Agent: Quarles & Brady LLP

20080146492 - Insulin production methods and pro-insulin constructs: Novel pro-insulin having specific amino acid and/or nucleic acid modifications suitable for improved methods of insulin production are provided. Novel and highly efficient processes for preparing the pro-insulin preparations and preparations containing them are also disclosed. The novel pro-insulin preparations may be converted into human insulin useful in therapeutic preparations.... Agent: Denise L. Mayfield

20080146493 - Use of haptoglobin and hemoglobin to modulate na ion transport in a vertebrate: The invention provides methods and compositions for increasing Na ion transport and/or epithelial fluid transport in a vertebrate by administering an effective amount of haptoglobin or haptoglobin and hemoglobin. The invention also provides a new therapeutic approach for treating disorders associated with insufficient epithelial Na ion and/or fluid transport, the... Agent: Myers Bigel Sibley & Sajovec

20080146494 - Glycoconjugation methods and proteins/peptides produced by the methods: The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.... Agent: Morgan, Lewis & Bockius LLP (sf)

20080146495 - Methods for treating hiv by inhibiting cd4 down-modulation: The present invention provides methods for inhibiting the ability of HIV genes products to bind to the cytoplasmic domain of a CD4 receptor. This domain is necessary to the ability of the HIV Nef and Vpu gene products to connect the CD4 receptor to cellular degradation pathways. The present invention... Agent: Biotactica, Llc

20080146496 - Novel melanocortin receptor templates, peptides, and use thereof: The present invention relates to novel chimeric peptides and templates containing a combination of antagonist and agonist endogenous ligand residues. In particular, the present invention relates to novel chimeric peptides and templates thereof based upon melanocortin agonist peptides and agouti related protein (AGRP). The present invention provides multifunctional chimeric peptides... Agent: Margaret Efron Saliwanchik, Lloyd & Saliwanchik

20080146497 - Cyclosporin compositions: Disclosed herein are therapeutic methods, compositions, and medicaments related to cyclosporine.... Agent: Allergan, Inc.

20080146505 - 47 human secreted proteins: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20080146503 - Albumin fusion proteins: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080146509 - Compositions for delivering parathyroid hormone and calcitonin: The present invention relates to a composition comprising a delivery agent, parathyroid hormone, and calcitonin. This composition exhibits increased delivery of parathyroid hormone and/or calcitonin and is useful for the treatment of osteoporosis. The composition also permits simultaneous oral delivery of parathyroid hormone and calcitonin. The composition of the present... Agent: Emisphere Technologies, Inc. C/o Darby & Darby P.c.

20080146498 - Diagnostic agent for ischemic heart disease risk group: The present invention relates to a diagnostic agent for an ischemic heart disease risk group comprising an anti-brain-derived neurotrophic factor antibody as an effective ingredient, to an assay method for an ischemic heart disease risk group performed by measuring a brain-derived neurotrophic factor concentration in blood, and to a suppressive/preventive... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080146499 - Identification of the precise amino acid sequence of the epitope recognized by the potent neutralizing human anti-hiv-1 monoclonal antibody igg1b12: The IgG1b12 human monoclonal antibody binds gp120 strongly, and is the most potent HIV neutralizing antibody known. The exact amino acid sequence of this binding site is not known. We identified the minimal terminal peptide parts of the HIV-1 gp120 (envelope) protein, which IgG1b12 binds to. We did this by... Agent: Ade & Company Inc.

20080146507 - Methods and compositions for using mhc class ii invariant chain polypeptide as a receptor for macrophage migration inhibitory factor: Methods and compositions for using the MHC class II invariant chain polypeptide, Ii (also known as CD74), as a receptor for macrophage migration inhibitory factor (MIF), are disclosed. These include methods and compositions for using this receptor, as well as agonists and antagonists of MIF which bind to this receptor,... Agent: Law Office Of John K. Pike, Pllc

20080146504 - Methods for designing and synthesizing directed sequence polymer compositions via the directed expansion of epitope permeability: The instant invention comprises a process for the solid phase synthesis of directed epitope peptide mixtures useful in the modulation of unwanted immune responses, such process defined by a set of rules regarding the identity and the frequency of occurrence of amino acids that substitute a base or native amino... Agent: Ropes & Gray LLP

20080146502 - Methods for modulating the sensation of satiety perception and agents useful for same: The invention relates generally to a method for modulating the sensation of satiety perception and to agents useful for same. Such agents are useful in modulating, controlling or otherwise affecting inter alia obesity, anorexia, weight maintenance, metabolic energy levels and/or inflammatory conditions in a subject. More particularly, the invention identifies... Agent: The Mccallum Law Firm, P. C.

20080146506 - Methods of suppressing microglial activation: Methods of suppressing the activation of microglial cells in the Central Nervous System (CNS), methods of ameliorating or treating the neurological effects of cerebral ischemia or cerebral inflammation, and methods of combating specific diseases that affect the CNS by administering a compound that binds to microglial receptors and prevents or... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20080146501 - Protective complement proteins and age-related macular degeneration: Methods for identifying a subject at risk for developing AMD are disclosed. The methods include identifying specific protective or risk polymorphisms or genotypes from the subject's genetic material. Therapeutic compositions and methods are also provided for delaying the progression or onset of the development of AMD in a subject, including... Agent: Townsend And Townsend And Crew, LLP

20080146500 - Selective vpac2 receptor peptide agonists: The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes.... Agent: Eli Lilly & Company

20080146508 - Soluble cyclic analogues of beta amyloid peptide: The invention concerns a peptide having the biological activity of an inhibitor of amyloid formation and its diagnostic and medical use.... Agent: Dickstein Shapiro LLP

20080146510 - Biologically active peptide vapeehptllteaplnpk derivatives: Peptides derived from the peptide CMS-010, which has the formula VAPEEHPTLLTEAPLNPK, are disclosed with their use as pharmaceutical compositions. A method is also disclosed for making a pharmaceutical composition comprising providing a peptide derived from CMS-010 and mixing said peptide with a pharmaceutical acceptable carrier.... Agent: Eagle Ip Limited

20080146511 - Selection method of peptides, peptides, method and kit of infection identification by mycobacterium leprae, pharmaceutical or immunological compositions containing peptides of mycobacterium leprae or sequences functionally equivalent: The present invention refers to a selection method of peptides, peptides, method and kit for the identification of infections by Mycobacterium leprae, as well as to pharmaceutical and immunological compositions containing as active principle(s), peptide(s) of Mycobacterium leprae or sequences functionally similar to the same one(s).... Agent: Klarquist Sparkman, LLP

20080146512 - Cyclin-dependent kinase inhibitors as targets for opiod growth factor treatment: The present invention provides methods of cell cycle control by administering opioid growth factor (OGF), which activates opioid growth factor receptor (OGFr) signaling. Particularly, the present invention provides a method for monitoring OGF modulation or treatment of a cell proliferation or growth related condition in a subject by assessing the... Agent: Scully Scott Murphy & Presser, Pc

20080146513 - Synthetic ion channels: Provided herein are self-assembling compounds that can form ion channels in lipid bilayers or cell membranes and ion-channel-forming compositions comprising the self-assembling compounds. Also provided are methods of making and using the ion channels formed from a plurality of molecules of the self-assembling compounds. Further, provided are methods of treating... Agent: Jones Day

20080146515 - Crystalline form of 1-(beta-d-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate: A novel crystal form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate, and having favorable characteristics, is characterized by its x-ray powder diffraction pattern and/or by its infra-red spectrum.... Agent: Birch Stewart Kolasch & Birch

20080146514 - Method and compositions for improving pulmonary hypertension: This invention discloses a method and compositions for treatment or prevention of pulmonary hypertension in a mammal. Representative mammals include humans and horses. The invention further relates to supplements especially beneficial in preventing or stopping the progression of pulmonary hypertension. The supplements include ribose and folate. Additional nutrients include omega-3... Agent: Kathleen R. Terry

20080146516 - Novel c-glycosides, uses thereof: The present invention relates to novel C-glycoside compounds of given absolute configuration, to a process for synthesising them and to compositions containing them. The invention also relates to the cosmetic use of these C-glycoside compounds as agents to stimulate the synthesis of glycosaminoglycans containing a D-glucosamine and/or N-acetyl-D-glucosamine residue, advantageously... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080146517 - Indole antiviral compositions and methods: The present invention provides novel chemical compounds, and methods for their use. In particular, the present invention provides indole derivatives (e.g. as shown in Formula (I)) and related compounds and methods of using indole derivatives and related compounds as therapeutic agents to treat a number of conditions, including those associated... Agent: Casimir Jones, S.c.

20080146518 - Cationic lipids for the transfection of nucleic acids: (see formulas (I) and (Ia), wherein E is a heteroaryl; R1 and R2 are selected from H, —R7-NH2, aklyl; R7 is selected from alkyl, alkenyl, aryl, (C1-C20) alkyl-aryl-(C0-C20) alkyl; R3 and R4 are selected from: H, —R8-SH, R8-NH—NH2/—R8-CO—R9 or —R8-NH2; R8 is selected from: alkyl, alkenyl, aryl, (C1-C20) alkyl-aryl-(C0-C20) alkyl;... Agent: Arent Fox LLP

20080146519 - Il-14alpha rna inhibitors and antibodies to il-14alpha for treatment of autoimmune diseases and lymphomas: Provided are antisense poly-2′-O-(2,4-dinitrophenyl)oligoribonucleotides which are complementary to the IL-14α gene and/or transcribed IL-14α mRNA. Also provided are monoclonal antibodies reactive with discreet IL-14α peptides. The oligoribonucleotides and monoclonal antibodies are useful in inhibiting the growth of lymphocytes.... Agent: Hodgson Russ LLP The Guaranty Building

20080146520 - Animal feeds containing polyols: Animal feed compositions which include a polyol are described. Processes for producing an animal feed composition with a polyol are disclosed. Methods of feeding an animal the polyol are also disclosed.... Agent: Kirkpatrick & Lockhart Preston Gates Ellis LLP Henry W. Oliver Building

20080146521 - Adhesive n, o-carboxymethylchitosan coatings which inhibit attachment of substrate-dependent cells and proteins: The present invention relates to a method of inhibiting cellular and protein attachment to substrates by applying a composition containing an effective amount of adherent N,O-carboxymethylchitosan to a substrate with such that cellular and protein attachment are prevented or greatly reduced.... Agent: Edwards Angell Palmer & Dodge LLP

20080146522 - Therapeutic heparins and their binding to interleukins 4 and 5 and pecam-1: The present invention relates generally to chemical agents useful in the prophylaxis and/or treatment of disease conditions and in particular chronic disease conditions such as inflammatory including allergic diseases, metastatic cancers and infection by pathogenic agents including bacteria, viruses or parasites. More particularly, the chemical agents contemplated by the present... Agent: Knobbe Martens Olson & Bear LLP

20080146523 - Imidazole derivatives: e

20080146524 - Selective inhibitors of neurotensin degrading enzymes:

20080146525 - Composition for promoting cognitive attributes: A nutritional composition and method is provided for enhancing cognition, providing nootropic effects to improve concentration in an individual by supporting the biological activity of the neurotransmitters comprising therapeutically effective amounts of Sulbutiamine or derivatives thereof, an effective amount of Huperzine-A or derivatives thereof and an effective amount of Tyrosine... Agent: Torys LLP

20080146526 - Acyloxyalkyl carbamate prodrugs, methods of synthesis and use: Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphinic acid and analogs thereof, methods of making acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphinic acid and analogs thereof, methods of using acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphinic acid and analogs thereof, and pharmaceutical compositions comprising acyloxyalkyl carbamate prodrugs 3-aminopropylphosphinic acid and analogs thereof for treating diseases or disorders... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080146527 - Antibacterial 1-(4-mono- and di-halomethylsulphonylphenyl)-2-acylamino-3-fluoroproponals and preparation thereof: or a pharmaceutically-acceptable salt thereof or a solvate thereof, or prodrug thereof, wherein R1 is CHCl2, CHClF, CHF2, CHBrCl, CH3, CH2N3, CH2CN, CH(R2)NH2 or CH X1X2; where R2 is H, CH3 or CH2OH, and X1 and X2 are independently selected halogens; and R3 is CH2Cl, CH2F, CHF2, CHCl2 or CH2OH... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080146528 - Synthesis of combretastatin a-4 prodrugs and trans-isomers thereof: Combretastatin A-4 has been previously selected for pre-clinical development as antineoplastic agent. However, it is essentially insoluble in water. New water soluble derivatives of combretastatin A-4 and its qualified analogs have been discovered and synthesized through a multistage process using other derivatives of combretastatin A-4 as intermediates. These water soluble... Agent: Fennemore Craig

20080146529 - Skin peeling composition and method: The present invention relates to methods of peeling skin using certain salicylic acid derivatives, to chemical skin peel compositions containing these certain salicylic acid derivatives in a carrier, preferably a dermatologically acceptable carrier, to methods of making these compositions, and methods of applying this certain compound and/or composition to skin... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080146530 - Re-epithelializing pharmaceutical compositions comprising xanthan gum: The present invention relates to the use of xanthan gum as re-epithelializing agent and, in particular, to a pharmaceutical formulation comprising xanthan gum as a re-epithelializing active principle eventually mixed with hyaluronic acid. Said use and composition speed up and improve advantageously the formation of newly grown epithelium.... Agent: Merchant & Gould Pc

20080146531 - Therapeutically active triazoles and their use: Estratrien-triazoles corresponding to formula (I) (shown below) which are useful in therapy, especially for the treatment and/or prevention or inhibition of a steroid hormone dependent disorder, preferably a steroid hormone dependent disease or disorder requiring the inhibition of a 17β-hydroxysteroid dehydrogenase (17β-HSD) such as 17β-HSD type 1, type 2 or... Agent: Crowell & Moring LLP Intellectual Property Group

20080146532 - Drug screening and treatment methods: The invention relates to methods identify or characterize compounds that can be used to treat specified clinical disorders such as hyperglycemia and type 2 diabetes. Compounds that can be used in these methods include 4α-fluoro-17α-ethynylandrost-5-ene-3β, 7β,17β-triol, 4α-fluoro-17α-ethynylandrost-5-ene-3β,7α,17β-triol, 4α-fluoro-17α-ethynylandrost-5-ene-3α,7β,17β-triol and 4α-fluoro-17α-ethynylandrost-5-ene-3β,17β-triol-7-one.... Agent: Hollis-eden Pharmaceuticals, Inc.

20080146533 - Amino ceramide-like compounds and therapeutic methods of use: The present invention provides amino ceramide-like compounds which inhibit glucosyl ceramide (GlyCer) formation by inhibiting the enzyme GlyCer synthase, thereby lowering the level of glycosphingolipids. The compounds of the present invention have improved GlcCer synthase inhibition activity and are therefore useful in therapeutic methods for treating various conditions and diseases... Agent: Hamilton, Brook, Smith & Reynolds, P.c.

20080146534 - Pharmaceutical composition for reducing the risks associated with cardiovascular and cerebrovascular diseases: Methods and compositions enable treating atherosclerosis and atherosclerotic related diseases and/or lowering the risk of developing atherosclerosis related diseases. The composition includes an antilipemic agent combined with a vasodilator and/or an inhibitor of platelet aggregation for treating cardiovascular and cerebrovascular related diseases. In one embodiment, a pharmaceutical composition includes ezetimibe... Agent: Patterson & Sheridan, L.l.p.

20080146535 - Compositions comprising carbacephem beta-lactam antibiotics and beta-lactamase inhibitors: The present invention relates to pharmaceutical compositions of carbocephem antibiotics with β-lactamase inhibitors useful for the treatment of bacterial infections, in particular infections caused by bacteria that express β-lactamases as a mechanism of resistance to β-lactam antibiotics.... Agent: Squire, Sanders & Dempsey L.l.p.

20080146536 - 2-aminoimidazopyridines for treating neurodegenerative diseases: The invention relates to 2-aminoimidazopyridine derivatives useful in treating disorders that are mediated by A2a receptor function, including neurodegenerative diseases including Parkinson's disease and inflammation. The compounds have general formula I:... Agent: Heslin Rothenberg Farley & Mesiti Pc

20080146538 - Compounds 614: The present invention relates to new compounds of formula I, to pharmaceutical compositions comprising said compounds, and to the use of said compounds in therapy. The present invention further relates to processes for the preparation of compounds of formula I.... Agent: White & Case LLP Patent Department

20080146537 - Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors: The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.... Agent: Louis J. Wille Bristol-myers Squibb Company

20080146539 - New carboxylic acid amides, the preparation thereof and their use as medicaments: e

20080146540 - Methods of diagnosis and treatment for asthma, allergic rhinitis and other respiratory diseases based on haplotype association: Methods for diagnosis of asthma or allergic rhinitis or a susceptibility to asthma or allergic rhinitis based on detection of at-risk haplotypes associated with MAP3K9 are disclosed. Also methods for treatment of asthma or allergic rhinitis or a susceptibility to asthma or allergic rhinitis based on detection of at-risk haplotypes... Agent: Hamilton, Brook, Smith & Reynolds, P.c.

20080146541 - Methods for treating or preventing sysmptoms of hormonal variations: A method for treating or preventing symptoms of hormonal variation includes administering an effective amount of a receptor antagonist to a subject having one or more symptoms of hormonal variations, wherein the receptor antagonist binds to at least one selected from the group consisting of a serotonin type 2A (5-HT2A)... Agent: Osha Liang L.l.p.

20080146542 - Hydrazinocarbonyl-thieno[2,3-c]pyrazoles, process for preparing them, compositions containing them and use thereof: m

20080146543 - Angiotensin ii receptor antagonist for the prevention or treatment of systemic diseases in cats: The present invention relates to a method of prophylaxis or treatment of systemic diseases in cats, wherein the method comprising administration of a therapeutically effective amount of angiotensin II receptor 1 (AT-1) antagonist (sartan) to a cat in need of such a treatment.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20080146544 - Lisofylline analogs and methods for use: The present invention provides analogs of a Lysofylline (LSF), and synthetic methods for the preparation of such analogs. The have the active side chain moiety (5-R-hydroxyhexyl) of LSF and can have greater potency and oral bioavailability than LSF.... Agent: Iplm Group, P.a.

20080146545 - Macrocyclic compounds useful as inhibitors of kinases and hsp90: Disclosed are macrocyclic compounds of formulae I-V, which are analogs of the pochonin resorcylic acid lactones, and processes for the preparation of the compounds. The compounds disclosed are useful as inhibitors of kinases and Heat Shock Protein 90 (HSP 90). Also disclosed are pharmaceutical compositions comprising an effective kinase-inhibiting amount... Agent: King & Spalding LLP

20080146546 - Bicyclic and tricyclic heteroaromatic compounds: and the pharmaceutically acceptable salts thereof, wherein W, Q, X, X1, Y and Z are as defined herein. These compounds bind with high selectivity and/or high affinity to the benzodiazepine site of GABAA receptors and are therefore useful in the treatment of central nervous system (CNS) diseases and as probes... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080146547 - Phthalazine derivatives: The present invention relates to novel phthalazine derivatives and, more particularly, to phthalazine derivatives that are useful as protein kinase inhibitors. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and methods of treatment using the compounds.... Agent: Forest Laboratories, Inc. Attn: Charles S. Ryan

20080146548 - Amide, aryl sulfonamide, aryl urea, and a,b-diketone derived carboxylesterase inhibitors, and their methods of use: This disclosure relates to amides, aryl sulphonamides, aryl ureas, and α,β-diketones derivatives useful as carboxylesterase esterase inhibitors. The disclosure is also directed to the use of these compounds as selective human intestinal carboxylesterase inhibitors and insect carboxylesterase inhibitors. The disclosure is also directed to pharmaceutical compositions and pesticide formulations containing... Agent: St. Jude Children''s Research Hospital C/o Darby & Darby P.c.

20080146549 - Accelerated opiate dependence detoxification process: The present invention provides accelerated detoxification methods for the treatment of a substance abuse-related condition in a subject. A method of the present invention may comprise administering to the subject an effective amount of at least one sedative (e.g, clonidine, diazepam, or olanzapine) and a micro-dose of an opioid antagonist... Agent: Troutman Sanders LLP

20080146550 - Heteroarylacetamide inhibitors of factor xa: e

20080146551 - Antibacterial agents: Naphthyridine and related derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed herein.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080146552 - Anthranilamide derivatives as insecticides: Compounds of formula (I) wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts and all stereoisomers and tautomeric forms of the compounds of formula (I) can be used as agrochemical active ingredients and can be prepared in a manner known per se.... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20080146553 - Antibiotic compostions and methods for using same: Compositions including a quinolone component in an amount effective as an antibiotic when the composition is placed in a mammalian eye, and a carrier component in an amount effective to act as a carrier for the quinolone component are provided. The present compositions are substantially free of other components effective... Agent: Stout, Uxa, Buyan & Mullins LLP

20080146554 - Substituted cycloalkyl derivatives, process for the manufacture thereof and use thereof as medicament: m

20080146555 - Uses of kinase inhibitors and compositions thereof: The invention pertains to inhibitors of various kinases (e.g. S/T kinases, Tyr kinases, etc.), which inhibitors are previously known as cyclin dependent kinase inhibitors (CDKs). As described herein, the inhibitors of this invention are capable of inhibiting various wild-type and mutant form kinases, including drug resistant forms of mutant kinases.... Agent: Ropes & Gray LLP

20080146557 - Indol-3-yl-carbonyl-spiro-piperidine derivatives as via receptor antagonists: wherein the spiro-piperidine head group A and the residues R1, R2 and R3 are as defined herein. The invention further relates to pharmaceutical compositions containing such compounds, methods for preparing the compounds and pharmaceutical compositions, and their use in the treatment of dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of... Agent: Hoffmann-la Roche Inc. Patent Law Department

20080146556 - Method of radio-sensitizing tumors using a radio-sensitizing agent: e

20080146559 - 4,5,6,7-tetrahydro-thieno [2,3-c] pyridine derivatives:

20080146558 - 4,5,6,7-tetrahydro-thieno [3,2-c] pyridine derivatives:

20080146560 - 4-amino-5-oxo-8-phenyl-5h-pyrido(2,3-d) pyrimidine derivatives as tyrosine kinase and raf kinase inhibitors for the treatment of tumours: Compounds of the formula (I), in which R6, R7, R8, R9, Het1, X and X′ have the meanings indicated in claim 1, are inhibitors of tyrosine kinases, in particular TIE-2, and Raf kinases and can be employed, inter alia, for the treatment of tumours... Agent: Baker & Daniels LLP

20080146561 - Certain chemical entities, compositions and methods: Provided are certain chemical entities, and methods of use to modulate skeletal myosin, skeletal actin, skeletal tropomyosin, skeletal troponin C, skeletal troponin I, skeletal troponin T, and skeletal muscle, including fragments and isoforms thereof, as well as the skeletal sarcomere, and methods of use in the treatment of obesity, sarcopenia,... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080146564 - 1,3-dihydro-benzimidazol-2-ylidene amines as inhibitors of respiratory syncytial virus replication: wherein R6 is hydrogen, C1-6alkyl, substituted C1-6alkyl; R7, R8, R9 are halo, cyano, C1-6alkyl, substituted C1-6alkyl, C2-6alkenyl, cyanoC2-6alkenyl, C2-6alkynyl, cyanoC2 6alkynyl, Ar1, R10a—0—, R10a —S—, —N(R5aR5b), R10a—O—C(═O)—, N(R5aR5b)—C(═O)—, R10a—C(═O)—NR5b1', R10b—C(═O)—O—; and R8 and/or R9 may also be hydrogen; which are RSV inhibitors. Compositions containing these compounds and processes for preparing... Agent: Philip S. Johnson Johnson & Johnson

20080146563 - 1,7-naphthyridines as pde4 inhibitors: wherein R1 is selected from the group consisting of C1-4alkyl, C4-6cycloalkyl(CH2)m—, methoxyC2-4alkyl, HOCH2CH2—, R3(O)2S(CH2)2—, R5R4NCO(CH2)n—, and heterocyclyl(CH2)m— wherein any nitrogen heteroatom of the heterocyclyl radical may be unsubstituted or substituted by methyl; R2 is hydrogen or methyl; R3 is methyl or NH2; R4-5 independently represent methyl, m is 0, 1... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20080146562 - Halogenated quinazolinyl nitrofurans as antibacterial agents: The invention also includes pharmaceutically acceptable formulations of said compounds which exhibit antibiotic activity against a wide spectrum of microorganisms including organisms which are resistant to multiple antibiotic families and are useful as antibacterial agents for treatment or prophylaxis of bacterial infections, or their use as antiseptics, agents for sterilization... Agent: Klarquist Sparkman, LLP

20080146565 - Jnk modulators: e

20080146566 - Amide derivatives: The invention concerns a compound of the Formula I (A chemical formula should be inserted here—please see paper copy enclosed herewith) wherein m is 0-2 and each R1 is a group such as hydroxy, halogeno, trifluoromethyl heterocyclyl and heterocyclyloxy; R2 is halogeno, trifluoromethyl or (1-6C)alkyl; R3 is hydrogen, halogeno or... Agent: Morgan Lewis & Bockius LLP

20080146567 - Quinolines: and pharmaceutically-acceptable acid-addition salts thereof, wherein R1, R2 and X are as defined in the specification. The compounds may be used as 5-HT5A receptor antagonists. The present invention relates also to processes for making such a compound and a pharmaceutical composition comprising such a compound. Compounds of the present invention... Agent: Hoffmann-la Roche Inc. Patent Law Department

20080146568 - Spiro-piperidine derivatives: d

20080146569 - Nicotinamide derivatives:

20080146570 - Chemical compounds: The invention relates to chemical compounds, or pharmaceutically acceptable salts thereof, of the formula (I): which possess B-Raf inhibitory activity and are accordingly useful for their anti-cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of... Agent: Astrazeneca R&d Boston

20080146572 - N-sulfonylurea apoptosis promoters: e

20080146571 - O-linked pyrimidin-4-amine-based compounds, compositions comprising them, and methods of their use to treat cancer: O-linked pyrimidin-4-amine-based compounds, pharmaceutical compositions comprising them, and methods of their use are described. Particular compounds of the invention are of formula I:... Agent: Lexicon Pharmaceuticals, Inc.

20080146573 - Preparation and utility of substituted oxzolidinones: Disclosed herein are substituted oxazolidinones of Formula I, processes of preparation thereof, pharmaceutical compositions thereof, and the methods of their use thereof.... Agent: Global Patent Group - Apx Ms. Lavern Hall

20080146574 - Heterocycle substituted carboxylic acids: Compounds of the invention include inhibitors of Protein tyrosine phosphatases, in particular Protein tyrosine phosphatase-1B (PTP-1B), that are useful in the treatment of diabetes and other PTP mediated diseases, such as cancer, neurodegenerative diseases and the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080146576 - N-(1-phthalazin-1-ylpiperidin-4-yl)amides as ep2 receptor modulators: The present invention relates to phthalazin-1-ylpiperidin-4-ylamides of the general formula I, to processes for their preparation and to their use for producing pharmaceutical compositions for treatment of disorders and indications connected to the EP2 receptor.... Agent: Millen, White, Zelano & Branigan, P.c.

20080146575 - Phthalazinone derivatives: 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one as crystalline Form A.... Agent: Michael Best & Friedrich LLP

20080146578 - Indolylmaleimide derivatives: Provided are compounds of Formula (I), which are useful in the treatment and/or prevention of diseases or disorders mediated by T lymphocytes and/or PKC, e.g. acute or chronic rejection of organ or tissue allo- or xenografts, graft versus host diseases, atherosclerosis, vascular occlusion due to vascular injury such as angioplasty,... Agent: Novartis Corporate Intellectual Property

20080146577 - Methods and compositions for the treatment of attention deficit hyperactivity disorder and hyperphenylalanemia: Disclosed is a composition that includes a tetrahydrobiopterin in a controlled-release pharmaceutical preparation. Also disclosed is a method of treating a patient with phenylketonuria that includes administering, to the patient, a composition that contains tetrahydrobiopterin in a controlled-release pharmaceutical preparation. Also disclosed is a method of treating a patient with... Agent: Marshall, Gerstein & Borun LLP

20080146580 - Anititumoral ecteinascidin derivatives: This invention relates to antitumoral ecteinascidin derivatives.... Agent: Fish & Richardson Pc

20080146579 - Treatment of patients with chronic pulmonary diseases and nutritional compositions therefore: The invention pertains to a method and compositions for treatment or prevention of chronic pulmonary dysfunction in a patient.... Agent: Foley And Lardner LLP Suite 500

20080146581 - Solubility of hydrophobic drugs with a compound having a carboxylic acid moiety: A pharmaceutical composition having improved solubility comprising a hydrophobic drug or pharmaceutically acceptable salt thereof and a compound having at least one carboxylic acid moiety, wherein the molar ratio of the compound having at least one carboxylic acid moiety to the hydrophobic drug or pharmaceutically acceptable salt thereof is from... Agent: Sandoz

20080146582 - Diazabicyclic aryl derivatives and their use as chinolinergic ligands at the nicotinic acetylcholine receptors: This invention relates to novel diazabicyclic aryl derivatives which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse... Agent: Birch Stewart Kolasch & Birch

20080146583 - Treatment of incontinence: The present invention relates to the use of agonists of 5-HT2C receptors for the treatment of urinary incontinence, preferably mixed incontinence or stress urinary incontinence. The invention also relates to the use of antagonists of 5-HT2C receptors for the treatment of urine retention. The present invention also relates to a... Agent: Pfizer Inc.

20080146584 - Method of treating cancers using beta-lapachone or analogs or derivatives thereof: Cancers and/or malignancies can be treated by administration of a cell cycle checkpoint activator, which is preferably β-lapachone, or a derivative or analog thereof, combined with an oncogenic kinase modulator, preferably imatinib. This combination of the cell cycle checkpoint activator with the oncogenic kinase modulator results in an unexpectedly greater... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c Attn: Patent Intake Customer No. 30623

20080146586 - Dicarbonyl derivatives and methods of use: Derivatives of dicarbonyl compounds having antitumor and antibiotic activity which can be used as anticancer agents.... Agent: Leydig Voit & Mayer, Ltd

20080146585 - Use of c-kit inhibitors for treating inflammatory muscle disorders including myositis and muscular dystrophy: The present invention relates to a method for treating inflammatory muscle disorders including myositis and muscular dystrophy comprising administering a compound capable of depleting mast cells or a compound inhibiting mast cell degranulation, to a human in need of such treatment. Such compounds can be chosen from c-kit inhibitors and... Agent: Foley And Lardner LLP Suite 500

20080146587 - Indole and benzofuran 2-carboxamide derivatives and uses thereof: e

20080146589 - Chromenone derivatives:

20080146588 - Piperidinyl piperidine tachykinin receptor antagonists: The present invention is directed to certain piperidine compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in... Agent: Merck And Co., Inc

20080146590 - P38 map kinase inhibitors and methods for using the same: e

20080146591 - Novel pharmaceutical dosage forms comprising valganciclovir hydrochloride: The present invention provides novel solid pharmaceutical dosage forms for oral administration, after being constituted in water. The solid dosage forms comprise a therapeutically effective amount of valganciclovir hydrochloride and a non-hygroscopic organic acid present in an amount sufficient to stabilize the valganciclovir hydrochloride in a predetermined amount of water.... Agent: Hoffmann-la Roche Inc. Patent Law Department

20080146592 - Method of treating preeclampsia employing metolazone: A method of treating preeclampsia includes administering to a patient a therapeutically effective dose of metolazone. The dose is less than a diuretic dose. The treatment is effected without adverse on the fetus and without substantial volume reduction of intravascular extracellular fluid... Agent: Eckert Seamans Cherin & Mellott

20080146593 - Substituted 5-phenyl pyrimidines i in therapy: The present invention relates to substituted 5-phenyl pyrimidines I, which carry a radical X in the 4-position of the pyrimidine ring, a radical Y in the 6-position of the pyrimidine ring, the radical X denoting a group of the formula NR1R2, OR1a or SR1a, in which R1, R2, independently of... Agent: Connolly Bove Lodge & Hutz, LLP

20080146594 - Thrombopoietin activity modulating compounds and methods: e

20080146595 - Non-nucleoside reverse transcriptase inhibitors: The present invention provides for compounds useful for treating an HIV infection, or preventing an HIV infection, or treating AIDS or ARC. The compounds of the invention are of formula I wherein R1, R2, R3, R4, R5a, R5b, R6a, R6b and X are as herein defined. Also disclosed in the... Agent: Roche Palo Alto Llc Patent Law Dept. M/s A2-250

20080146596 - (r)-phenyl(heterocycle)methanol-based compounds, compositions comprising them and methods of their use: Multicyclic compounds, pharmaceutical compositions comprising them, and methods of their use are described. Compounds described include those of formula I:... Agent: Lexicon Pharmaceuticals, Inc.

20080146598 - Combinatorial drug therapy using polymer-drug conjugates: The present invention discloses combinations of drug conjugates with other therapeutic agents, including chemotherapy drugs. The invention also provides methods of using the combinations for the treatment of diseases associated with cell proliferation, such as tumors.... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20080146597 - Therapeutic tetrahydroisoquinoline-based compositions for cancer therapy: Disclosed are therapeutic tetrahydroisoquinoline compositions for the treatment of cancer, these compositions having selectivity for cancer cells while demonstrating few, if any, deleterious side effects on normal cells.... Agent: Donna J. Russell

20080146600 - (s)-phenyl(heterocycle)methanol-based compounds, compositions comprising them and methods of their use: Multicyclic compounds, pharmaceutical compositions comprising them, and methods of their use are described. Compounds described include those of formula I:... Agent: Lexicon Pharmaceuticals, Inc.

20080146599 - Pyrimidine compounds having tie-2 (tek) inhibitory activity: The invention relates to a compound of the Formula (I) or salt, prodrug or solvate thereof, wherein Rx, Ry, Rz, R5, R6, A, B, L, n and m are as defined in the description. The invention also relates to pharmaceutical compositions of said compounds, the use of said compounds as... Agent: Astrazeneca R&d Boston

20080146601 - Method for making analgesics: Improved analgesic oxymorphone hydrochloride contains less than 10 ppm of alpha, beta unsaturated ketones and pharmaceutical preparations comprising such oxymorphone hydrochloride. The oxymorphone hydrochloride is produced by reducing a starting material oxymorphone hydrochloride using gaseous hydrogen and under specified acidity, solvent system and temperature conditions. A specific polymorph of oxymorphone... Agent: Ratnerprestia

20080146603 - Combinations comprising antimuscarinic agents and beta-adrenergic agonists: Combinations comprising (a) a β2 agonist and (b) an antagonist of M3 muscarinic receptors which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid are useful, e.g., for the treatment of respiratory disease, e.g., asthma... Agent: Hoxie & Associates Llc

20080146602 - Thienopyridine derivatives, production method and use thereof: wherein R is a hydrogen atom or a C1-4 alkyl group, and X is CH2, O or S, or a salt thereof. The present invention provides a novel thienopyridine derivative having an anti-inflammatory effect, a bone resorption suppressing effect, an immune cytokine production suppressing effect and the like, and useful... Agent: Edwards Angell Palmer & Dodge LLP

20080146604 - Triazolo-quinolin derivatives useful as adenosine receptor ligands: The present invention relates to adenosine A3 receptor ligands of the general formula (I), within those preferably antagonists, as well as their salts, solvates and isomers, and the pharmaceutical compositions containing them, to the use of the compounds of the general formula (I), as well as their salts, solvates and... Agent: Andrea Q. Ryan Sanofi-aventis U.s. Llc

20080146605 - Preparation and utility of ccr5 inhibitors: Disclosed herein are substituted 8-azabicyclo[3.2.1]octane-based anti-infective agents of Formula I, processes of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Global Patent Group - Apx Ms. Lavern Hall

20080146608 - Derivatives of 5-pyridinyl-1-azabicyclo[3.2.1]octane, preparation method thereof and use of same in therapeutics: s

20080146607 - Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives and uses thereof:

20080146606 - Novel compounds:

20080146609 - Substituted thienopyridone compounds with antibacterial activity: Novel bicyclic heteroaromatic compounds are provided that are inhibitors of bacterial methionyl tRNA synthetase (MetRS). Compounds of the invention generally have a left hand side chroman group or left hand side tetrahydroquinoline group and a right hand side thienopyridone group. Also disclosed are methods for their preparation and their use... Agent: Swanson & Bratschun, L.l.c.

20080146610 - Isotopically substituted proton pump inhibitors: v

20080146611 - Compounds for modulating trpv3 function: The present application relates to compounds and methods for treating pain and other conditions related to TRPV3.... Agent: Ropes & Gray LLP

20080146612 - Novel biaromatic compounds, inhibitors of the p2x7-receptor: The invention provides compounds of formula (I), or a pharmaceutically acceptable salt thereof, wherein Ar1 represents a group (II), (III), (IV) or (V), and A, Ar2, n, R1, R2, R3, R4 and R5 are as defined in the specification; a process for their preparation; pharmaceutical compositions containing them; and their... Agent: Fish & Richardson P.c.

20080146613 - Piperidine-amino-benzimidazole derivatives as inhibitors of respiratory syncytial virus replication: their prodrugs, N-oxides, addition salts, quaternary amines, metal complexes and stereochemically isomeric forms wherein Q is C1-6alkyl optionally substituted with trifluoromethyl, C3-7cycloalkyl, Ar2, hydroxy, C1-4alkoxy, C1-4alkylthio, Ar2-oxy-, Ar2-thio-, Ar2(CH2)noxy, Ar2(CH2)nthio, hydroxycarbonyl, aminocarbonyl, C1-4alkyl-carbonyl, Ar2-carbonyl, C1-4alkoxycarbonyl, Ar2(CH2)ncarbonyl, aminocarbonyloxy, C1-4alkylcarbonyloxy, Ar2-carbonyloxy, Ar2(CH2)ncarbonyloxy, C1-4alkoxy-carbonyl(CH2)noxy, mono- or di(C1-4alkyl)aminocarbonyl, mono- or di(C1-4alkyl)-aminocarbonyloxy, aminosulfonyl, mono- or... Agent: Philip S. Johnson Johnson & Johnson

20080146614 - Therapeutic agents: The present invention relates to 1,5-diphenylpyrazole compounds of formula I (A chemical formula should be inserted here—please see paper copy enclosed herewith) and processes for preparing such compounds, their use in the treatment of obesity, psychiatric and neurological disorders, to methods for their therapeutic use and to pharmaceutical compositions containing... Agent: Morgan Lewis & Bockius LLP

20080146615 - Pharmaceutical compositions comprising amorphous benzimidazole compounds: Compositions comprising amorphous substituted benzimidazole compounds.... Agent: Dr. Reddy's Laboratories, Inc.

20080146616 - Indoles useful in the treatment of inflammation: There is provided a compound of formula (I), wherein X, R1, R2, R3, R4, R5 and R6 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of microsomal prostaglandin E synthase-1 is desired and/or... Agent: Morgan Lewis & Bockius LLP

20080146617 - Methods of treating inflammatory diseases: Methods relating to selective inhibitors of the casein kinase 1 isoforms that are useful for the treatment of inflammatory diseases are presented.... Agent: Roche Palo Alto Llc Patent Law Dept. M/s A2-250

20080146618 - Ca ix-specific inhibitors: t

20080146619 - Certain chemical entities, compositions, and methods: Chemical entities that modulate smooth muscle myosin and/or non-muscle myosin, and chemical entities, pharmaceutical compositions and methods of treatment of diseases and conditions associated with smooth muscle myosin and/or non-muscle myosin are described.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080146620 - Dibenzylamine compounds and pharmaceutical use thereof: wherein R1 and R2 are each a C1-6 allyl group optionally substituted by halogen atoms and the like; R3, R4 and R5 are each a hydrogen atom, a halogen atom and the like, or R3 and R4 may form, together with carbon atoms bonded thereto, a homocyclic or heterocyclic ring... Agent: Leydig Voit & Mayer, Ltd

20080146621 - Polysubstituted 1,1-pyridylaminocyclopropanamine compounds: e

20080146623 - Inhibitors of histone deacetylase and prodrugs thereof: The invention relates to the inhibition of histone deacetylase. The invention provides compounds, prodrugs thereof, and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080146622 - Use of substituted 2-aminotetralins for preventive treatment of parkinson's disease: e

20080146624 - Amidines as modulators of indoleamine 2,3-dioxygenase: The present invention is directed to amidino heterocyclic compounds which are modulators of indoleamine 2,3-dioxygenase (IDO), as well as compositions and pharmaceutical methods thereof.... Agent: Fish & Richardson Pc

20080146625 - Oxime glucokinase activators: e

20080146627 - Derivatives of heterocycles with 5 members, their preparation and their use as medicaments:

20080146626 - Use of epothilones in the treatment of osteoporosis and related diseases: The present invention relates to the use of natural or synthetic Epothilones for the treatment prevention or alleviation of diseases caused by a dysbalance of osteoclast and osteoblast activity, especially osteoporosis.... Agent: Millen, White, Zelano & Branigan, P.c.

20080146628 - Pramipexole for the treatment of adhd: A method for prevention and/or treatment of ADHD in a patient in need thereof, the method comprising administering to the patient an effective amount of 2-amino-4,5,6,7-tetrahydro-6-n-propylaminobenzothiazole or a pharmacologically acceptable acid addition salt, hydrate, or solvate thereof.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20080146629 - Novel thiazolidin-4-one derivatives: The invention relates to pharmaceutical compositions containing at least one thiazolidin-4-one derivative to prevent or treat disorders associated with an activated immune system. Furthermore, the invention relates to novel thiazolidin-4-one derivatives notably for use as pharmaceutically active compounds. Said compounds particularly act also as immunosuppressive agents.... Agent: Dickstein Shapiro LLP

20080146630 - Crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol: The present invention is directed to an anhydrate crystal form (designated as Form E herein) of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol, an estrogenic receptor modulator useful in the treatment of, for example, diseases related to abnormal levels of estrogen.... Agent: Pepper Hamilton LLP/wyeth

20080146631 - Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists: Compounds represented by the following structural formula (I), and pharmaceutically acceptable salts, solvates and hydrates thereof, wherein R1 is an unsubstituted or substituted aryl, heteroaryl, cycloalkyl, aryl-alkyl, heteroaryl-alkyl or cycloalkyl-alkyl, R2 is H, alkyl or haloalkyl, the polymethylene chain (II), is saturated or may contain a carbon-carbon double bond, while... Agent: Eli Lilly & Company

20080146632 - Fc receptor modulating compounds and compositions: The present invention provides compounds capable of binding to an Fc receptor and modulating Fc receptor activity comprising a core lipophilic group in the form of an Aryl zing substituted with a group rich in p-electrons. The invention further provides for a method of treating an autoimmune disease involving Fc... Agent: Sheridan Ross Pc

20080146633 - Compositions for skin lightening and toning down pigment disorders, comprising creatinine and/or creatinine derivatives as active substances: e

20080146635 - 2-((2-thioxo-2,3-dihydro-1h-imidazol-4-yl)methyl)-3,4-dihydronaphthalen-1(2h)-one:

20080146634 - 2-imidazoles:

20080146637 - Benzimidazole trpv1 inhibitors:

20080146638 - Combination therapy with parp inhibitors: The present invention describes benzimidazole derivatives of Formula (I) which constitute potent PARP inhibitors in combination with radiotherapy or in combination with other chemotherapeutic agents.... Agent: Paul D. Yasger Abbott Laboratories

20080146636 - Diaminocycloalkane mch receptor antagonists: e

20080146639 - Pharmaceutical combination of angiotensin ii antagonists and angiotensin i converting enzyme inhibitors: A method of treatment of indications which can be positively influenced by inhibition of AT1 mediated effects with maintenance of AT2 receptor mediated effects of angiotensin II and by ACE inhibition, thus also increasing bradykinin mediated effects, e.g., to reduce the incidence of stroke, acute myocardial infarction or cardiovascular death,... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20080146640 - Water-soluble prodrugs of chloramphenicol, thiamphenicol, and analogs thereof: The present invention discloses certain novel prodrugs of chloramphenicol or thiamphenicol, or of an analog of either, including prodrugs of pharmaceutically acceptable salts of chloramphenicol or thiamphenicol or of their analogs, including nitrogen-containing esters of both alcohol groups of such compounds. In certain embodiments these novel prodrugs are sufficiently water-soluble... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080146641 - Antibacterial composition: Antibacterial compositions containing either a calcium oxide.α-amino acid chelate compound or a calcium hydroxide.α-amino acid chelate compound or both of them. The compositions contain a high concentration of antibacterial calcium oxide, calcium hydroxide, or a mixture of both, and moreover, a water solution thereof exhibits a low degree of pH.... Agent: Dickstein Shapiro LLP

20080146642 - Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid: The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compounds that will yield or generate 3APS, either in vitro or in vivo. Preferred compounds include amino acid prodrugs of 3APS for use, including but not... Agent: Millen, White, Zelano & Branigan Pc

20080146643 - Combination: Compounds of formula (I) are used in combination with a second antiparasitic agent for the treatment of parasitic infestations in a host animal.... Agent: Pharmacia & Upjohn

20080146644 - Tricyclic cytoprotective compounds: [in which: X is a group of formula >CR1R2 or >SO2; Y is a group of formula >NH or >CR1R2; Z is a group of formula >C═O or >CH2 or a direct bond; R1 is hydrogen and R2 is hydrogen, carboxy or hydroxy; or R1 and R2 together represent an... Agent: Greenlee Winner And Sullivan P C

20080146645 - Process for preparing indolinone phenylaminopropanol derivatives: n

20080146647 - Acetylene derivatives having mglur 5 antagonistic activity:

20080146646 - N-(heteroaryl)-1-heteroarylalkyl-1h-indole-2-carboxamide derivatives, preparation and therapeutic use thereof:

20080146648 - Methods for treating or preventing metastatic cancer using benzopyranone compounds:

20080146649 - Substituted pyrrolidine and related compounds: wherein R1-R5 and a-e are as defined in the specification; or pharmaceutically-acceptable salt or solvate or stereoisomer thereof. The invention also directed to pharmaceutical compositions containing such compounds; processes and intermediates useful for preparing such compounds; and methods for treating disease conditions mediated by muscarinic receptors using such compounds.... Agent: Theravance, Inc.

20080146650 - Pharmaceutical composition comprising a-lipoic acid for inflammatory diseases: The present invention relates to a pharmaceutical composition containing α-lipoic acid (LA) as an active ingredient. α-lipoic acid is an inhibitor of fractalkine expression, and exhibits effects of alleviating inflammation due to endotoxemia by decreasing expression of fractalkine and attachment of endothelial cells to monocytes in endothelial cells of an... Agent: Birch Stewart Kolasch & Birch

20080146651 - Injectable composition for the treatment of cancers: Disclosed herein is an injectable composition for the treatment of cancers comprising a poorly water-soluble anti-cancer drug, and glycofurol and Solutol HS15 as solubilizer, of the anticancer drug.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080146652 - Micellar drug delivery vehicles and precursors thereto and uses thereof: Anhydrous formulations are formed of a diblock copolymer (X-Y) having a hydrophilic block X comprising residues of monomer x, and a hydrophobic block Y comprising residues of monomer y; an additive selected from a polymer and an organic solvent, where the solvent is water-miscible and biocompatible, and the polymer is... Agent: Seed Intellectual Property Law Group Pllc

20080146653 - Synergistic anti-cancer compositions: The present invention provides compositions useful in treating cancer. The compositions include a synergistic combination of an antineoplastic thiol-binding mitochondrial oxidant with an antineoplastic nucleic acid binding agent, an antineoplastic antimetabolite base analog, or docetaxel. Also provided are methods of assaying the synergistic effects of the combinations and methods of... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080146654 - Motilide polymorphs: The invention provides polymorphs of a motilide having a structure represented by formula Ia... Agent: Foley And Lardner LLP Suite 500

20080146655 - Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dyfunction diseases: Provided is a pharmaceutical composition for the treatment and prevention of obesity, diabetes, metabolic syndromes, degenerative diseases and mitochondrial dysfunction-related diseases, comprising: a therapeutically effective amount of a compound represented by Formula I below, or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, and a pharmaceutically acceptable carrier, a... Agent: Cantor Colburn, LLP

20080146656 - Use of a steroid sulphatase inhibitor for inhibiting the synthesis of androstenedione and/or testosterone: There is provided use of a compound capable of inhibiting a steroid sulphatase enzyme (E.C.3.1.6.2) in the manufacture of a medicament for inhibiting in vivo synthesis of at least one of androstenedione and testosterone, which may be useful for the treatment of hirsutism, excess sebum production, benign breast disease, benign... Agent: Frommer Lawrence & Haug

20080146658 - Compounds and methods for treating estrogen receptor-related diseases: Provided herein in certain embodiments are compounds, pharmaceutical compositions and methods for modulating the functions of estrogen receptor alpha 36, for preventing and/or treating diseases related to estrogen receptor alpha 36, for preventing and/or treating respiratory diseases such as asthma, for inducing cell death and/or inhibiting cell proliferation and for... Agent: Perkins Coie LLP

20080146657 - Plant-origin alpha3-adrenoceptor agonist and use of the same: The present inventors produced lotus leaf extracts, and discovered that quercetin is one of the active ingredients. As a result of treating β3-adrenergic receptor-expressing cells and feeding diabetes model mice with quercetin and evaluating its effects, the present inventors discovered specifically that quercetin produces obesity-improving effects and antidiabetic effects by... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080146659 - Hypoglycemic agent, hepatoprotecting agent and anticancer agent containing lignans derived from hongdoushan: Drugs containing Taxiresinol, (7′R)-7′-Hydroxylariciresinol, Secoisolariciresinol and Isotaxiresinol, which are lignans contained in Hongdoushan, as the active ingredients. Drugs containing an extract, which is obtained by extracting a Hongdoushan plant with water and further extracting the obtained extract with an organic solvent, as the active ingredient. These drugs are useful particularly... Agent: Westerman, Hattori, Daniels & Adrian, LLP

20080146660 - Novel curcumin analogues and uses thereof: The present invention relates to compounds capable of acting as androgen receptor antagonists, pharmaceutical formulations containing the same, and methods of use thereof. Such uses include, but are not limited to, use as antitumor agents, particularly for the treatment of cancers such as colon, skin and prostate cancer and to... Agent: Myers Bigel Sibley & Sajovec

20080146661 - Substituted arylamino -1,2,3,4-tetrahydro naphthalenes and -2,3-dihydro-1h-indenes as potassium channel modulators: e

20080146662 - Methods and compositions for treatment of cancer pain: The invention provides a method of treating cancer pain, e.g. bone cancer pain, in a subject in need of such treatment which comprises administering to the subject an effective amount of a COX-2 inhibitor; advantageously a compound of formula (I); wherein R, R1, R2, R3, R4, and R5 are as... Agent: Novartis Corporate Intellectual Property

20080146663 - Compositions and methods for the treatment of renal and cardiovascular disease: Derivative compounds of 11-nonyloxy-undec-8(Z)-eonic acid that mimic epoxide metabolites are provided. Also provided are compositions comprising a therapeutically effective amount of the derivative compounds. The present invention further provides methods for the use of such compositions for the treatment of renal or cardiovascular disease and/or related conditions.... Agent: Sutherland Asbill & Brennan LLP

20080146664 - Method for treating diseases caused by accumulation of body fat: According to the present invention, there is provided a method of treating diseases caused by the accumulation of body fat, comprising the step of administering a therapeutically effective amount of punicic acid or its ester to a mammal or fish.... Agent: Wenderoth, Lind & Ponack, L.l.p.

20080146665 - Synergistically heat stable oil media having eicosa pentanoic acid (epa) and docosa hexaenoic acid (dha): A synergistically heat stable therapeutically active triglyceride and cholesterol controlling oil composition including the usually highly unsaturated Eicosa Pentaenoic Acid (EPA) and Docosa Hexaenoic Acid (DHA). The invention avoids limitations of presently available impure sources of EPA/DHA such as fish oil, algae and the like and provides for a synergistically... Agent: Neifeld Ip Law, Pc

20080146666 - Method of treatment of skin: A method for treating a region of skin. An amount of at least one photolabile compound or a compound converted into a photolabile compound when present in the skin is applied to the region of skin. The photolabile compound generates a biologically active agent when in the skin and the... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080146667 - Method of treatment of skin: A method for treating a region of skin. An amount of at least one photolabile compound or a compound converted into a photolabile compound when present in the skin is applied to the region of skin. The photolabile compound generates a biologically active agent when in the skin and the... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080146668 - Method for stimulating weight loss and/or for lowering triglycerides in patients: Administration of a therapeutically effective amount of 3,5-diiodothyropropionic acid stimulates weight loss in patients, lowers triglyceride levels and reduces risk of death or progression of coronary heart disease in patients with metabolic syndrome.... Agent: Morrison & Foerster LLP

20080146669 - Novel chloride channel pore openers: Described is a method for treating and/or preventing disease states and conditions associated with defects in the activity of chloride channels, such as the CFTR channel. The present disclosure also described compounds useful in such treatment and prevention methods and methods for the identification of compounds for use in such... Agent: Bradley Arant Rose & White, LLP Intellectual Property Department-nwj

20080146670 - Guanylhydrazone salts, compositions, processes of making, and methods of using: The invention relates to pharmaceutically acceptable salts of guanylhydrazone-containing compounds, for example, Semapimod. The invention also relates to pharmaceutically acceptable compositions comprising the salts and methods for their use.... Agent: Law Office Of John K. Pike, Pllc

20080146671 - Microemulsion preconcentrate comprising a renin inhibitor: The present invention relates to pharmaceutical compositions for oral administration comprising a δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amide renin inhibitors as the active ingredient. In particular, the present invention relates to galenic formulations in the form of microemulsion preconcentrates comprising the active ingredient and at least one absorption enhancing excipient which preconcentrates provide... Agent: Novartis Corporate Intellectual Property

20080146672 - Topical eutectic anesthetic composition for oral or dermal tissue: A pharmaceutical anesthetic composition for topical administration for dental, emergency and general medical use is described. The composition is a eutectic composition of anesthetic agents, sugar alcohol, and menthol for the purpose of numbing oral or dermal tissue. Methods of making and of using the composition are described.... Agent: Kammer Browning Pllc

20080146673 - Pentafluorosulfanylbenzoylguanidines, process for their preparation, use as a medicament or diagnostic aid, and medicament comprising same: wherein R1 to R4 have the meanings stated in the claims, are suitable, for example, as antiarrhythmic medicaments with a cardioprotective component for the prophylaxis of infarction and treatment of infarction and for the treatment of angina pectoris. They also inhibit preventively the pathophysiological processes associated with the development of... Agent: Andrea Q. Ryan Sanofi-aventis U.s. Llc

20080146674 - Use of gentian violet in treatment of atopic dermatitis: A composition and method for treating a skin problem, particularly atopic dermatitis, the composition comprising an antiseptic dye, preferably gentian violet, in a vehicle effective for topical administration.... Agent: Pearne & Gordon LLP

20080146675 - Stable atomoxetine hydrochloride, a process for the preparation thereof, and an analytical control of its stability: Stable Atomoxetine hydrochloride, a process for the manufacture thereof, the use of stable Atomoxetine Hydrochloride for making a pharmaceutical formulation, a process for the preparation of any form of Atomoxetine Hydrochloride, and an analytical method for analyzing the stability of Atomoxetine Hydrochloride are provided.... Agent: Kenyon & Kenyon LLP

20080146676 - Tannate salt of rasagiline: The subject invention provides rasagiline tannate, compositions and a process for manufacture thereof.... Agent: Cooper & Dunham, LLP

20080146677 - Method and article of manufacture for encapsulating a homeopathic ingredient with a second ingredient: An apparatus, system, and method are disclosed for encapsulating a homeopathic ingredient with a second ingredient. A homeopathic carrier is prepared by applying the homeopathic ingredient to at least one element. The element is selected from the second ingredient, an excipient, and a capsule assembly. The second ingredient is encapsulated... Agent: Kunzler & Mckenzie

20080146678 - O/w emulsion composition: The present invention provides an O/W emulsion composition which stimulates little when used on the skin, is safe, can be preserved stably over a long period of time and has excellent feel when used by adding 40 wt % or less of a specific oil component relative to the total... Agent: Sughrue Mion, Pllc

20080146679 - Methods of therapeutic treatment of eyes and other human tissues using an oxygen-enriched solution: Particular embodiments disclosed herein relate to electrokinetically altered gas-enriched fluids, methods of making the same, systems for making the same and/or methods of treatment utilizing the gas-enriched fluids for eye related conditions and/or diseases. In certain embodiments, the electrokinetically altered gas-enriched fluid is oxygen-enriched water. Certain embodiments relate to cosmetic... Agent: Davis Wright Tremaine, LLP/seattle

20080139450 - Antimicrobial compositions and uses thereof: The present invention includes compositions for preventing growth and proliferation of biofilm embedded microorganisms comprising: (a) a cationic polypeptide and (b) a bis-guanide or a salt thereof. The invention further provides methods for preparing objects with such compositions, and objects and consumables (such as household cleaners) comprising such compositions.... Agent: Merchant & Gould Pc

20080139451 - Compositions for treating ocular surface pathologies: The invention concerns compositions and methods for treating and/or preventing ocular pathologies. The invention also concerns compositions and methods enabling the regulation of paracellular permeability of the ocular epithelium. The compositions and methods of the invention are based in particular on the use of agents or conditions modulating the opening... Agent: Nixon & Vanderhye, Pc

20080139454 - Method for stabilizing polypeptides lacking methionine: Methionine is an effective antioxidant for polypeptides having an amino acid sequence lacking methionine. Compositions containing polypeptides having an amino acid sequence that is free of methionine residues are stabilized from oxidative degradation by combining methionine in the composition in an amount effective to inhibit oxidation of the polypeptide.... Agent: Howard Eisenberg, Esq.

20080139453 - Multiple emulsion compositions: The present invention relates to an O/W/O emulsion comprising; a) an external oil phase which comprises an emulsifying crosslinked siloxane elastomer and a solvent for the emulsifying crosslinked siloxane elastomer; and b) an O/W type primary emulsion which comprises an internal oil phase dispersed in an aqueous phase dispersed in... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080139452 - Secreted proteins and polynucleotides encoding them: Novel polynucleotides and the proteins encoded thereby are disclosed.... Agent: Fitzpatrick Cella Harper & Scinto

20080139449 - X-ray structure of human fpps and use for selecting fpps binding compounds: The present invention relates to crystalline human farnesyl diphosphate synthase (FPPS), to the three-dimensional structure of free FPPS as well as the three-dimensional structures of FPPS in complex with substrates such as IPP (isopentenyl diphosphate) and/or with inhibitors such as Zometa® or Aredia®. Further, methods for preparing crystals of human... Agent: Novartis Corporate Intellectual Property

20080139455 - Compounds and methods of treating metabolic syndrome and inflammation: Novel compounds, compositions comprising compounds, and methods for preparing and using compounds are described herein. Methods of treating or ameliorating various conditions, including insulin resistance, pancreatic beta cell apoptosis, obesity, pro-thrombotic conditions, myocardial infarction, hypertension, dyslipidemia, manifestations of Syndrome X, congestive heart failure, inflammatory disease of the cardiovascular system, atherosclerosis,... Agent: Kirton And Mcconkie

20080139456 - Macrocyclic sh2 domain binding inhibitors: Disclosed are compounds for inhibiting the binding of an SH2 domain-containing protein, for example, a compound of formula (I): FORMULA (I) wherein R1 is a lipophile; R2, in combination with the phenyl ring, is a phenylphosphate mimic group or a protected phenylphosphate mimic group; R3 is, for example, hydrogen, azido,... Agent: Leydig, Voit & Mayer, Ltd.

20080139460 - Binding agents for cd44 glycoproteins and methods of use: Thus, the present invention concerns the use of an active agent for achieving a therapeutic effect on a target cell, the therapeutic effect comprises binding of said active agent to a standard CD44 (CD44std) glycoprotein or to a CD44 variant (CD44v) expressed by said target cell, the active agent being... Agent: Martin D. Moynihan Prtsi, Inc.

20080139459 - Conjugates a polypeptide and a pentasaccharide: The present invention relates to conjugates of a polypeptide and an oligosaccharide, wherein the polypeptide is conjugated to at least one oligosaccharide-spacer residue, the oligosaccharide being a synthetic sulfated oligosaccharide comprising 4-18 monosaccharide units and per se having affinity to antithrombin III and the spacer being a bond or an... Agent: Organon Usa, Inc. Patent Department

20080139458 - Methods of treatment for injured or diseased joints: The invention features pharmaceutical compositions that include lubricin, a compound that inhibits an enzyme selected from the group consisting of neutrophil elastase, cathepsin B, cathepsin K, cathepsin L, cathepsin S, papain, trypsin, chymotrypsin, subtilisin, pepsin, bromelain, ficin, Protease A, Protease B, Protease D, granzyme A, granzyme B, granzyme K, pepsin,... Agent: Clark & Elbing LLP

20080139457 - Therapeutic compositions comprising chorionic gonadotropins and hmg coa reductase inhibitors: The invention provides improved methods and compositions for the treatment of cancer in a subject comprising administering to said subject a therapeutically effective amount of a composition comprising a chorionic gonadotropin or a therapeutically active fragment or analogue thereof in combination with an HMG CoA reductase inhibitor. The compositions and... Agent: Marshall, Gerstein & Borun LLP

20080139461 - Peptidomimetic compounds and preparation of biologically active derivatives: The invention relates to novel cyclic peptidomimetic compounds containing the sequence RGD for the preparation of appropriately functionalised antagonists of αvβ3 and αvβ5 integrins, and intended, for example, for the treatment of altered angiogenic phenomena or for the preparation of diagnostically useful compounds.... Agent: Nixon & Vanderhye, Pc

20080139462 - Treatment of membrane-associated diseases and disorders using lantibiotic containing compositions: Compositions useful for treating membrane-associated diseases, conditions, and disorders, including inflammatory diseases, dry mouth, primary ciliary dyskinesia and platelet aggregating disorders, are disclosed which comprise at least one lantibiotic compound. Also disclosed are pharmaceutical compositions and methods of treatment for membrane-associated diseases such as inflammation and dermal irritation, as well... Agent: King & Spalding LLP

20080139463 - Use of [d-meala]3-[etval]4-cyclosporin for the treatment of hepatitis c infection and pharmaceutical composition comprising said [d-meala]3-[etval]4-cyclosporin: This invention relates to the use in the treatment of HCV infection, either as single active agents or in combination with another active agent, of a cyclosporin having increased cyclophilin binding activity and essentially lacking immunosuppressive activity.... Agent: Nixon & Vanderhye, Pc

20080139476 - Caspase-8 interacting proteins: There are provided polypeptides which bind to caspase-8. Production and use of such polypeptides is also provided, as well as DNA encoding them, and vectors and host cells having such DNA.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080139471 - Compositions and methods to prevent cancer with cupredoxins: The present invention relates to compositions comprising peptides that may be variants, derivatives and structural equivalents of cupredoxins that inhibit the development of premalignant lesions in mammalian cells, tissues and animals. Specifically, these compositions may comprise azurin from Pseudomonas aeruginosa, and/or the 50-77 residue region of azurin (p28). The present... Agent: Don J. Pelto Sheppard, Mullin, Richter & Hampton LLP

20080139466 - Dna sequence and expressed recombinant glycoproteins related to feline thyrotropin: Amino acid sequences of feline thyrotropin and polynucleotide sequences encoding feline thyrotropin are provided, as well as methods of making and using said sequences.... Agent: Mueting, Raasch & Gebhardt, P.a.

20080139470 - Erythropoietin compositions: Methods and materials are provided for the production of compositions of erythropoietin protein, wherein said compositions comprise a pre-selected N-linked glycosylation pattern as the predominant N-glycoform.... Agent: Merck And Co., Inc

20080139475 - Inhibition of atf2 activity to treat cancer: The present invention relates to novel therapies for cancer and, in particular, to therapies that are particularly suited to tumor cells resistant to other types of therapies such as radiation, chemotherapy, or combinations of both approaches. The invention provides methods for identifying and implementing strategies to inhibit a transcription factor... Agent: Darby & Darby P.c.

20080139464 - Isolated ny-eso-1 peptides which bind to hla class ii molecules and uses thereof: The invention relates to peptides which consist of amino acid sequences found in the NY-ESO-1 molecule, which bind to MHC-Class II molecules. These can be used alone, or in combination with other peptides.... Agent: Norman D Hanson Fulbright & Jaworski

20080139473 - Kallikrein-inhibitor therapies: Methods are described for preventing or reducing ischemia, e.g., cerebral ischemia, and/or reperfusion injury, e.g., reperfusion injury associated with cerebral ischemia, in a patient.... Agent: Fish & Richardson Pc

20080139465 - Large scale preparation of alpha-1 proteinase inhibitor and use thereof: A process suitable for processing scaled-up amounts of source material in the range of tens of kilograms for the purification of alpha-1 proteinase inhibitor (API) from a mixture of unpurified proteins is provided. More particularly, a process for the purification of API from blood plasma or from plasma fractions to... Agent: Heslin Rothenberg Farley & Mesiti Pc

20080139467 - Method and products for the selective degradation of proteins: The present invention provides a method of controlling levels/concentrations of a target moiety. The method of the present invention includes introducing into a cell a product comprising at least one of each of the following modules: a targeting module, a destruction module and a replacement module. The method further comprises... Agent: Myers Bigel Sibley & Sajovec

20080139468 - Method for control of invasion and use of adiponectin: Physical condition under stress can be controlled by using adiponectin in blood as a stress marker and measuring a level thereof. Moreover, endotoxin activity can be inhibited by using adiponectin.... Agent: Nixon & Vanderhye, Pc

20080139477 - Method for producing, in yeast, a hydroxylated triple helical protein, and yeast host cells useful in said method: The invention relates to a method for producing hydroxylated triple helical proteins in yeast host cells by introducing to a suitable yeast host cell, DNA sequences encoding the triple helical protein as well as prolyl 4-hydroxylase (PH4), in a manner wherein the introduced DNA sequences are replicated, stably retained and... Agent: Sughrue Mion, Pllc

20080139474 - Recombinant bone morphogenetic protein heterodimers, compositions and methods of use: The present invention relates to methods for producing recombinant heterodimeric BMP proteins useful in the field of treating bone defects, healing bone injury and in wound healing in general. The invention also relates to the recombinant heterodimers and compositions containing them.... Agent: Wyeth/finnegan Henderson, LLP

20080139469 - Therapeutic agent for hair-related problems and method for screening for the same: e

20080139472 - Upregulating bdnf levels to mitigate mental retardation: This invention provides methods of preserving, improving, or restoring cognitive function in mammal having one or more mutations in the FMR1 gene (e.g. at risk for or having fragile x syndrome), where the methods involve the brain derived neurotrophic factor (BDNF) level or activity in the brain of said mammal.... Agent: Beyer Weaver LLP

20080139479 - Bladder tumor-targeting peptide and use thereof: The present invention relates to a bladder tumor-targeting peptide and use thereof. More particularly, the present invention relates to a bladder tumor-targeting peptide having an amino acid sequence represented by SEQ ID NO: 7 and use thereof. The peptide according to the present invention is capable of specific binding to... Agent: Buchanan, Ingersoll & Rooney Pc

20080139478 - Il-10 related peptides for wound healing: The present invention relates to the use of a peptide, or derivative thereof of general formula X1-X2-X3-ThT-X4-LyS-X5-ATg-X6 for promoting accelerated wound healing with reduced scarring. X1 is Ala or Gly; X2 is Tyr or Phe; X3, X4 and X5 are independently selected from the group comprising Met, He, Leu and... Agent: Nixon & Vanderhye, Pc

20080139480 - Combination of (a) n--4-(3- pyridyl)-2-pyrimidine-amine and (b) at least one hypusination inhibitor and the usethereof: The invention relates to a method of treating a warm-blooded animal, especially a human, having a proliferative disease comprising administering to the animal a combination which comprises (a) N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and (b) at least one hypusination inhibitor, to a combination comprising (a) and (b) as defined above and optionally at least... Agent: Novartis Corporate Intellectual Property

20080139481 - Non-natural amino acids: This invention relates to non-natural desamino alkyl amino acid compounds, methods of making, and peptides containing these compounds as their N-terminus moieties. A preferred example is neurotensin (8-13) in which the N terminus is an alpha desamino, alpha methyl N,N dimethyl homolysine residue.... Agent: Drinker Biddle & Reath LLP One Logan Square

20080139482 - Intermediate duration neuromuscular blocking agents and antagonists thereof: The invention provides novel neuromuscular blocking agents, methods of using the neuromuscular blocking agents as well as reagents, methods and kits for reversing the effects of the neuromuscular blocking agents.... Agent: Schwegman, Lundberg & Woessner, P.a.

20080139483 - Drug combination for hypertensive disorders: Therapeutic combinations and pharmaceutical compositions are provided comprising ambrisentan and an inhibitor of renin activity or release. Such combinations and compositions are useful to treat hypertensive disorders, particularly pulmonary hypertension conditions such as pulmonary arterial hypertension, to prevent cardiovascular adverse events related thereto, to enhance pulmonary function and to extend... Agent: Harness, Dickey, & Pierce, P.l.c

20080139484 - 1(beta-d-glycopyranosyl)-3-substituted nitrogenous heterocyclic compound, medicinal composition containing the same, and medicinal use thereof: A compound having SGLT1 and/or SGLT2 inhibitory activity which is usable as an agent for the prevention or treatment of diabetes, postprandial hyperglycemia, impaired glucose tolerance, diabetic complications, obesity, etc. It is a 1-(β-D-glycopyranosyl)-3-substituted nitrogen-containing heterocyclic compound represented by the general formula (I), a prodrug, or a pharmaceutically acceptable salt... Agent: Sughrue Mion, Pllc

20080139485 - Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells: The invention provides therapeutic methods and compositions for the prevention and treatment of Siglec-8 associated diseases and disorders such as asthma and allergic reactions. In particular, the invention provides methods and compositions for the prevention and treatment of diseases and disorders associated with Siglec-8 expressing cells in humans, as well... Agent: Edwards Angell Palmer & Dodge LLP Client: Jhu

20080139486 - Flavonol-based medicine for treating and/or preventing endoprosthetic restenosis and atheromatous disease in coronary patients: The invention concerns a composition for implementing a preventive therapeutic treatment method against restenosis, characterized in that it comprises 60 to 80 wt. % of compounds of the flavonol family. The composition is useful for implementing a preventive therapeutic treatment method against restenosis and atheromatous disease in coronary patients.... Agent: Young & Thompson

20080139488 - Compositions comprising avermectin/azelaic acid compounds useful for treating, e.g., rosacea: Pharmaceutical/dermatological compositions useful for the prevention/treatment of disorders of the skin, especially rosacea, contain thus effective amounts of at least one avermectin compound, e.g., ivermectin, and at least one azelaic acid compound or salt or derivative thereof, formulated into a physiologically acceptable medium therefor.... Agent: Buchanan, Ingersoll & Rooney Pc

20080139487 - Stable needle-shaped crystals of natamycin: The present invention describes natamycin comprising needle shaped crystals.... Agent: Nixon & Vanderhye, Pc

20080139489 - Use of ketolides for preventing arterial thrombotic complications related to atherosclerosis: The invention relates to a novel therapeutic application of ketolides. The invention relates to the use of ketolides for the preparation of pharmaceutical compositions intended for preventing arterial thrombotic complications associated with atherosclerosis.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. Llc

20080139490 - Crystalline forms of valrubicin and processes for their preparation: Provided are polymorphic forms of valrubicin and processes for their preparation.... Agent: Kenyon & Kenyon LLP

20080139493 - Bi- or tetra-guanidino-biphenyl compounds as small molecule carriers: o

20080139492 - Compositions and methods that enhance rna interference: The invention features nucleobase oligomeric compositions useful in enhancing RNA interference in a wide variety of cell types for the treatment of virtually any disease or disorder related to the overexpression of a gene or genes, as well as methods of identifying and using such compositions.... Agent: Clark & Elbing LLP

20080139491 - Method for investigating cytosine methylation in dna sequences by means of triplex-forming oligomers: A method is described for the investigation of cytosine methylation in DNA sequences. Triplex-forming oligomers are utilized, which preferably form triplex structures at positions where cytosine unmethylated at position 5 is present. The triplexes block the transcription, replication and amplification of the DNA. In particular, peptide nucleic acid oligomers with... Agent: Kriegsman & Kriegsman

20080139494 - Methods of inducing mucosal immunity: Methods of inducing mucosal immunity in individuals against proteins and peptides are disclosed. The methods comprise the step of administering topically or by lavage into mucosal tissue selected from the group consisting of rectal, vaginal, urethral, sublingual and buccal, a nucleic acid molecule that comprises a nucleotide sequence that encodes... Agent: Pepper Hamilton LLP

20080139496 - Combination therapy for reduction of toxicity of chemotherapeutic agents: There are provided compositions, pharmaceuticals formulations and kits for treating neoplasms and tumours, viral infections, bacterial infections or parasite infections. There are also provided compositions, pharmaceutical formulations and kits for suppression of immune response rejection in tissue transplantation. Also provided are methods of treating such conditions.... Agent: Burr & Brown

20080139495 - Pharmaceutical composition of antiviral agents: e

20080139497 - Use of atp in controlled regional reperfusion as treatment during acute myocardial infarction: The invention is a method for controlled regional reperfusion using ATP-MgCl2 after percutaneous coronary revascularization for acute myocardial infarction, the method comprising the step of administering an effective amount of ATP-MgCl2 to the step of administering an effective amount of ATP-MgCl2 to the infarct-related vessel(s), such as at a dosage... Agent: Roger A. Gilcrest

20080139498 - Agents containing folic acid, vitamin b6 and vitamin b12, and the use thereof: (EN) The invention relates to agents that contain folic acid, vitamin B6 and vitamin B12. and to the use thereof in hyperhomocysteinemia for controlling homocysteine levels. The agents are mainly suitable for the preventive and acute treatment of vascular diseases, of pregnant women and neurodegenerative diseases and are particularly advantageous... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080139499 - Beta-serum dairy products, neutral lipid-depleted and/or polar lipid-enriched dairy products, and processes for their production: Processes for producing dairy products having lower levels of neutral lipids, and/or higher levels of polar lipids, by extraction using near critical carbon dioxide or dimethyl ether. These products may be used as ingredients in infant formulas. Infant formulas containing beta-serum are also claimed. “Beta-serum” means an aqueous dairy ingredient... Agent: Knobbe Martens Olson & Bear LLP

20080139501 - Hyaluronic acid linked with a polymer of an alpha hydroxy acid: The invention concerns a product comprising hyaluronic acid or a salt thereof, wherein the hyaluronic acid has been partially or fully linked or crosslinked with a polymer of an alpha hydroxy acid. The invention also concerns manufacture of the product, uses of the product of the invention in the field... Agent: Novozymes North America, Inc.

20080139502 - Re-epithelializing pharmaceutical compositions comprising xanthan gum: The present invention relates to the use of xanthan gum as re-epithelializing agent and, in particular, to a pharmaceutical formulation comprising xanthan gum as a re-epithelializing active principle eventually mixed with hyaluronic acid. Said use and composition speed up and improve advantageously the formation of newly grown epithelium.... Agent: Merchant & Gould Pc

20080139500 - Use of composite monomer or monomers, catalyst, sodium hyaluronate or hyaluronic acid, glucosamide sulfate, chondroiten sulfate or chlorides, for the treatment of osteoarthritis by intraarticular application to a hip or knee joint: This invention relates to the methods of treatment of osteoarthritis of the hip or knee joint by intraarticular application of a mixture of certain monomer or monomers, catalyst, sodium hyaluronate, glucosamine sulfate, and chondroiten sulfate.... Agent: Isadore Elliott Goldberg

20080139503 - Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect: i

20080139504 - Method for improving the fertility of animals: This invention is in the field of animal food, in particular food for female animals in their reproductive phase. Food according to the invention improves the fertility of animals and increases their chances on a pregnancy. It was found that the fertility of animals may be improved by feeding the... Agent: Nixon & Vanderhye, Pc

20080139506 - Fungicidal compositions and their applications in agriculture: Fungicidal compositions are provided that comprise a silthiofam-type fungicide and a fungicide that is selected from the group consisting of diazole fungicides, triazole fungicides and strobilurin type fungicides. Combinations of fluquinconazole and simeconazole or azoxystrobin, and simeconazole and azoxystrobin are also provided. Methods for treating plants and plant propagation materials... Agent: Charles E. Dunlap

20080139507 - Method of treating skin condition including acne, skin aging, body odor & diaper rash by zinc zeolite clathrates: The present invention discloses a method of treating skin conditions that include acne, skin wrinkles, age spots, pimples, scars, skin rash including diaper rash, dry skin, scalp dandruff, scalp dry skin, darkened skin, skin discoloration, broken skin, chafed skin, sunburn, skin damage from UV, skin irritation, body odor, or a... Agent: Shyam K. Gupta Bioderm Research

20080139505 - Potentiators of glutamate receptors: The present invention provides compounds of formula (I): pharmaceutical compositions thereof, and methods of using the same, processes or preparing the same, and intermediates thereof.... Agent: Eli Lilly & Company

20080139508 - Ibandronate sodium propylene glycol solvate and processes for the preparation thereof: A novel form of Ibandronate sodium which is particularly suitable for pharmaceutical applications, and a process for preparing said novel form.... Agent: Ivor M. Hughes, Barrister & Solicitor, Patent & Trademark Agents

20080139509 - Pancratistatin cyclic phosphate prodrugs and phenpanstatin cyclic phosphate prodrugs: Selective phosphorylation of phenpanstatin (3a) with tetrabutylammonium dihydrogen phosphate and dicyclohexylcarbodiimide in pyridine followed by cation exchange chromatographic procedures was found to provide an efficient route to a new series (3b-3d) of promising 3,4-O-cyclic phosphate prodrugs designated phenpanstatin phosphates. Application of analogous reaction conditions to pancratistatin (1a) led to a... Agent: Fennemore Craig

20080139511 - Combination therapies employing ace inhibitors and uses thereof for the treatment of diabetic disorders: The present invention includes use of an angiotensin-converting enzyme (ACE) inhibitor in combination with a vitamin B6 related compound for the treatment of diabetes and diabetic related disorders and in particular the treatment of diabetic hypertension.... Agent: Merchant & Gould Pc

20080139510 - Treatment of migraine headaches with sublingual amino acids: The invention relates to compositions and methods for treating, or managing the acute pain of a classic migraine headache through the combined-sublingual administration-of therapeutically effective amounts of amino acids, and vitamin cofactors. By bypassing gut metabolism common through conventional oral administration, bio-active nutrients are transfered directly to the central nervous... Agent: Abe Rose

20080139512 - Method for minimizing or avoiding adverse effects of vesicants: The invention pertains to compositions and methods to treat the adverse effects of mustard chemicals and other toxic compounds, such as chemical warfare agents, exposure to which normally induces vesicating type response in mammals. In a rodent eye model at fixed concentrations of such a vesicant, compositions comprising a matrix... Agent: Elman Technology Law, P.c.

20080139514 - Diphosphonic acid pharmaceutical compositions: Solid pharmaceutical compositions comprising a diphosphonic acid or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, enantiomer or racemic mixture thereof. The invention includes compositions with inner and outer phases, wherein the inner phase comprises no more than about 80% w/w and the outer phase comprises at least about 20% w/w.... Agent: Dr. Reddy's Laboratories, Inc.

20080139513 - Transdermal deliver of active agents: A composition for transdermal delivery of a non-traditional active agent is described. The compositions comprise: (a) a non-traditional transdermal active agent; (b) a solvent; (c) a non-miscible liquid; (d) a stabilizer; and (e) water, wherein the composition is formulated into an emulsion.... Agent: Foley And Lardner LLP Suite 500

20080139515 - Stable amifostine liquid concentrate: A storage stable aqueous solution of amifostine at a pH of at least 10.0, in an amifostine concentration of about 50 to about 250 mg/l, which formulation is storage stable under refrigerated conditions.... Agent: Irving M. Fishman C/o Cohen, Tauber, Spievack & Wagner

20080139516 - Intestinal polyp inhibitor: s

20080139517 - Methods of treating age associated memory impairment (aami), mild cognitive impairment (mci), and dementias with cell cycle inhibitors: Therapeutic methods for treatment of age associated memory impairment (AAMI), mild cognitive impairment (MCI), Alzheimer's disease (AD), cerebrovascular dementia (CVD), and related neurodegenerative conditions by administering an agent capable of inhibiting cell cycle progression, comprising administering one or more agents that are capable of inhibiting neuronal cell cycle progression at... Agent: Klauber & Jackson

20080139518 - Topical compositions for treatment of skin conditions: The invention provides a topical formulation adapted for treatment of a skin condition comprising (i) at least one retinoid; and (ii) salicylic acid or an ester, amide, salt, or solvate thereof. The invention also includes a kit for treatment of skin conditions comprising a retinoid and salicylic acid, as well... Agent: Alston & Bird LLP

20080139519 - Heat sterilization of glucocorticosteroids: The present invention provides a method for the sterilization of a labile glucocorticosteroid, which method comprises heat-treating by moist heat the labile glucocorticosteroid in the form of a suspension for a sterilizing-effective time. The methods and compositions according to the invention are useful as therapeutic tools to prevent, reverse, and/or... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20080139520 - Altering cholesterol and fat uptake by novel allosteric inhibitors of pancreatic phospholipase a2: Disclosed herein are methods for regulation of fat and/or cholesterol uptake from the gastrointestinal tract and/or regulation of plasma fat and/or cholesterol levels comprising administering to a mammal in need thereof an effective amount of a regulator of pancreatic IB PLA2 functionality. Also disclosed herein are methods of regulating the... Agent: Potter Anderson & Corroon LLP Attn: Kathleen W. Geiger, Esq.

20080139521 - Use of megestrol acetate for improving heart function and the treatment of heart insufficiency: The present invention relates to improving the heart function, the survival and/or the treatment of heart insufficiency using megestrol acetate (Megace®; MA) in patients with heart insufficiency and after a myocardial infarction.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080139522 - Re-epithelializing pharmaceutical compositions comprising xanthan gum: The present invention relates to the use of xanthan gum as re-epithelializing agent and, in particular, to a pharmaceutical formulation comprising xanthan gum as a re-epithelializing active principle eventually mixed with hyaluronic acid. Said use and composition speed up and improve advantageously the formation of newly grown epithelium.... Agent: Merchant & Gould Pc

20080139523 - Oxime-containing macrocyclic acyl guanidines as beta-secretase inhibitors: wherein R1, R2, R3, R4, n and X as defined herein, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein (APP) by β-secretase and, more specifically, inhibit the production of Aβ-peptide. The present disclosure is directed to compounds useful in the treatment... Agent: Louis J. Wille Bristol-myers Squibb Company

20080139525 - Antioxidant therapies: The invention relates, in part, to methods of treatment of inflammatory, autoimmune, vascular and cardiovascular conditions with a combination of a superoxide dismutase (SOD) mimetic and a selenium (Se) compound. The invention also relates to compositions comprising a SOD mimetic(s) and a Se compound.... Agent: Wolf Greenfield & Sacks, P.c.

20080139524 - Pharmaceutical formulation comprising a metaloporphyrin and method for its purification and use: Pharmaceutical formulation for the prophylaxis, pretreatment and treatment of a poisoning caused by exposure to (either singly or as a mixture of agents) organophosphorus cholinesterase inhibitors, vesicating agents, polycyclic aromatic hydrocarbons, and aflatoxin B1. This invention is characterized by active substance comprised of a metaloporphyrin molecule with an associated metal... Agent: Klarquist Sparkman, LLP

20080139526 - Modified release dosage forms of amoxicillin: An amoxicillin product comprising: at least one modified release component(s), wherein the at least one modified release component(s) comprises at least amoxicillin and a pharmaceutically acceptable carrier; and wherein the product exhibits a mean in-vitro dissolution profile within a defined range characterized as follows: 1) the percent dissolved at 0.25... Agent: Raymond E. Stauffer, Esq. C/o Carella, Byrne, Bain, Gifillan, Cecchi,

20080139527 - Methods for treatment of heart disease: Methods relate to preventing, limiting and/or reversing coronary heart disease, such as heart disease caused by atherosclerosis. These methods for cardiac wellness include administration of therapeutically effective amounts of cholesterol altering medications to a patient in combination with a restricted diet intake of the patient such that the patient attains... Agent: Patterson & Sheridan, L.l.p.

20080139528 - Cefdinir oral suspension: The present invention discloses a novel powder for oral suspension of cefdinir. Also disclosed are methods of preparing the suspension and methods of treatment using the suspension.... Agent: Paul D. Yasger Abbott Laboratories

20080139529 - Benzoxapzepine derivatives and their use as ampa receptor stimulators: The present invention relates to benzoxazepine derivative having the general formula I, wherein X represents CO or S02; R1, R2, R3 and R4 are independently selected from H, (C1-4)alkyl, (C1-4)alkyloxy, (C1-4)alkyloxy(C1-4)alkyl, halogen, nitro, cyano, NR8R9, NR8COR10, and CONR8R9, R5, R6 and R7 are independently H or (C1-4)alkyl; R8 and R9... Agent: Organon Usa, Inc. Patent Department

20080139530 - 7-aryl 1,5-dihydro-4,1-benzoxazepin-2(3h)-one derivatives and their use as progesterone receptor modulators: e

20080139531 - Use of connective tissue mast cell stabilizers to facilitate ocular surface re-epithelization and wound repair: Disclosed are methods of treating a wound in a subject that involve administering to the subject a pharmaceutically effective amount of a composition that includes one or more human connective tissue mast cell stabilizers, wherein administration of the composition results in treatment of the wound. In particular embodiments, the wound... Agent: Alcon

20080139532 - Tetrahydrobenzazepine derivatives as modulators of dopamine d3 receptors (antipsychotic agents): The present invention relates to novel compounds of formula (I) or a pharmaceutically acceptable salt thereof, processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as modulators of dopamine D3 receptors, e.g. as agents to treat various aspects drug dependency or... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080139533 - Substituted 4-imidazoles: e

20080139534 - Bisbenzamidines and bisbenzamidoximes for the treatment of human african trypanosomiasis: Disclosed are bisbenzamidine and bisbenzamidoxime compounds useful for treatment of treatment of trypanosomiasis. The compounds disclosed are useful for treating mammals infected with parasitic hemoflagellates, in particular Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense.... Agent: Adams And Reese LLP

20080139535 - Inhibitors of histone deacetylase: Disclosed are compounds which inhibit histone deacetylase (HDAC) enzymatic activity. Also disclosed are pharmaceutical compositions comprising such compounds as well as methods to treat conditions, particularly proliferative conditions, mediated at least in part by HDAC.... Agent: King & Spalding LLP

20080139536 - Benzodiazepines for treating or preventing rsv infection: Use of a compound which is (a) a benzodiazepine derivative of the formula (I) or an N-oxide thereof or (b) a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in treating or preventing an RSV infection wherein: —R1 represents C1-6 alkyl, aryl or heteroaryl; —R2 represents... Agent: Lahive & Cockfield, LLP

20080139537 - Cgrp antagonists: The invention relates to a method for preventing and treating visceral pain and gastrointestinal disorders such as functional bowel disorders and inflammatory bowel diseases through the use of effective amounts of a compound acting as CGRP antagonist.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20080139538 - Tertiary carbinamines having substituted heterocycles which are active as beta-secretase inhibitors for the treatment of alzheimer's disease: The present invention is directed to tertiary carbinamine compounds having substituted heterocycles, which are inhibitors of the beta-secretase enzyme, and are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and... Agent: Merck And Co., Inc

20080139539 - Antibacterial agents: Naphthyridine and quinoline derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed herein.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080139540 - Antibacterial agents: Naphthyridine and related derivatives useful in the treatment of bacterial infections, particularly humans, are disclosed herein.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080139541 - Method of treating diseases and conditions associated with an altered level of amyloid beta peptides and new enolcarboxamide compounds: p

20080139544 - Heterocyclic antiviral compounds: This invention relates to piperidine derivatives of formulae Ia and Ib with substituents as defined herein useful in the treatment of a variety of disorders, including those in which the modulation of CCR5 receptors is implicated. More particularly, the present invention relates to 1-oxa-3,8-diaza-spiro[4.5]decan-2-one and 1-oxa-3,9-diaza-spiro[5.5]undecan-2-one compounds and related derivatives,... Agent: Roche Palo Alto Llc Patent Law Dept. M/s A2-250

20080139542 - Synergistic insecticidal compositions: i

20080139543 - Synergistic insecticidal compositions:

20080139545 - Formulation to treat ear infection: The present invention provides a pharmaceutical composition that includes: (a) at least one of a non-aminoglycoside antibiotic and an anti-inflammatory agent; and (b) a biofilm-dissolving agent. The present invention also provides for methods of killing or inhibiting the growth of a fungus by contacting the fungus with a composition of... Agent: Schwegman, Lundberg & Woessner, P.a.

20080139546 - Tetrahydroquinoline, indoline, and related aniline derivatives of heterocycle-fused benzodioxan methylamines: e

20080139547 - Acetylene derivatives as inhibitors of histone deacetylase: The present invention is directed to certain hydroxamate derivatives that are inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also disclosed.... Agent: Wilson Sonsini Goodrich & Rosati

20080139548 - Indoles: e

20080139549 - Indoles:

20080139550 - Indoles:

20080139555 - Arylthiobenzylpiperidine derivatives: This invention is directed to Arylthiobenzylpiperidine derivatives which are ligands at the MCH1 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by admixing a therapeutically effective amount... Agent: Lundbeck Research Usa, Inc. Attention: Stephen G. Kalinchak, Legal

20080139552 - Indoles: i

20080139553 - Spiro-piperidine derivatives:

20080139554 - Spiro-piperidine derivatives:

20080139551 - Tumor necrosis factor alpha inhibitors and their use in the treatment of human diseases:

20080139557 - Certain substituted amides, method of making, and method of use thereof:

20080139556 - Fkbp binding composition and pharmaceutical use thereof:

20080139559 - Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors: Described herein are compounds that include a diarylamine structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of c-kit receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions... Agent: Wilson Sonsini Goodrich & Rosati

20080139558 - Quinolones useful as inducible nitric oxide synthase inhibitors: The present invention relates to novel quinolones of Formula I that inhibit inducible NOS synthase together with methods of synthesizing and using the compounds including methods for inhibiting or modulating nitric oxide synthesis and/or lowering nitric oxide levels in a patient by administering the compounds for the treatment of disease.... Agent: Global Patent Group - Kal Attn: Ms Lavern Hall

20080139560 - Ion channel modulators: The invention relates to compounds, compositions comprising the compounds, and methods of using the compounds and compound compositions. The compounds, compositions, and methods described herein can be used for the therapeutic modulation of ion channel function, and treatment of disease and disease symptoms, particularly those mediated by certain calcium channel... Agent: Wyeth Patent Law Group

20080139561 - Pyrazolylaminopyridine derivatives useful as kinases inhibitors: This invention relates to novel compounds having the Formula (I) to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment for cancer.... Agent: Astrazeneca R&d Boston

20080139562 - Heteroaromatic glucokinase activators: The present invention describes 2,3-di-substituted N-heteroaromatic propionamides, of Formula (I) wherein the substitution at the 3-position is an optionally substituted phenyl ring and the substitution at the 2-position is an alkyl or cycloalkyl group; pharmaceutical compositions comprising the same; and, methods of using the same. The propionamides are glucokinase activators... Agent: Novo Nordisk, Inc. Intellectual Property Department

20080139563 - Oxazolidinone derivatives and methods of use: This invention relates to novel N-[[3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-acetamide derivatives, their acceptable acid addition salts, solvates and hydrates. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by antimicrobial agents.... Agent: Edwards Angell Palmer & Dodge LLP

20080139564 - Substituted phenyl propyl amines as histamine h3 receptor and serotonin transporter modulators: Certain substituted phenyl propyl amine compounds are histamine H3 receptor and/or serotonin transporter modulators useful in the treatment of histamine H3 receptor- and/or serotonin-mediated diseases.... Agent: Philip S. Johnson Johnson & Johnson

20080139565 - Anthranilic acid derivatives and their use in treatment of diseases of lipid metabolism, in particular dyslipidaemia: Therapeutically active anthranilic acid derivatives of Formula (I) wherein R1, R2, W, Y and Z are as defined in the specification, processes for the preparation of said derivatives, pharmaceutical formulations containing the active compounds and the use of the compounds in therapy, particularly in the treatment of diseases in which... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080139567 - 4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl)pyrazolo-[1,5-a]-1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands: e

20080139566 - Substituted oxetanes, method of making, and method of use thereof: Oxetane-containing nucleosides, particularly non-reducing psiconucleoside oxetanes are described herein. Therapeutic application of these oxetane compounds toward the treatment of nucleoside analog related disorders such as disorders involving cellular proliferation and infection are also described.... Agent: Cantor Colburn, LLP

20080139569 - Novel crystalline form: Disclosed are a novel crystalline form of 7-chloro-N,N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide, processes of preparing said crystalline form of 7-chloro-N,N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide, compositions comprising said form in admixture with one or more pharmaceutically acceptable excipients, and uses for the same.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. Llc

20080139568 - Phthalazine derivatives as parp inhibitors: The present invention provides compounds of formula (I), their use as PARP inhibitors as well as pharmaceutical compositions comprising said compounds of formula (I) wherein R1, R2 L1, L2, X, Y, Q and Z have defined meanings.... Agent: Philip S. Johnson Johnson & Johnson

20080139570 - Bicyclic nitrogen-containing heterocyclic compounds for use as stearoyl coa desaturase inhibitors: The present invention discloses bicyclic nitrogen-containing heterocyclic compounds for use as inhibitors of stearoyl-CoA desaturase. The compounds are useful in treating and/or preventing various human diseases, mediated by stearoyl-CoA desaturase (SCD) enzymes, especially diseases related to abnormal lipid levels, cardiovascular disease, diabetes, obesity, oily skin conditions, metabolic syndrome, and the... Agent: Cv Therapeutics, Inc.

20080139571 - Imidazopyrazines as protein kinase inhibitors: In its many embodiments, the present invention provides a novel class of imidazopyrazine compounds as inhibitors of protein and/or Aurora kinases, methods of preparing such compounds, pharmaceutical compositions including one or more such compounds, methods of preparing pharmaceutical formulations including one or more such compounds, and methods of treatment, prevention,... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080139572 - Diketo-piperazine and piperidine derivatives as antiviral agents: This disclosure provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the disclosure is concerned with diketo piperazine and piperadine derivatives that possess unique antiviral activity. More particularly, the present disclosure relates to compounds useful for the treatment of HIV and AIDS.... Agent: Louis J. Wille Bristol-myers Squibb Company

20080139573 - Treatment of resistant schizophrenia and other cns disorders: A method of mono-therapeutically treating a patient suffering from a condition selected from naïve schizophrenia, therapy resistant schizophrenia, therapy refractory schizophrenia, therapy resistant depression, chronic depression, recurrent depression, and resistant bipolar disorder comprises the administration of a pharmacologically effective amount of a thioxanthene, such as chlorprothixene, flupenthixol, thiotixene, zuclopenthixol, zuclopenthixol... Agent: Dickstein Shapiro LLP

20080139574 - Novel quinoline derivatives: The present invention relates to novel compounds of general formula (I), their tautomeric forms, their pharmaceutically acceptable salts and pharmaceutical compositions containing them. The present invention also relates to a process for preparing compounds of general formula (I), their tautomeric forms, their pharmaceutically acceptable salts and pharmaceutical compositions containing them.... Agent: Ladas & Parry LLP

20080139575 - Certain chemical entities, compositions, and methods: Chemical entities that modulate smooth muscle myosin and/or non-muscle myosin, and chemical entities, pharmaceutical compositions and methods of treatment of diseases and conditions associated with smooth muscle myosin and/or non-muscle myosin are described.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080139576 - 5-substituted 1,1-dioxo- 1,2,5- thiadiazolidin-3-one derivatives: provide pharmacological agents which are inhibitors of PTPases, in particular, the compounds of formula I inhibit PTP-1B and TC PTP, and thus may be employed for the treatment of conditions associated with PTPase activity. The compounds of the present invention may also be employed for inhibition of other enzymes with... Agent: Novartis Institutes For Biomedical Research, Inc.

20080139577 - Nitroheteroaryl-containing rifamycin derivatives: Substituted rifamycin derivatives in which a nitroimidazole, nitrothiazole or nitrofuran pharmacophore is covalently bonded to a rifamycin, methods of using the rifamycin derivatives, and pharmaceutical compositions containing the rifamycin derivatives are disclosed. Methods of synthesizing these substituted rifamycin derivatives are also disclosed. The rifamycin derivatives possess antibacterial activity, and are... Agent: Jackson Walker LLP

20080139578 - Substituted piperizines for the treatment of pain: The present invention is directed to the use of substituted piperizine compounds represented by Formula I, for the treatment of pain, including acute pain, chronic pain, cancer pain, visceral pain, inflammatory pain, neuropathic pain, post-herpetic neuralgia, diabetic neuropathy, trigeminal neuralgia, migraine, and fibromyalgia.... Agent: Merck And Co., Inc

20080139579 - Hiv integrase inhibitors: Compounds of Formula I are inhibitors of HIV integrase and inhibitors of HIV replication: (I) wherein Z, R1, R2, R3, R4, R5, R6, R7, R8 and R9 are defined herein. The compounds are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the... Agent: Merck And Co., Inc

20080139581 - 2-substituted 7-aminoazolopyrimidines, processes for their preparation and their use for controlling harmful fungi, and compositions comprising these compounds: m

20080139580 - Imidazo-pyrimidines and triazolo-pyrimidines: benzodiazepine receptor ligands: are provided, as are methods for their preparation. The variables Z1, Z2, Z3, R4, R5, R6, R7, R8 and Ar in the above formula are defined herein. Such compounds may be used to modulate ligand binding to GABAA receptors in vivo or in vitro, and are particularly useful in the... Agent: Edward Angell Palmer & Dodge, LLP Client: Neurogen Corporation

20080139582 - Inhibitors of bruton's tyrosine kinase: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination... Agent: Wilson Sonsini Goodrich & Rosati

20080139584 - Method for healing a wound: A method for healing a wound comprising the steps of: topically administering a wound healing composition to a wounded area, wherein the wound healing composition comprises: a first medicament characterized as a calcium channel blocker or pharmaceutically acceptable salts or solvates thereof; a second medicament characterized as a hemorrheologic agent... Agent: King & Partners, Plc

20080139585 - Specific inhibitors for vascular endothelial growth factor receptors: The present application describes isoindoles and derivatives thereof, or pharmaceutically acceptable salt forms thereof, which are useful inhibitors of VEGFR.... Agent: Feldmangale, P.a.

20080139583 - Phosphodiesterase 4 inhibitors: e

20080139586 - Mitotic kinesin inhibitors: The present invention relates to fluorinated aminoalkyl-4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine derivatives that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.... Agent: Merck And Co., Inc

20080139587 - Combinations comprising epothilones and protein tyrosine kinase inhibitors and pharmaceutical uses thereof: The invention relates to a combination which comprises: (a) an epothilone; and (b) a protein tyrosine kinase inhibitor; and optionally (c) a derivative of rapamycin; for simultaneous, separate or sequential use, in particular, for the delay of progression or treatment of a proliferative disease, especially cancer.... Agent: Novartis Corporate Intellectual Property

20080139588 - Pyrrolo[2,3-d]pyrimidine cytokine inhibitors: The present invention relates to 2,6,7-substituted pyrrolo[2,3-d]pyrimidines which inhibit the extracellular release of inflammatory cytokines, said cytokines responsible for one or more human or higher mammalian disease states. The present invention further relates to compositions comprising said 2,6,7-substituted pyrrolo[2,3-d]pyrimidines and methods for preventing, abating, or otherwise controlling enzymes which are... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080139589 - Crystal of 4(3h)-quinazolinone derivative: A substance that has a potency antagonistic to coupling of histamine with histamine H3 receptor or a potency of inhibiting the constant activity of histamine H3 receptor. There is provided a form I crystal of 2-methyl 3-{4-[3-(1-pyrrolidinyl)propoxy]phenyl}-5-trifluoromethyl-4(3H)-quinazolinone that in the powder X- ray diffractometry, has peaks at 6.4°, 9.7°, 10.2°,... Agent: Merck And Co., Inc

20080139591 - Cgrp antagonists: The invention relates to a method for preventing and treating visceral pain and gastrointestinal disorders such as functional bowel disorders and inflammatory bowel diseases through the use of effective amounts of a compound acting as CGRP antagonist.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20080139590 - Quinazoline based egfr inhibitors containing a zinc binding moiety: The present invention relates to quinazoline containing zinc-binding moiety based derivatives that have enhanced and unexpected properties as inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and their use in the treatment of EGFR-TK related diseases and disorders such as cancer. The said derivatives may further act as HDAC... Agent: Elmore Patent Law Group, Pc

20080139593 - Method for treating a pulmonary hypertension condition: A method for treating a pulmonary hypertension condition such as pulmonary arterial hypertension (PAH) in a subject comprises administering to the subject a therapeutically effective amount of ambrisentan, wherein, at baseline, time from first diagnosis of the condition in the subject is not greater than about 2 years.... Agent: Harness, Dickey, & Pierce, P.l.c

20080139592 - Use of carboxiamidotriazole (cai) orotate in macular degeneration: Method and composition of Carboxyamidotriazole orotate for treating age-related macular degeneration and other angiogenesis-dependent diseases.... Agent: Rashida A. Karmali

20080139598 - Amine-linked multicyclic compounds and methods of their use: This invention relates to multicyclic compounds, pharmaceutical compositions comprising them, and methods of their use. Particular compounds of the invention are of formula I:... Agent: Lexicon Pharmaceuticals, Inc.

20080139597 - Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors: Described herein are compounds that include a diarylamine structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of c-kit receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions... Agent: Wilson Sonsini Goodrich & Rosati

20080139595 - Hetaryloxy-substituted phenylamino pyrimidines as rho kinase inhibitors: The invention relates to hetaryloxy-substituted phenylaminopyrimidines, to a process for their preparation and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases in humans and animals, in particular cardiovascular disorders.... Agent: Bayer Health Care Llc

20080139594 - Imidazo-pyridine derivatives for use in the treatment of herpes viral infection: e

20080139596 - Modulators of hcv replication: The present invention is directed to the use of certain 2,4,5-trisubstituted imidazole derivatives in modulating the replication of Hepatitis C virus RNA and/or virus production in cells.... Agent: Merck And Co., Inc

20080139599 - Phenylbenzoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and therapeutic uses thereof: Compounds of the formula (1) in which R1, R2,X, Y and Z are as defined in the description, the processes for the preparation of these compounds, the uses thereof for the treatment of dyslipidaemia, atherosclerosis and diabetes, and the pharmaceutical compositions comprising them.... Agent: Millen, White, Zelano & Branigan, P.c.

20080139600 - Nicotinic acetylcholine receptor ligands 101: m

20080139601 - 3-cyano-quinoline derivatives with antiproliferative activity:

20080139603 - Azabicycloalkane compounds: wherein R1, R2, R3, R4, R5, R6 and R7 are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The compounds of this invention possess both β2 adrenergic receptor agonist and muscarinic receptor antagonist activity. Such compounds are useful for treating pulmonary disorders, such... Agent: Theravance, Inc.

20080139602 - Ccr1 antagonists and methods of use therefor: e

20080139604 - Method of treating atherosclerosis, dyslipidemias and related conditions: A method of treating atherosclerosis is disclosed wherein nicotinic acid or another nicotinic acid receptor agonist is administered to the patient in combination with a DP receptor antagonist. The DP receptor antagonist is administered to reduce, prevent or eliminate flushing that may otherwise occur.... Agent: Merck And Co., Inc

20080139605 - Substituted prolinamides, manufacturing, and the use thereof as medicaments: m

20080139606 - Substituted pyrrolopyridines, compositions containing them, manufacturing process therefor and use thereof:

20080139607 - New compounds:

20080139608 - 2,6,8, trisubstituted 1-deazapurines and their different uses:

20080139609 - Granisetron compositions: Stable liquid pharmaceutical compositions comprise granisetron or a pharmaceutically acceptable salt thereof.... Agent: Dr. Reddy's Laboratories, Inc.

20080139610 - Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators: where X═O or S; Y is O or S; q=1 or 0; and other substituents are defined herein. Such compounds can affect the opening of, or otherwise modulate, voltage-gated potassium channels. They are potentially useful for the treatment and prevention of diseases and disorders which are affected by activation or... Agent: Mcdermott, Will & Emery

20080139611 - Methods of using 4-phenylaminoquinolines as topical non-steroidal antiinflammatory compounds: A skin disorder, a disorder associated with pain, fever, or inflammation, a proliferative disorder, or an ocular disorder is treated by topically administering a pharmaceutically acceptable formulation containing a therapeutically effective amount of a 4-phenylaminoquinoline compound.... Agent: Goodwin Procter LLP Patent Administrator

20080139612 - Chemical compound: s

20080139613 - Chemical compound:

20080139615 - Combination of a hypnotic agent and r (+)-alpha-(2,3-dimethoxy-phenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol and therapeutic application thereof:

20080139614 - Treatment of stroke with histamine h3 inverse agonists or histamine h3 antagonists: Histamine H3 inverse agonists or histamine H3 antagonists are useful, alone or in combination with an anti-stroke agent, for treating stroke.... Agent: Merck And Co., Inc

20080139616 - Non-anilinic derivatives of isothiazol-3(2h)-thione 1,1-dioxides as liver x receptor modulators: The present invention relates to certain novel compounds of the formula (I) to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) α (NR1H3) and/or β (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis;... Agent: Pepper Hamilton LLP

20080139617 - Indoles: e

20080139618 - Indoles:

20080139619 - Novel derivatives of benzimidazale and imidazo-pyridine and their use as medicaments: A subject of the present application is novel derivatives of benzimidazole and imidazo-pyridine which have a good affinity for certain sub-types of melanocortin receptors, in particular the MC4 receptors. They are particularly useful for treating pathological conditions and diseases in which one or more melanocortin receptors are involved. The invention... Agent: Charles A. Muserlian C/o Hedman And Costigan

20080139620 - Pyrazole derivatives for the inhibition of cdk's and gsk's: The invention provides a compound of the formula (I): or salts, tautomers, solvates and N-oxides thereof; wherein: R1 is 2,6-dichlorophenyl; R2a and R2 are both hydrogen; and R3 is a group: where R4 is C1-4 alkyl. The compounds have activity as inhibitors of CDK kinases and inhibit the proliferation of... Agent: Heslin Rothenberg Farley & Mesiti Pc

20080139621 - Thrombopoietin mimetics: The invention relates to compounds and their use in the treatment of thrombocytopenia resulting from diseases or conditions such as immune thrombocytopenic purpura, cancer chemotherapy, surgery, bone marrow or stem cell transplantation, radiation injury or treatment, chronic viral infection, and pancytopenia. The invention further relates to pharmaceutical compositions containing the... Agent: Morgan, Lewis & Bockius LLP (sf)

20080139622 - Decahydronaphthalene compounds: e

20080139623 - Amorphous and crystalline forms of pantoprazole magnesium salt: Provided are amorphous and crystalline forms of pantoprazole magnesium salt and processes for their preparation.... Agent: Kenyon & Kenyon LLP

20080139624 - Oral dosage form comprising rosiglitazone: An oral dosage form comprising pellets of a first composition and pellets of a second composition, each composition comprising 5-[4-[2-(N-methyl-N-(2 pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable carrier therefor, wherein the first and second compositions are arranged to release drug at differing release rates... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080139625 - Pyrrolidin-2-one and piperidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors: Formula (I), the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein n is 1 or 2; L represents a C1-3alkyl linker optionally substituted with one or two substituents selected from C1-4alkyl, C1-3alkyloxy-C1-4alkyl-, hydroxy-C1-4alkyl, hydroxy, C1-3alkyloxy- or phenyl-C1-4alkyl; M represents a direct bond or a... Agent: Philip S. Johnson Johnson & Johnson

20080139626 - Novel method: A method for the treatment or prophylaxis of an infection in a mammal, said infection caused by an anti-microbial resistant bacteria, comprising, administering, to the mammal a pleuromutilin derivative is disclosed.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080139627 - Heterocyclic amide and imine derivatives, processes for their preparation, compositions comprising them and their use as pesticides: m

20080139628 - Compositions for treating flushing and lipid-associated disorders comprising niacin receptor partial agonists: The invention provides a method of reducing flushing induced by niacin or a niacin analog in a subject, comprising administering to said subject an effective flush reducing amount of a niacin receptor partial agonist. In addition, the invention provides a method of reducing flushing induced by niacin or a niacin... Agent: Fish & Richardson P.c.

20080139629 - Method for controlling angiogenesis in animals: Disclosed are methods for the inhibition of angiogenesis comprising administering an organic arsenical compound.... Agent: Ropes & Gray LLP

20080139630 - N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators: Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis,... Agent: Merck And Co., Inc

20080139631 - Chemical compounds: This invention relates to non-steroidal compounds that are modulators of androgen receptor, and also to the methods for the making and use of such compounds.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20080139632 - Hydroxylated 1,2,4-oxadiazole benzoic acid compounds, composistions thereof and the use for nonsense suppression: Novel hydroxylated 1,2,4-oxadiazole benzoic acid compounds, methods of using and pharmaceutical compositions comprising a hydroxylated 1,2,4-oxadiazole benzoic acid derivative are disclosed. The methods include methods of treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay, or ameliorating one or more symptoms associated therewith.... Agent: Jones Day

20080139633 - Crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol: The present invention is directed to a hydrate crystal form (designated as Form F herein) of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol, an estrogenic receptor modulator useful in the treatment of, for example, diseases related to abnormal levels of estrogen.... Agent: Pepper Hamilton LLP/wyeth

20080139634 - Diarylthiohydantoin compounds: The present invention relates to diarylthiohydantoin compounds and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer.... Agent: Venable LLP

20080139635 - Inflammation therapy: A method is provided for treating a patient in need of therapy for central nervous system inflammation comprising administering to that patient a therapeutically effective amount of a cannabinoid agonist having efficacy at the CB2 receptor but having substantially no efficacy at the CB1 receptor at that amount.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080139636 - Adamantane derivatives: The invention provides adamantane derivatives of formula (I), a process for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy. In formula (I) D represents CH2 or CH2CH2, E represents C(O)NH or NHC(O) and R3 represents a group of formula (I).... Agent: Morgan Lewis & Bockius LLP

20080139637 - Catalyzed reaction for forming indole-based compounds and their application in anticancer agents: The present invention discloses a method for forming indole-based compounds, wherein the method comprises a reaction of α,β-unsaturated ketone or aldehyde with indole or its derivative in the presence of at least one kind of Lewis acid. The Lewis acid comprises one of the following groups: metal halides, halogens, inorganic... Agent: Wpat, Pc

20080139638 - Method of increasing growth hormone secretion: The present invention relates to a method of administering to a mammal between from about 0.01 mg and about 4.9 mg of melatonin followed by physical exercise wherein said exercise occurs within 60 minutes following said administration of melatonin to increase serum growth hormone levels.... Agent: Torys LLP

20080139639 - Proton pump inhibitors: wherein X and Y are the same or different and each is a bond or a spacer having 1 to 20 carbon atoms in the main chain, R1 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, R2, R3 and R4 are the same or different and... Agent: Edwards Angell Palmer & Dodge LLP

20080139640 - Hydroxamates, their manufacture and use as pharmaceutical agents: Objects of the present invention are the compounds of formula (I), their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the In preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such... Agent: Hoffmann-la Roche Inc. Patent Law Department

20080139642 - Artemisinin (qinghaosu) derivatives, their preparation methods and their use, and pharmaceutical compositions containing the same: The invention provides a type of artemisinin derivatives having following structure I, its preparation method and use, as well as a pharmaceutical composition containing such artemisinin derivatives and its use. The artemisinin derivatives of the present invention and their pharmaceutical composition containing the artemisinin derivatives. have immunosuppressive activities and can... Agent: Nixon & Vanderhye, Pc

20080139643 - Synergistic insecticidal compositions: e

20080139641 - Use of resiniferatoxin (rtx) for producing an agent for treating joint pains and method for applying said agent: The use of resiniferatoxin (RTX) relates to a formulation, which does not contain any local anesthetic and preferably also no other pharmacologically active substances, for the preparation of an agent for the treatment of different pain conditions.... Agent: Rankin, Hill & Clark LLP

20080139644 - Composition comprising (-)-delta9-trans-tetrahydrocannabinol: A composition comprising a tetrahydrocannabinol compound, a solvent and an acid, wherein the tetrahydrocannabinol compound may be Δ8 tetrahydrocannabinol, (−)-Δ9-trans-tetrahydrocannabinol or a side chain alkyl derivative of either compound, the solvent may be an oil or C1-C4 alcohol (e.g. sesame oil or ethanol), and the acid may be an organic... Agent: Ratnerprestia

20080139645 - Solid pharmaceutical compositions containing benzofuran derivatives: The present invention relates to a solid pharmaceutical composition for oral administration characterized in that it comprises a benzofuran derivative with antiarrhythmic activity, or one of the pharmaceutically acceptable salts thereof, as an active principle, and a pharmaceutically acceptable nonionic hydrophilic surfactant optionally in combination with one or more pharmaceutical... Agent: Andrea Q. Ryan Sanofi-aventis U.s. Llc

20080139646 - Mixtures of aromatic esters for marking or tagging organic products, marker compositions comprising the same and manufacturing methods thereof: wherein R1 represents a straight chain alkyl group having 1 to 11 carbon atoms; R2 represents a hydrogen atom or a group of the formula C(O)R4 where R4 is a hydrogen atom or a straight chain alkyl group having 1 to 11 carbon atoms; X2-X5 independently represent hydrogen; X6-X13 is... Agent: Kelley Drye & Warren LLP

20080139647 - Cosmetic preparations: A cosmetic preparation comprising about 50% to about 80% by weight of the finished preparation silicone fluid having a kinematic viscosity in the range of about 10,000 cs to about 15,000 cs, about 20% to about 40% by weight of the finished preparation silicone fluid having a kinematic viscosity in... Agent: Barnes & Thornburg LLP

20080139648 - Product containing prostaglandin having fluorine atom in its molecule: An object of the present invention is to provide a prostaglandin-containing product, wherein when an aqueous liquid preparation containing a prostaglandin derivative having at least a fluorine atom in its molecule as an active ingredient is stored in a resin container subjected to a sterilization treatment, a decrease in the... Agent: Frishauf, Holtz, Goodman & Chick, Pc

20080139649 - Fatty acid-benzenediol derivatives and methods of making and using thereof: Disclosed are compounds comprising a benzenediol derivative bound to one or more fatty acids. Also disclosed are nutritional supplements, pharmaceutical formulations, delivery devices, and foodstuffs comprising the disclosed compounds. Methods of using the disclosed compounds and compositions to improve health are also disclosed.... Agent: Needle & Rosenberg, P.c.

20080139651 - Compounds useful for treating neurological disorders: The invention relates to the use of compounds for the preparation of a medicament for treating neuropathic pain, migraine, psychiatric disorder and/or neuronal degeneration. The invention additionally relates to a pharmaceutical composition comprising compounds for treating neuropathic pain, migraine, psychiatric disorder and/or neuronal degeneration. A method for treating neuropathic pain,... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080139650 - Fungicidally active polymer dispersions and use thereof: e

20080139652 - Pharmaceutical composition containing prostaglandin: An object of the present invention is to provide a stable aqueous pharmaceutical composition which suppresses degradation of prostaglandin F2α in a preparation containing prostaglandin F2α. The object was attained by formulating a prostaglandin F2α derivative into an oil-in-water emulsion together with an oil, for example, medium chain fatty acid... Agent: Blakely Sokoloff Taylor & Zafman

20080139653 - Non-standard amino acid conjugates of amphetamine and processes for making and using the same: Disclosed are amphetamine prodrug compositions comprising at least one non-standard amino acid conjugate of amphetamine, a salt thereof, a derivative thereof, or a combination thereof. Methods of making and using the same are also disclosed.... Agent: Mcandrews Held & Malloy, Ltd

20080139654 - Acetaminophen compositions having minimized side effects including reduced hepatotoxicity: Solid tablets or gel capsules comprising acetaminophen and an agent that promotes glutathione production that mitigates adverse hepatic effects of acetaminophen. The glutathione production promoter is preferably n-acetylcysteine or other mercapto-2-amino alkyl carboxylic acid having glutathione production promoting properties. A preferred composition comprises acetaminophen (200 mg to 750 mg) and... Agent: Daniel B. Schein, Ph.d., Esq., Inc.

20080139655 - Sustained-release composition and method of use thereof: A pharmaceutical composition comprising levodopa is provided that, when administered in a unit dosage amount of levodopa of about 100 to about 500 mg at a dosage interval of about 6 to about 24 hours, exhibits a sufficiently long release period and a sufficiently long residence time in the upper... Agent: Kv Pharmaceutical Company

20080139656 - Compositions having a high antiviral and antibacterial efficacy: Antimicrobial compositions having a rapid antiviral and antibacterial effectiveness, and a persistent antiviral effectiveness, are disclosed. The antimicrobial compositions contain a phenolic antimicrobial agent, a disinfecting alcohol, a gelling agent, and an organic acid, wherein the phenolic antimicrobial agent is present in a continuous aqueous phase in an amount of... Agent: Marshall, Gerstein & Borun LLP (dial)

20080139657 - Method for increasing serotonin levels in a person by administration of a composition incorporating (-)hydroxycitric acid, and related compositions thereof: A method for increasing serotonin levels in a person includes identifying a person having a deficient serotonin level and administering to the person a composition incorporating hydroxycitric acid, preferably in the form of an extract of Garcinia cambogia, in an amount sufficient to increase the person's serotonin levels. The method... Agent: Marshall, Gerstein & Borun LLP

20080139658 - Synergistic insecticidal compositions: m

20080139659 - Methods for treating neural cell swelling: A composition comprising a novel Ca2+-activated, [ATP]i-sensitive nonspecific cation (NCCa-ATP) channel is described. The channel is found in mammalian neural cells and exhibits a different sensitivity to block by various adenine nucleotides, and is activated by submicromolar [Ca]i. The NCCa-ATP channel is activated under conditions of ATP depletion, which causes... Agent: Fulbright & Jaworski, LLP

20080139660 - Tablets comprising entacapone and crospovidone: Pharmaceutical tablets comprising entacapone and crospovidone.... Agent: Nixon & Vanderhye, Pc

20080139661 - Fragranted moistening fluids that destroy and/or inhibit the growth of biological organisms while minimizing a tacky build up: Moistening fluids are disclosed that are capable of being used in mail processing machines and systems. Mail processing equipment can automatically feed and moisten envelopes at slow to very high speeds of 30 inches per second. The moistening system becomes contaminated with paper dust, talc, and common envelope adhesives. The... Agent: Pitney Bowes Inc. 35 Waterview Drive

20080139664 - Anti-glycation agents for preventing age-, diabetes-, and smoking-related complications: The invention provides new inhibitors of protein glycation, identified from compound libraries by a high throughput screening assay. The anti-glycation agents so identified are characterized by a variety of chemical structures and are useful for the prevention or treatment of age-, diabetes-, and smoking-related complications, including neuropathy, nephropathy, ocular pathologies,... Agent: Borden Ladner Gervais LLP Anne Kinsman

20080139663 - Synthesis, methods of using, and compositions of cycloalkylmethylamines: The present invention provides novel cycloalkylmethylamine analogs, and methods of preparing cycloalkylmethylamine analogs. The present invention also provides methods of using cycloalkylmethylamine analogs and compositions of cycloalkylmethylamine analogs. The pharmaceutical compositions of the compounds of the present invention can be advantageously used for treating and/or preventing obesity and obesity related... Agent: Fenwick & West LLP

20080139662 - Use of sphingosine-1-phosphate (s1p) receptor agonists for the treatment of brain degenerative diseases: Disclosed is the use of sphingosine-1-phosphate (S1P) receptor agonists, preferably 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol, in the treatment of progressive dementia or brain degenerative diseases.... Agent: Novartis Corporate Intellectual Property

20080139665 - Androgen receptor-dependent gene expression control: The invention relates to the use of at least one amine oxidase inhibitor for modulating the activity of the lysine-specific demethylase (LSD1) in a mammal and to pharmaceutical compositions for controlling the androgen receptor-dependent gene expression, comprising an effective dose of at least one amine oxidase inhibitor suitable for modulating... Agent: Greenblum & Bernstein, P.L.C

20080139666 - Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues: The present invention provides novel methods of treating psoriasis, protein tyrosine kinase-associated disorders, inflammation, epidermal hyperproliferation, diabetes, immune and autoimmune diseases, eczema, and inflammatory bowel disease, inhibiting protein kinase, neutrophil activation, cell proliferation, tumour growth, metastasis, and the development of atheromatous plaque and restonosis, controlling angiogenesis, and preventing inflammatory bowel... Agent: Oyen, Wiggs, Green & Mutala LLP 480 - The Station

20080139667 - Pharmaceutical compositions for the treatment of disease and/or symptoms in arthritis: The invention relates to the use of a combination of cannabinoids for the treatment of pain, inflammation and/or disease modification in arthritis. Preferably the cannabinoids are selected from cannabidiol (CBD) or cannabidivarin (CBDV) and delta-9-tetrahydrocannabinol (THC) or tetrahydrocannabinovarin (THCV). More preferably the cannabinoids are in a predefined ratio by weight... Agent: Wolf Greenfield & Sacks, P.c.

20080139668 - Pharmaceutical composition for obovatol for the prevention and treatment of restenosis: Disclosed herein is a pharmaceutical composition for the prevention and treatment of restenosis following a blood vessel injury procedure, comprising obovatol as an active ingredient.... Agent: Lucas & Mercanti, LLP

20080139669 - Use of a blood-flow decrease preventing agent in conjunction with insufflating gas: A blood-flow decrease preventing agent is used to negate or reduce the decreased oxygen delivery in abdominal organs caused by insufflating gas. Preferably a gas is delivered into the abdominal cavity consisting essentially of the insufflating gas and the blood-flow decrease preventing agent. Very preferably, a gas is used consisting... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c Attn: Patent Intake Customer No. 30623

20080139670 - Drug delivery system: (A compound comprises a thiopeptide, or derivative or analogue thereof, the thiopeptide comprising a C-terminal carboxylic acid group, and a functional group for attachment to a drug, characterised in that the compound is adapted to carry or transport a drug.... Agent: Nixon & Vanderhye, Pc

20080139671 - Method and material for in situ corneal structural augmentation: A method and material for augmenting the shape and thickness of the cornea in situ includes applying a clear liquid collagen mixed with a customized crosslinker onto the augmentation surface or in a cavity (with or without a mold) and exposing the mixture to UVA radiation in vivo. Application of... Agent: Townsend And Townsend And Crew, LLP

20080139672 - Synergistic preservative systems and their use in cosmetic compositions: The present invention provides a preservative system having at least one preservative component and at least one oil-miscible glycol component, and cosmetic compositions formulated with the preservative system. It has unexpectedly been found that the preservative system according to the present invention results in a synergistic preservative effect. This synergistic... Agent: Ohlandt, Greeley, Ruggiero & Perle, LLP

20080139674 - Methods of wound care and treatment: Particular embodiments disclosed herein relate to gas-enriched fluids, methods of making the same, systems for making the same and/or methods of treatment utilizing the gas-enriched fluids for wound care related conditions and/or diseases. In certain embodiments, the gas-enriched fluid is oxygen-enriched water. Certain embodiments relate to cosmetic and/or therapeutic fluids... Agent: Davis Wright Tremaine, LLP/seattle

20080139673 - Potentiation of antifungal compounds: The invention provides methods and models for understanding how HDAC inhibitors interact with antifungal azole compounds to potentiate the activity of such compounds, using fungal strains which have selective knockouts of fungal HDAC genes. The invention further provides methods for testing antifungal agents for potential synergy with fungal HDAC inhibitors,... Agent: Keown & Zucchero, LLP

20080132442 - Compositions and methods for treating conditions of the nail unit: The biodegradable drug delivery systems described here are formulated for implantation into the nail unit and its surrounding tissues for the treatment of various nail unit conditions. The systems include greater than 30% by weight of the active agent, and may be formulated as solutions, solids, semisolids, microparticles, or crystals.... Agent: Morrison & Foerster LLP

20080132441 - Methods and compositions for modulating medial-lateral neuronal topographic maps: Methods and kits are provided for modulating the axonal growth of a neuron comprising contacting the neuron with a Wnt3 polypeptide or expressing an exogenous polynucleotide encoding a Wnt3 polypeptide. Also provided are compositions for modulating the medial-lateral axonal growth of a neuron comprising a Wnt3 polypeptide and a pharmaceutically... Agent: Michael Best & Friedrich LLP

20080132440 - Poly-gamma-glutamic acid-vitamin complex and use thereof: The present invention relates to PGA-vitamin complex containing poly-γ-glutamic acid(PGA), vitamin preparations containing said PGA-vitamin complex or cosmetic compositions. The inventive PGA-vitamin complex having excellent hygroscopicity, moisturizing property and skin compatibility, which is a complex of poly-γ-glutamic acid and vitamin, has the effect of sustained-release as well as improves stability... Agent: Intellectual Property / Technology Law

20080132443 - Novel heat shock protein 20-related polypeptides and uses therefor: The present invention provides novel HSP20-based polypeptides and pharmaceutical compositions thereof, and methods for using such polypeptides and pharmaceutical compositions for various therapeutic uses.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080132444 - Ocular agent delivery systems: This invention is directed to novel ocular agent delivery systems and, in particular, emulsions and molecular dispersions in the form of a gel comprising a hydrophobic ocular agent.... Agent: Technology & Intellectual Property Strategies Group Pc (dba Tips Group)

20080132448 - Conserved neisserial antigens: To ensure maximum cross-strain recognition and reactivity, regions of proteins that are conserved between different Neisserial species, serogroups and strains can be used. The invention provides proteins which comprise stretches of amino acid sequence that are shared across the majority of Neisseria, particularly N. meningitidis and N. gonorrhoeae.... Agent: Novartis Vaccines And Diagnostics Inc.

20080132449 - Decorin gene delivery system and cancer treatment: A novel gene delivery system and recombinant adenovirus includes a decorin-encoding sequence to enhance transduction efficiency of transgenes. A pharmaceutical anti-tumor composition includes the recombinant adenovirus, as well as a pharmaceutical composition having improved tissue penetration potency and a pharmaceutical composition for treating a disease or disorder associated with accumulation... Agent: The Rafferty Patent Law Firm

20080132445 - Method for inducing mammary epithelial cell differentiation: The present invention relates to compositions and methods for inducing mammary epithelial cell differentiation in mammalian subjects. More specifically, the present invention relates to methods for inducing mammary epithelial cell differentiation which comprise increasing the levels of galanin in the mammary tissue of the subject. In one aspect the present... Agent: Foley & Lardner LLP

20080132447 - Method of screening for a carnitine transporter agonist or antagonist and it uses: The present invention is directed to a method of screening for a carnitine transporter agonist or for a carnitine transporter antagonist, to a kit for carrying out the method of screening for a carnitine transporter agonist or for a carnitine transporter antagonist, to a method for the manufacture of a... Agent: Andrea Q. Ryan Sanofi-aventis U.s. Llc

20080132451 - Modulation of polysialylated neural adhesion molecules (psa-ncam) as a regulator of ocular disease: A method of treating dry eye or dry eye symptom includes topically administering a formulation to the eye. The formulation includes an ophthalmically acceptable carrier and a pharmaceutically effective amount of a positive modulator of PSA-NCAM. The administered formulation treats dry eye or dry eye symptoms. A method of stimulating... Agent: Alcon

20080132450 - Pharmaceutical composition for suppression of apoptosis and method for delivering the same: The present invention relates to a pharmaceutical composition for treating heart diseases, neurodegenerative diseases, and diseases and conditions caused by apoptosis, which contains a conjugate of a heat shock protein (Hsp) and a protein transduction domain (PTD). According to the present invention, PTD-Hsp70 effectively suppresses apoptosis under low-oxygen conditions.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080132446 - Uses of neuronal pannexins for therapy and diagnosis in mammals: e

20080132452 - Novel goodpasture antigen-binding protein isoforms and protein misfolded-mediated disorders: The present invention provides novel isoforms of the Goodpasture antigen binding protein (GPBP), and related reagents, and also provides methods for isolating and detecting such novel GPBP isoforms. The invention further provides methods identifying compounds to treat one or more of an autoimmune condition and a protein deposit-mediated disorder, as... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080132453 - Neuromedin b and somatostatin receptor agonists: A novel class of analogs which exhibit both high affinity and selectivity for Neuromedin B and Somatostatin receptors are claimed. One example is Nal-Tyr-cyclo(D-Cys-D-Trp-Lys-D-Cys)-Abu-Nal-NH2.... Agent: Biomeasure, Incorporated

20080132454 - Antihypertensive peptides: The present invention refers to novel antihypertensive peptides which may be used as active ingredients in pharmaceutical preparations, dietary supplements, or as food ingredients.... Agent: Intellectual Property / Technology Law

20080132455 - Process for producing enriched fractions containing up to 100% of bacopasaponins from the plant materials of bacopa species: This invention describes a process for producing a fraction enriched with jujubogenin and psudojujubogenin lycosides from Bacopa species, wherein the total Bacopa saponin concentration is up to 100% when estimated by HPLC method of analysis. The present invention also describes the processes for the enrichment of new compositions and individual... Agent: Fitch Even Tabin And Flannery

20080132457 - Bacterial efflux pump inhibitors for the treatment of ophthalmic and otic infections: Efflux pump inhibitors are co-administered with antimicrobial agents for the treatment of ophthalmic or otic infections. The agents may be co-administered directly to the site of infection (e.g., the eye or ear).... Agent: Knobbe Martens Olson & Bear LLP

20080132456 - Pharmaceutical formulation comprising low crystallinity cellulose: A pharmaceutical composition comprises a pharmaceutically effective amount of an active ingredient and low crystallinity cellulose having a crystallinity index of less than about 75% as measured by X-ray diffraction. The compositions advantageously may be provided in tablet form or granulate form and provide good stability against moisture degradation.... Agent: Dinsmore & Shohl, LLP

20080132458 - Hypoxia-activated anti-cancer agents: Prodrugs of cyclic anthracyclin toxins comprising a hypoxia-activated trigger and are disclosed. In addition, methods of treating cancer using the compounds of the invention are disclosed.... Agent: Townsend And Townsend And Crew, LLP

20080132459 - Inhibitors of histone deacetylase: The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080132463 - Pharmaceutical use of alpha antigen or alpha antigen gene: The α antigen-encoding gone and the α antigen protein suppress the production of interleukin-4 etc., improve the Th2 type cytokine-dominant state, and furthermore inhibit various conditions of allergic diseases such as IgE production, histamine release and eosinophil infiltration, and therefore they are very effective for the prevention or treatment of... Agent: Sughrue Mion, Pllc

20080132461 - Rna sequence-specific mediators of rna interference: The present invention relates to a Drosophila in vitro system which was used to demonstrate that dsRNA is processed to RNA segments 21-23 nucleotides (nt) in length. Furthermore, when these 21-23 nt fragments are purified and added back to Drosophila extracts, they mediate RNA interference in the absence of long... Agent: Wolf Greenfield & Sacks, P.c.

20080132460 - Role of p62 in aging-related disease: The application discloses a role of p62 in aging-related disease, such as development of obesity, type 2 diabetes mellitus, non-alcoholic fatty liver, various tumors, increased male mortality, intracellular inclusion named sequestosome, and redox regulation. In particular the application discloses a method of detecting the formation of inclusion bodies in neurodegenerative... Agent: Joseph Hyosuk Kim Jhk Law

20080132464 - Selective induction of apoptosis to treat ocular disease: The invention is directed to a method of prophylactically or therapeutically treating choroidal neovascularization, wherein the method comprises directly administering to the eye a therapeutic factor or a nucleic acid sequence that encodes a therapeutic factor, which he expressed to produce the therapeutic factor, to selectively induce apoptosis of endothelial... Agent: Leydig Voit & Mayer, Ltd

20080132462 - Shc proteins as therapeutic targets in proliferative diseases: This invention provides methods for treating a subject afflicted with a proliferative disorder comprising administering to the subject a therapeutically effective amount of an agent which inhibits the expression of p46 Shc and/or p52 Shc, inhibits the activity of p46 Shc and/or p52 Shc in the subject, or increases the... Agent: Hamilton, Brook, Smith & Reynolds, P.c.

20080132465 - Apparatus and method for isolating iron components from serum: A method and apparatus for isolating iron components in serum is provided. The method includes passing a serum sample through a separation column having a solid phase and retaining with the solid phase an iron component, such as an iron carbohydrate, in the column. Elution of the solid phase may... Agent: Baxter Healthcare Corporation

20080132466 - Blood cholesterol reducing oral composition: A composition capable of remedying hypercholesterolemia through enhancing of the blood total cholesterol reducing potency of isoflavone. There is provided a blood cholesterol reducing oral composition, comprising difructose anhydride and isoflavone and/or its derivative as an active ingredient.... Agent: Knobbe Martens Olson & Bear LLP

20080132467 - Bioadhesive for tissue repair: The invention provides a bioadhesive composition comprising a polysaccharide and an energy converter, wherein the energy converter is activated by non-UV light. The composition may be prepared by dissolving the polysaccharide and the energy converter in an aqueous acidic solution. The composition, in the form of a film or a... Agent: Nath & Associates

20080132468 - Monitoring of wounds by measurement of protease and protease inhibitor levels in wound fluids: A diagnostic test apparatus for determining a ratio of: (a) at least one endogenous protease enzyme inhibitor, to (b) at least one endogenous protease enzyme, in a sample of a wound fluid. Suitably the protease enzyme is a neutrophil elastase and the protease enzyme inhibitor is alpha-1-antitrypsin. Also provided are... Agent: Philip S. Johnson Johnson & Johnson

20080132469 - Sh2 domain binding inhibitors: or a pharmaceutically acceptable salt or isomer thereof, wherein R1-R6 are as defined in the specification. These compounds are targeted for use as inhibitors of SH2 domain binding with a phosphoprotein, and are contemplated for use in a number of diseases including cancer. Also disclosed are pharmaceutical compositions comprising a... Agent: Leydig, Voit & Mayer, Ltd.

20080132470 - Synergistic insecticidal compositions:

20080132471 - Bisphosphonate inhalant formulations and methods for using the same: The present invention provides for methods of administering by a pulmonary route an effective amount of a bisphosphonate active agent to a subject. Aspects of the invention including administering the active agent to the subject in conjunction with one or more mucosal membrane protecting agents, where the protecting agent may... Agent: Bozicevic, Field & Francis LLP

20080132472 - Compounds for the treatment of psychiatric or substance abuse disorders: The invention provides methods for treating or preventing psychiatric and substance abuse disorders, involving administration of a therapeutically-effective amount of a cytosine-containing or cytidine-containing compound, creatine-containing compound, adenosine-containing, or adenosine-elevating compound to a mammal.... Agent: Clark & Elbing LLP

20080132473 - Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology: This invention relates to a method of preventing pregnancy and treating PMS including PMDD. More particularly, the invention relates to a method, which involves administering one of several combination oral contraceptive regimens in combination with an antidepressant and a kit containing the same.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080132474 - Breast cancer screening and treatment methods: A method for selecting a female breast cancer patient for AT1 receptor antagonist therapy comprises (a) determining whether the cancer comprises a tumor that is ER+ and/or PR+; and (b) selecting the patient for AT1 receptor antagonist therapy only if the cancer is determined to comprise an ER+ and/or PR+... Agent: Harness, Dickey, & Pierce, P.l.c

20080132475 - Treatment for dry eye: The present invention comprises a composition and method treating eye diseases using a composition having a therapeutically effective amount of a progestagen and a pharmaceutically acceptable carrier, wherein the composition is applied to the palpebral part of the eye and/or ocular surface.... Agent: Reed Smith LLP

20080132476 - Substituted estratrienes as selectively active estrogens: e

20080132477 - Macrocyclic compounds useful as bace inhibitors: The invention relates to novel macrocyclic compounds of the formula (I), in which all of the variables are as defined in the specification, the number of ring atoms included in the macrocyclic ring being 14, 15, 16 or 17, in free base form or in acid addition salt form, to... Agent: Novartis Institutes For Biomedical Research, Inc.

20080132478 - Modified release amoxicillin products: An amoxicillin product comprising: at least one modified release component(s), wherein the at least one modified release component(s) comprises at least amoxicillin and a pharmaceutically acceptable carrier; and wherein when administered to a patient or subject in the fed state said amoxicillin product exhibits a pharmacokinetic profile for amoxicillin in... Agent: Raymond E. Stauffer, Esq. C/o Carella, Byrne, Bain, Gilfillan, Cecchi

20080132480 - Biphenyloxyacetic acid derivatives for the treatment of respiratory disease: The invention relates to substituted phenoxyacetic acids of formula (I), where the variables are as defined in claim 1, as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.... Agent: Fish & Richardson P.c.

20080132481 - Interleukin-4 gene expression inhibitors: wherein X, Y, Z, R1, R2 and R3 are as defined in the specification; or a pharmaceutically acceptable salt thereof. In preferred embodiments of this invention it is also disclosed and claimed that the compounds of this invention are capable of modulating T helper (Th) cells, Th1/Th2, and thereby capable... Agent: Andrea Q. Ryan Sanofi-aventis U.s. Llc

20080132479 - Oxime derivative and preparations thereof: e

20080132482 - Hydroxyalkanoylaminolactams and related structures as inhibitors of a beta protein production: to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of... Agent: Kelley Drye & Warren LLP

20080132483 - Agent for preventing or treating organ functional disorders and organ dysfunction: The present invention provides an agent for preventing or treating organ functional disorders, an agent for preventing or treating organ dysfunction and an agent for preventing or treating obesity and deuteropathy thereof, each of which comprises a compound having an effect of increasing ubiquinone or a salt thereof or a... Agent: Edwards Angell Palmer & Dodge LLP

20080132484 - Method for identifying inhibitors using a homology model of polo-like kinase 1: The present invention relates to a homology model for PLK, and the use thereof in assays for the identification of small molecule PLK modulators. The invention further relates to PLK modulators identified by said assays, and their use in the treatment of PLK-related disorders such as proliferative disorders.... Agent: Lahive & Cockfield, LLP

20080132485 - Conformationally constrained smac mimetics and the uses thereof: The invention relates to conformationally constrained mimetics of Smac which function as inhibitors of Inhibitor of Apoptosis Proteins. The invention also relates to the use of these mimetics for inducing apoptotic cell death and for sensitizing cells to inducers of apoptosis.... Agent: Medlen & Carroll, LLP

20080132486 - Ligands for nicotinic acetylcholine receptors, and methods of making and using them: One aspect of the present invention relates to heterocyclic compounds that are ligands for nicotinic acetylcholine receptors. A second aspect of the invention relates to the use of a compound of the invention for modulation of a mammalian nicotinic acetylcholine receptor. The present invention also relates to the use of... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20080132487 - 5-aminopyrazole derivatives as pesticidal compounds: The invention relates to 5-Aminopyrazole derivatives of formula (I) or salts thereof, a process for their preparation, to compositions thereof and to their use for the control of pests, including arthropods and helminths.... Agent: Frommer Lawrence & Haug

20080132491 - Indazole-carboxamide compounds: The invention provides novel indazole-carboxamide 5-HT4 receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HT4 receptor activity, and processes and intermediates useful for preparing such compounds.... Agent: Theravance, Inc.

20080132489 - Novel alkyl substituted homopiperazine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors: e

20080132488 - Prodrugs of (2r)-2-propyloctanoic acid for the treatment of stroke: Disclosed are prodrugs of (2R)—2-propyloctanoic acid, and pharmaceutical compositions comprising them, which may be effective in modulating multiple events in the biochemical cascade of stroke. Also disclosed are methods of treating patients who have had a stroke, or are at risk of stroke, by administering the compounds or compositions of... Agent: Merck And Co., Inc

20080132490 - Substituted diazepan orexin receptor antagonists: The present invention is directed to substituted diazepan compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the... Agent: Merck And Co., Inc

20080132492 - Use of flumazenil in the production of a drug for the treatment of alcohol dependency: The invention relates to the use of flumazenil in developing a drug used for the sequential administration of small quantities of flumazenil at short intervals, until a therapeutically effective quantity is administered to treat alcohol dependence.... Agent: John S. Pratt, Esq Kilpatrick Stockton, LLP

20080132493 - Highly concentrated stable meloxicam solutions for needleless injection: Aqueous cyclodextrin-free solution of meloxicam suitable for administration by needleless injection, containing a pharmacologically acceptable meloxicam salt of an organic or inorganic base and one or more suitable excipients, the content of dissolved meloxicam salt being from 35 to 100 mg/ml. The formulation according to the invention has a shelf-life... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20080132494 - Thiazole and oxazole-substituted arylamides as p2x3 and p2x2/3 antagonists: u

20080132496 - Carboxylic acid amides, the preparation thereof, and their use as pharmaceutical compositions:

20080132495 - Pyrazole compounds that modulate the activity of cdk, gsk and aurora kinases: The invention provides a compound of the formula (I): or a salt, solvate, tautomer or N-oxide thereof, wherein M is selected from a group D1 and a group D2: and R′, E, A and X are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds, processes... Agent: Heslin Rothenberg Farley & Mesiti Pc

20080132497 - Novel heterocycles: This invention relates to novel compounds and processes for their preparation, methods of treating diseases, particularly hyperproliferative diseases such as cancer, comprising administering said compounds, and methods of making pharmaceutical compositions for the treatment or prevention of disorders, particularly hyperproliferative diseases such as cancer.... Agent: Bayer Health Care Llc

20080132498 - Synergistic insecticidal compositions: i

20080132499 - Platelet adp receptor inhibitors: Compounds are provided which are useful as platelet ADP receptor inhibitors, for treating thrombosis and for reducing the likelihood and/or severity of a secondary ischemic event in a patient.... Agent: Townsend And Townsend And Crew, LLP

20080132500 - Antibiotic compounds: Certain water-soluble thiazolyl peptides are antibiotic capable of treating serious bacterial infections in mammals, and particularly, in humans. Some of the analogs can also be employed as versatile intermediates for the preparation of new derivatives with useful antibacterial activity.... Agent: Merck And Co., Inc

20080132501 - Indazole compounds: This invention relates to indazole compounds of formula (I) or (II) shown below. Each variable in formula (I) or (II) is defined in the specification. These compounds can be used to treat cancer.... Agent: Occhiuti Rohlicek & Tsao, LLP

20080132502 - 5-heteroaryl thiazoles and their use as pi3k inhibitors: The invention provides thiazole derivatives of formula (I), or pharmaceutically acceptable salts thereof in which Ring A, R1, R2 and R3 are as defined in the specification; a processes for their preparation; pharmaceutical compositions containing them; and their use in therapy, for example in the treatment of disease mediated by... Agent: Morgan Lewis & Bockius LLP

20080132503 - Inhibitors of histone deacetylase: The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080132504 - 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders: e

20080132505 - Combination of cb2 modulators and pde4 inhibitors for use in medicine: Combination of one or more CB2 modulators and one or more PDE4 inhibitors, and method of treating conditions which are mediated by the activity of CB2 receptors or conditions which are mediated by PDE4.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20080132506 - Anti-inflammatory medicaments: Novel compounds and methods of using those compounds for the treatment of inflammatory conditions are provided. In a preferred embodiment, modulation of the activation state of p38 kinase protein comprises the step of contacting the kinase protein with the novel compounds.... Agent: Hovey Williams LLP

20080132507 - Hydrazide derivatives: v

20080132508 - Method and system for altering dysfunctional lipid metabolism in diabetic complications: Diabetic retinopathy is a debilitating complication of diabetes and a leading cause of vision loss, however the fundamental mechanisms contributing to vision loss remain undefined. Several novel observations are described: 1) diabetic retinas demonstrate decreased total ceramide levels; 2) with a concomitant increase in glucosylceramides; 3) which mediates decreased insulin... Agent: Laurence A Weinberger, Esq.

20080132509 - Substituted biaryl analogues: Substituted biaryl analogues of Formula (I) are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions... Agent: Edwards Angell Palmer & Dodge LLP

20080132510 - Imidazolylmethyl and pyrazolylmethyl heteroaryl derivatives: Compounds of Formula I and Formula II are provided, as are methods for their preparation. The variables Y, Z1, Z2, Z3, R4, R5, R6, R7, R8 and Ar in the above formula are defined herein. Such compounds may be used to modulate ligand binding to GABAA receptors in vivo or... Agent: Neurogen Corporation

20080132512 - Combination of brimonidine and timolol for topical ophthalmic use: Disclosed are pharmaceutical compositions comprising brimondine and timolol for topical ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma and associated conditions such as elevated intraocular pressure in the eyes of humans.... Agent: Allergan, Inc.

20080132511 - Sulfonamide compounds: Certain sulfonamide compounds are dual CCK1/CCK2 inhibitors useful in the treatment of CCK1/CCK2 mediated diseases.... Agent: Philip S. Johnson Johnson & Johnson

20080132513 - Fused ring compounds for inflammation and immune-related uses: The invention relates to certain fused ring compounds, or pharmaceutically acceptable salts, solvates, clathrates, or prodrugs thereof, that are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.... Agent: Edwards Angell Palmer & Dodge LLP

20080132514 - Serotonin reuptake inhibitors: A serotonin reuptake inhibitor which can be used in the treatment of depression and which has a decreased occurrence of unwanted side effects. The serotonin reuptake inhibitors are bi-functional organic molecules which combine serotonin transporter reuptake inhibition with serotonin (5-HT, such as 5-HT2A) receptor antagonism in one molecular entity. The... Agent: Jackson Walker LLP

20080132515 - Substituted azaquinazolines having an antiviral action: This invention relates to substituted azaquinazolines, to a process for their preparation, to pharmaceutical compositions containing them, and to their use for the treatment and/or prophylaxis of diseases, especially for use as antiviral agents, in particular against cytomegaloviruses.... Agent: Bayer Health Care Llc

20080132516 - Indole, azaindole and related heterocyclic n-substituted piperazine derivatives: i

20080132517 - Method of enhancing absorptions of transmucosal administration formulations: A method for enhancing absorption of a compound in a medicament that is suitable for administering transmucosally to a subject is conducted in an environment having a suitable pH. The suitable pH is determined based on the ionization constant (dissociation constant) of the compound in water, the solubility of the... Agent: Knobbe Martens Olson & Bear LLP

20080132518 - Organic compounds: The present invention relates to novel polymorphic forms of aripiprazole and processes for producing them. It further relates to pharmaceutical compositions comprising the novel forms and to the use of the novel forms in the treatment of schizophrenia.... Agent: Novartis Corporate Intellectual Property

20080132520 - Compositions, kits and methods for administering a titration schedule comprising bifeprunox compounds: The present disclosure is directed to a composition regimen, a titration kit, and methods of administration to facilitate the initiation of the treatment of at least one central nervous system condition or disorder by administering a plurality of dosage units of at least one bifeprunox compound, such as 7-[4-([1,1′-biphenyl]-3-ylmethyl)-1-piperazinyl ]-2(3H)-benzoxazolone... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080132519 - Heterocyclic compounds as pharmaceutical agents: Compounds, compositions and methods for modulating the activity of receptors are provided. In particular, compounds and compositions are provided for modulating the activity of receptors and for the treatment, prevention, or amelioration of one or more symptoms of the disease or disorder directly or indirectly related to the activity of... Agent: Mcdonnell Boehnen Hulbert @ Berghoff LLP

20080132521 - Isoquinolinone derivatives and their use as therapeutic agents: m

20080132522 - 2-substituted pyrimidines, method for their production and their use for controlling pathogenic fungi:

20080132523 - N-ureidoalkyl-piperidines as modulators of chemokine receptor activity:

20080132524 - Ortho-heterocyclic substituted aryl amides for controlling invertebrate pests: wherein A is O or S; G is a 5- or 6-membered heteroaromatic ring or a 5- or 6-membered nonaromatic heterocyclic ring optionally including one or two ring members selected from the group consisting of C(═O), SO or S(O)2, each ring optionally substituted with from one to four R2; each... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20080132526 - Purine derivative: The present invention provides a compound of formula (I) and salts and solvates thereof. Compounds of formula (I) are agonists of the adenosine A2A receptor and are believed to be of potential use in the treatment of inflammatory diseases such as asthma and chronic obstructive pulmonary disease.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20080132527 - Compositions for delivering acyclovir: The present invention relates to an acyclovir formulation having improved bioavailability resulting in better efficacy and/or requiring less frequent administration.... Agent: Emisphere Technologies, Inc

20080132525 - Inhibitors of dna methyltransferase: The invention relates to the inhibition of DNA methyltransferase isoforms DNMT1 and DNMT3b2. The invention provides compounds and methods for inhibiting DNMT1 and DNMT3b2.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080132528 - Kinase inhibitors and methods for using the same: e

20080132529 - Method of improving bioavailability for non-sedating barbiturates: Administration of 1,3-dimethoxymethyl-5,5-diphenylbarbituric acid and its related compounds with food increases the bioavailability of these compounds. The ratios (fasting/fed) for geometric mean AUC0-t were 35.6% (DMMDPB), 36.6% (MMMDPB) and 65.3% (DPB) and the geometric mean Cmax were 14.6% (DMMDPB), 31.9% (MMMDPB) and 62.9% (DPB). The cyclic ureides may be administered... Agent: Taro Pharmaceuticals U.s.a., Inc. C/o Venable LLP

20080132530 - Use of polymorphic forms of rifaximin for medical preparations: The present invention relates to Rifaximin polymorphic forms α, β and γ, to their use in medicinal preparations for the oral or topical route and to therapeutic methods using them.... Agent: Rothwell, Figg, Ernst & Manbeck, P.c.

20080132532 - Opioid dosage forms having dose proportional steady state cave and auc and less than dose proportional single dose cmax: The present invention relates to a plurality of dosage forms comprising a first dosage form and second dosage form each comprising a therapeutic agent, such as an opioid; wherein the dosage strength of the second dosage form is greater than that of the first dosage form; and wherein the steady... Agent: Jones Day

20080132531 - Synergistic combinations of norketamine and opioid analgesics: The present invention relates to methods of alleviating pain with the administration of norketamine with a narcotic. More particularly, the invention provides a method of alleviating pain through the administration of a dose of norketamine, which, if administered alone would provide sub-optimal analgesic relief, yet provides analgesic relief when combined... Agent: Foley And Lardner LLP Suite 500

20080132534 - Pharmaceutical composition comprising a macrolide immunomodulator: Snyergistic combination of a macrolide T-cell immunomodulator or immunosuppressant such as 33-epichloro-33-desoxyascomycin and a ceramide such as ceramide 3, LPC-9S or linoleic acid are provided, which are useful in particular in the treatment of dermatological or mucosal diseases such as atopic or contact dermatitis or dry skin, asteatotic eczema or... Agent: Novartis Corporate Intellectual Property

20080132533 - Solid dispersion comprising tacrolimus and entericcoated macromolecule: This invention relates to a solid dispersion formulation comprising tacrolimus and enteric polymer. The solid dispersion formulation may contribute to better stability of tacrolimus preparation under high temperature and humidity condition through reduced recrystallization rate of tacrolimus. In addition, the solid dispersion formulation releases tacrolimus immediately in aqueous media and... Agent: Sughrue Mion, Pllc

20080132535 - Stabilized zolpidem pharmaceutical compositions: Pharmaceutical compositions for buccal delivery of zolpidem comprising an effective amount of zolpidem and a carbonate and bicarbonate buffer system in an amount sufficient to raise the pH of saliva to at least 8.5 irrespective of starting pH, and wherein the carbonate forms a coating on the bicarbonate wherein the... Agent: O''melveny & Myers LLP Ip&t Calendar Department La-1118

20080132536 - Pyrazolo [3,4-b] pyridine compounds, and their use as pde4 inhibitors: a

20080132537 - Tropane derivatives useful in therapy:

20080132538 - Pharmaceutical uses for fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles:

20080132539 - Hydroxamic acid derivative and age generation inhibitor containing the derivative: To provide a novel compound which inhibits the generation of AGE and an AGE generation inhibitor containing the compound. A compound represented by the following formula or a pharmaceutically acceptable salt thereof, a medicinal composition containing the compound or such a salt thereof, and an additive composition containing the compound.... Agent: Reed Smith LLP

20080132540 - Non-peptidic npy y2 receptor inhibitors: The invention provides novel non-peptidic NPY Y2 receptor inhibitors useful in treating or preventing: anxiolytic disorders or depression; injured mammalian nerve tissue; conditions responsive to treatment through administration of a neurotrophic factor; neurological disorders; bone loss; substance related disorders; obesity; or an obesity-related disorder. Compounds of the invention are also... Agent: Philip S. Johnson Johnson & Johnson

20080132541 - Methods for treating cancers using polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione: Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or... Agent: Jones Day

20080132542 - Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase: Azacycloalkane derivatives of structural formula I are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, such as atherosclerosis;... Agent: Merck And Co., Inc

20080132543 - Therapeutic and delivery methods of prostaglandin ep4, agonists: a

20080132544 - Peroxisome proliferator-activated receptor ligand: An object of the present invention is to provide a peroxisome proliferator-activated receptor γ (PPARγ) ligand derived from a natural product and to provide a composition for prevention or improvement of insulin resistant syndrome, diabetes mellitus, obesity, or visceral fat obesity, characterized by comprising the ligand as an active ingredient.... Agent: Sughrue Mion, Pllc

20080132545 - Certain chemical entities, compositions, and methods: Chemical entities that modulate smooth muscle myosin and/or non-muscle myosin, and chemical entities, pharmaceutical compositions and methods of treatment of diseases and conditions associated with smooth muscle myosin and/or non-muscle myosin are described.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080132547 - Benzimidazole compound crystal: A novel crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl],sulfinyl]-1H-benzimidazole or a salt thereof of the present invention is useful for an excellent antiulcer agent.... Agent: Hamre, Schumann, Mueller & Larson, P.c.

20080132546 - Chemical compounds: Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.... Agent: Astrazeneca R&d Boston

20080132548 - Certain chemical entities, compositions, and methods: Chemical entities that modulate smooth muscle myosin and/or non-muscle myosin, pharmaceutical compositions and methods of treatment of diseases and conditions associated with smooth muscle myosin and/or non-muscle myosin are described.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080132550 - Heterocyclic compounds as p2x7 ion channel blockers: wherein R, R1, R2, R3, R4, R5, X and Y are as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are P2X7 ion channel blockers and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety... Agent: Andrea Q. Ryan Sanofi-aventis U.s. Llc

20080132549 - Sulphur-linked imidazone compounds for the treatment of hiv/aids: e

20080132551 - Positive allosteric modulators of the nicotinic acetylcholine receptor:

20080132552 - N-methyl hydroxyethylamine useful in treating cns conditions: An N-methyl hydroxyethyleneamine useful in treating CNS conditions, including neurodegenerative ones such as Alzheimer's Disease, is disclosed.... Agent: Pfizer Inc Steve T. Zelson

20080132553 - Preventing and reversing the formation of advance glycosylation endproducts: The present invention relates to methods for inhibiting and reversing nonenzymatic cross-linking (protein aging). Accordingly, compositions are disclosed which comprise an agent capable of inhibiting the formation of advanced glycosylation endproducts of target proteins, and which additionally reverse pre-formed crosslinks in the advanced glycosylation endproducts by cleaving alpha-dicarbonyl-based protein crosslinks... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c.

20080132554 - Crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol: The present invention is directed to an anhydrate crystal form (Form D) of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol, an estrogenic receptor modulator useful in the treatment of, for example, diseases related to abnormal levels of estrogen.... Agent: Pepper Hamilton LLP/wyeth

20080132556 - 3-hydroxymethyl-4hydroxy-phenyl- derivatives for the treatment of respiratory diseases: e

20080132555 - Preparation and utility of substituted phenyltetrazoles: Disclosed herein are substituted phenyltetrazoles of Formula I, processes of preparation thereof, pharmaceutical compositions thereof, and the methods of their use thereof.... Agent: Global Patent Group - Apx Ms. Lavern Hall

20080132558 - 1-arylpyrazoles and their use as pesticide: Disclosed are compounds of formula (I) or pesticidally acceptable salts thereof, wherein, for example, W is ═N—, ═CH—, ═CR7— or ═C(NR8R9)—, R7 is halogen, R8 and R9 are independently of one another hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, aralkyl or heterocyclylalkyl, R1 is cyano, halogen, haloalkyl or CS NH2,... Agent: Frommer Lawrence & Haug

20080132557 - Heterocyclic carboxamides with microbiocidal activity: Compounds of the formula (I), in which the substituents are as defined in claim 1 are suitable for use as microbiocides.... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20080132560 - Solid dispersion composition: A solid dispersion composition containing fluvastatin and a polymer is provided. Optionally, a surfactant is included. The fluvastatin appears to be amorphous and the solid dispersion composition enables fluvastatin to be constantly released over a time period.... Agent: Patterson & Sheridan, L.l.p.

20080132559 - Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents: This invention is directed to substituted aryl compounds, which are linked to a substituted indole moiety by various linkers, and the kynurenine/kynuramine-like metabolites of these agents, their preparation and pharmaceutical compositions containing these compounds. This invention further is directed to the pharmaceutical use of the compounds for inhibiting GSK3β kinase... Agent: Rothwell, Figg, Ernst & Manbeck, P.c.

20080132561 - Materials and methods for treating hypercholesterolemia: The subject invention provides novel HMG-CoA-reductase inhibitors. In a preferred embodiment, the HMG-CoA reductase inhibitors of the subject invention can be deactivated to a primary inactive metabolite by hydrolytic enzymes. Compounds of the present invention can be advantageously used to treat patients suffering hypercholesterolemia.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080132562 - Tetronic and tetramic acids: e

20080132563 - 1-thio-d-glucitol derivatives: The present invention provides a 1-thio-D-glucitol compound of the following formula, which shows the action of inhibiting the activity of SGLT2, a pharmaceutically acceptable salt of the compound, or a hydrate of the compound or the salt; and a pharmaceutical comprising such a compound as an active ingredient, especially, a... Agent: Sughrue Mion, Pllc

20080132564 - Micellar drug delivery vehicles and precursors thereto and uses thereof: Anhydrous formulations are formed of a diblock copolymer (X—Y) having a hydrophilic block X comprising residues of monomer x, and a hydrophobic block Y comprising residues of monomer y; an additive selected from a polymer and an organic solvent, where the solvent is water-miscible and biocompatible, and the polymer is... Agent: Seed Intellectual Property Law Group Pllc

20080132566 - Metabolic syndrome-improving agent and medicine, supplement, functional food and food additive containing the same: A metabolic syndrome relieving agent that is free from a problem of side effects and can be taken for a long term is provided. Bergamottin is used as an agent for relieving a metabolic syndrome. Since bergamottin has functions of activating PPARα and PPARγ, promoting the secretion of adiponectin in... Agent: Hamre, Schumann, Mueller & Larson, P.c.

20080132565 - Polycyclic macrolactones: The invention provides novel polycyclic macrolactones which can be produced, in particular, by a representative of the bacterial genus Verrucosispora. These substances are preferentially distinguished by their pharmacological effect. In particular, they exhibit an antibiotic effect. This antibiotic effect is preferably directed against Gram-positive bacteria.... Agent: Flynn Thiel Boutell & Tanis, P.c.

20080132567 - Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders: Methods of using certain α-aminoamide derivatives to treat lower urinary tract disorders. The therapeutic agents of the invention are able to reduce or even stop the lower urinary tract disorders substantially without side effects.... Agent: Young & Thompson

20080132568 - Compounds with anti-androgenic activity and the use thereof: Compounds having anti-androgenic activities are disclosed. Further disclosed are methods of using the compounds to prevent or treat androgen-dependent diseases or to provide nutraceutical benefits. Pharmaceutical and nutraceutical compositions containing the anti-androgenic compounds are also disclosed.... Agent: Quarles & Brady LLP

20080132569 - Antifungal compositions for inhibiting growth of wood decay fungi and use thereof: The present invention is related to an antifungal composition for inhibition of wood decay caused by wood rot fungi. The invention further comprises a method for inhibition of wood decay with gallates.... Agent: Wpat, Pc Intellectual Property Attorneys

20080132570 - Levodopa prodrugs, and compositions and uses thereof: Prodrugs of levodopa, methods of making prodrugs of levodopa, methods of using prodrugs of levodopa, and compositions of prodrugs of levodopa are disclosed.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080132572 - Composition and method for repelling moles, voles and gophers: The present invention is a composition and method for repelling moles, voles, gophers, chipmunks and armadillos by applying a composition comprising castor oil, yellow grease and sodium lauryl sulfate to plant materials.... Agent: Reed Smith LLP

20080132571 - Nutrient sensor: The present invention includes compositions and methods for treating the effects of catabolism in a patient by providing the patient with an amount of an odd-chain fatty acid sufficient to increase the intracellular ratio of AMP to ATP and reduce the activity of AMPK.... Agent: Chalker Flores, LLP

20080132573 - Trpv1 agonists, formulations containing them and uses thereof: The compounds of the general formula (I) in which X is represents two hydrogen atoms, a π-bond, oxygen or methylene: R2 is a C6-C12 aryl, or arylalkyl residue: R3 is hydrogen, 2-hydroxyethyl or 2-aminoethyl are useful for the treatment of pathologies mediated by vanilloid receptors type I.... Agent: Young & Thompson

20080132574 - Novel blt2-mediated disease, blt2 binding agent and the compound: salt thereof, solvate thereof or prodrug thereof (symbols in formula have the same meanings as specification.) have BLT2 binding activity, it is useful for prevention and/or therapy of BLT2 mediated diseases, e.g., dermatosis, intestinal disease, HIV infection, acquired immunodeficiency syndrome, rejection to transplant, transplant rejection, graft-versus-host disease, autoimmune disease, allergic... Agent: Sughrue-265550

20080132575 - Formulations of suberoylanilide hydroxamic acid and methods for producing same: The present invention provides a pharmaceutical composition or crystalline composition with a specific dissolution profile, which comprises suberoylanilide hydroxamic acid or a pharmaceutically acceptable salt or hydrate thereof as an active ingredient. The present invention provides a process of producing said crystalline composition or pharmaceutical composition. The present invention also... Agent: Merck And Co., Inc

20080132576 - Methods and compositions for modulating alpha adrenergic receptor activity: Methods and compositions for the treatment of pain and intraocular pressure. Particularly disclosed are new compositions for the treatment of chronic pain, glaucoma and methods for their use.... Agent: Allergan, Inc.

20080132577 - Use of agomelatine in obtaining medicaments intended for the treatment of smith-magenis syndrome: The present invention relates to the use of agomelatine, or N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide, in obtaining medicaments intended for the treatment of Smith-Magenis syndrome.... Agent: The Firm Of Hueschen And Sage

20080132578 - Dosage forms of o-desmethylvenlafaxine: Methods of preparing, and compositions comprising, derivatives of venlafaxine are disclosed. Also disclosed are methods of treating and preventing diseases and disorders including, but not limited to, affective disorders such as depression, bipolar and manic disorders, attention deficit disorder, attention deficit disorder with hyperactivity, Parkinson's disease, epilepsy, cerebral function disorders,... Agent: Jones Day

20080132579 - Preparation of levalbuterol hydrochloride: Provided are processes for the preparation of (R)-SLB.D-DBTA salt and levalbuterol hydrochloride. Also provided are levalbuterol hydrochloride degradation products and processes for preparing them. Pharmaceutical compositions comprising at least one levalbuterol hydrochloride of the invention and at least one pharmaceutically-acceptable excipient are also provided.... Agent: Kenyon & Kenyon LLP

20080132580 - Dispersion for delivering active agents: A composition for topical application comprises a dispersed phase comprising an active agent and a polymer or lipid; and a gelled continuous phase comprising a viscosity modifier and a solvent. The composition can provide an active agent to skin or mucous membranes in a controlled release form.... Agent: Dr. Reddy's Laboratories, Inc.

20080132581 - Diarylalkanes as potent inhibitors of binuclear enzymes: The present invention implements a strategy that combines an enzyme inhibition assay with a chemical dereplication process to identify active plant extracts and the particular compounds—diarylalkanes and/or diarylalkanols within those extracts that specifically inhibit binuclear enzyme function. Included in the present invention are compositions of matter comprised of one or... Agent: Swanson & Bratschun, L.l.c.

20080132582 - Propofol formulation containing reduced oil and surfactants: Sterile, stable pharmaceutical formulations of emulsions of neat propofol or propofol dissolved in a solvent and containing no preservative are provided that comprise optimal amounts of surfactants such as lecithin and solvent such as soybean oil, with a suitable pH range to prevent significant growth of microorganisms for at least... Agent: Leydig Voit & Mayer, Ltd

20080132583 - Long-lasting insect repellant, pesticide and antifeedant compositions: An insect repellent material includes a carrier such as a polyethylene, a molecular sieve or zeolite material, and a repellent such as geraniol. The molecular sieve/zeolite material provides the insect repellent material with a slow-release quality and also permits the carrier to hold more insect repellent than it would otherwise... Agent: Gordon & Jacobson, P.c.

20080132584 - Biofunctional nanoprobes: Biofunctional nanoprobes are disclosed having nanoscale dimensions enabling the non-destructive penetration of lipid membranes. They are functionalized to perform a bio-chemical process using bio-compatible, porous coating in which enzymes are structurally constrained.... Agent: Woodcock Washburn LLP

20080132585 - Separate type medical material: A separate type medical material comprising liquid (A) which is an aqueous solution containing a hyaluronic acid ester derivative and buffered to a pH of from 4.5 to 6.5, and liquid (B) which is an aqueous solution having such a buffering power that when it is mixed with the liquid... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080132587 - Low peak exotherm curable compositions: Compositions having a curable unsaturated compound, an adhesion promoter and curing agent which have a peak exotherm of less than 50° C. are disclosed. The compositions when cured are flexible bioadhesives which are also disclosed. Non-curable diluents can be included in the compositions. Flexible bioadhesives formed on biological structures and... Agent: Discus Dental, Llc

20080132586 - Use of methionine synthase inhibitors for the treatment of fungal diseases of crops: The invention relates to the use of methionine synthase inhibitors for the treatment of fungal diseases of crops. The invention further relates to methods for treatment of crops against fungal diseases comprising the application of a methionine synthase inhibitor also methods for the identification of novel fungicidal compounds comprising a... Agent: Ostrolenk Faber Gerb & Soffen